U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Lin SY, Erekosima N, Suarez-Cuervo C, et al. Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma: Comparative Effectiveness Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Mar. (Comparative Effectiveness Reviews, No. 111.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma: Comparative Effectiveness Review

Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma: Comparative Effectiveness Review [Internet].

Show details

Appendix HExcluded Articles

  1. A trial of house dust mite extract in bronchial asthma. Mite Allergy Subcommittee of the Research Committee of the British Thoracic Association. Br J Dis Chest. 79; 73(3):260–70. It does not meet ALL the inclusion criteria. [PubMed: 399857]
  2. Assa’ad A. Allergy, asthma, and immunology. Pediatric Annals. 2011;40(4):179–180. It does not meet ALL the inclusion criteria. [PubMed: 21485991]
  3. Iglesias-Cadarso A, Hernandez-Weigand P, Reano M, Perez-Pimiento A, Vargas Nunez JA, De La Torre F. Risk factors for systemic reactions to allergen- specific subcutaneous immunotherapy. Journal of Investigational Allergology and Clinical Immunology. 2010;20(7):621–622. No original dataOther reason for exclusion (specify):case report. [PubMed: 21314007]
  4. Malet A, Lluch M, Valero AL, Casanovas M. Clinical and immunological effects of immunotherapy with glutaraldehyde modified house dust mite extract. Allergol Immunopathol (Madr). 1994;22(5):226–32. Not an RCT. [PubMed: 7840025]
  5. Aabel S. No beneficial effect of isopathic prophylactic treatment for birch pollen allergy during a low-pollen season: a double-blind, placebo-controlled clinical trial of homeopathic Betula 30c. Br Homeopath J. 2000;89(4):169–73. It does not meet ALL the inclusion criteria dose not quantifiable. [PubMed: 11055773]
  6. Aabel S. Prophylactic and acute treatment with the homeopathic medicine, Betula 30c for birch pollen allergy: a double-blind, randomized, placebo-controlled study of consistency of VAS responses. Br Homeopath J. 2001;90(2):73–8. It does not meet ALL the inclusion criteriaTherapy NOT AVAILABLE in the U.S. [PubMed: 11341460]
  7. Aabel S, Laerum E, Dolvik S, Djupesland P. Is homeopathic ‘immunotherapy’ effective? A double-blind, placebo-controlled trial with the isopathic remedy Betula 30c for patients with birch pollen allergy. Br Homeopath J. 2000;89(4):161–8. It does not meet ALL the inclusion criterianot a quantifiable dose. [PubMed: 11055772]
  8. AARONSON AL, FRANKEL DB, EHRLICH NJ. REPOSITORY THERAPY FOR AIRBORNE ALLERGENS. Chic Med Sch Q. 62; 22:45–8. It does not meet ALL the inclusion criteria. [PubMed: 14085296]
  9. Aaronson DW, Gandhi TK. Incorrect allergy injections: allergists’ experiences and recommendations for prevention. J Allergy Clin Immunol. 2004;113(6):1117–21. It does not meet ALL the inclusion criteriaNo SIT. [PubMed: 15208593]
  10. Aas K. Adequate clinical trials of immunotherapy. Allergy. 82; 37(1):1–14. No original dataOther reason for exclusion (specify): review on methodology of clinical trials.
  11. Aas K. Bronchoprovocative tests (BPT) in clinical and experimental allergy. Ann Allergy. 74; 33(6):320–4. No original dataOther reason for exclusion (specify): review. [PubMed: 4140702]
  12. Aas K. Hyposensitization in house dust allergy asthma. A double-blind controlled study with evaluation of the effect on bronchial sensitivity to house dust. Acta Paediatr Scand. 71; 60(3):264–8. Therapy NOT AVAILABLE in the U.S. [PubMed: 4931556]
  13. Aas K. Hyposensitization: action and immunological procedure. Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M. 78; 73:7–16. No original data. [PubMed: 318558]
  14. Aberer W, Von Weikersthal Drachenberg F. European outcomes amongst allergic rhinoconjunctivitis patients participating in a placebo-controlled study of ultra short course subcutaneous immunotherapy (USCIT) conducted during the 2007 grass pollen season. Allergy. It does not meet ALL the inclusion criteria.
  15. Acquistapace F, Agostinis F, Castella V, Kantar A, Novembre E, Perrone MR, Pietrasanta M, Sambugaro R, Milani M. Efficacy of sublingual specific immunotherapy in intermittent and persistent allergic rhinitis in children: an observational case-control study on 171 patients. The EFESO-children multicenter trial. Pediatr Allergy Immunol. 2009;20(7):660–4. It does not meet ALL the inclusion criteria dose. [PubMed: 19320852]
  16. Adamek-Guzik T, Szczeklik A, Woloszynski J. Multicenter controlled trial of desensitization treatment of pollen-induced hay fever and asthma with pollinex vaccine. Pol Tyg Lek. 79; 34(28):1111–3. Therapy NOT AVAILABLE in the U.S. [PubMed: 390511]
  17. Adamic K, Zidarn M, Bajrovic N, Erzen R, Kopac P, Music E. The local and systemic side-effects of venom and inhaled-allergen subcutaneous immunotherapy. Wien Klin Wochenschr. 2009;121(9–10):357–60. It does not meet ALL the inclusion criteria. [PubMed: 19562302]
  18. Addition of specific immunotherapy in patients with grass-pollen allergic asthma treated with inhaled steroid therapy. Library unable to locate.
  19. Adelsberg BR. Review: allergen-specific immunotherapies reduce symptoms, medication requirements, and bronchial hyperreactivity in asthma. ACP J Club. 2004;141(1):18. No original dataOther reason for exclusion (specify): quick summary of cochrane 2003 review. [PubMed: 15230566]
  20. Adinoff AD. Environmental controls and immunotherapy in the treatment of chronic asthma. J Asthma. 90; 27(5):277–89. No original dataOther reason for exclusion (specify): review. [PubMed: 2243075]
  21. Adkinson NF Jr. Con: Immunotherapy is not clinically indicated in the management of allergic asthma. Am J Respir Crit Care Med. 2001;164(12):2140–1. discussion 2141–2. Other reason for exclusion (specify):editorial. [PubMed: 11751175]
  22. Adkinson NF Jr. Immunotherapy for allergic rhinitis. N Engl J Med. 99; 341(7):522–4. Other reason for exclusion (specify):editorial. [PubMed: 10441610]
  23. Adler TR, Beall GN, Heiner DC, Sabharwal UK, Swanson K. Immunologic and clinical correlates of bronchial challenge responses to Bermuda grass pollen extracts. J Allergy Clin Immunol. 85; 75(1 Pt 1):31–6. Does not apply to any of the key questions. [PubMed: 3871447]
  24. Agati G, Sacco E, Riscica G. Treatment of bronchial asthma in children and chronic asthmatic bronchitis in adults by use of nonspecific immunodensensitization with bacterial vaccines. Minerva Med. 79; 70(41):2805–10. It does not meet ALL the inclusion criteria case series. [PubMed: 492549]
  25. Agostinis F, Foglia C, Bruno ME, Falagiani P. Efficacy, safety and tolerability of sublingual monomeric allergoid in tablets given without up-dosing to pediatric patients with allergic rhinitis and/or asthma due to grass pollen. Eur Ann Allergy Clin Immunol. 2009;41(6):177–80. Therapy NOT AVAILABLE in the U.S. [PubMed: 20128231]
  26. Agostinis F, Foglia C, Landi M, Cottini M, Lombardi C, Canonica GW, Passalacqua G. The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy. 2008;63(12):1637–9. It does not meet ALL the inclusion criteria. [PubMed: 19032238]
  27. Agostinis F, Forti S, Di Berardino F. Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis. Allergy. 2010;65(3):410–1. Therapy NOT AVAILABLE in the U.S Other reason for exclusion (specify):patch. [PubMed: 19804450]
  28. Agrawal S, Kandimalla ER. Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med. 2002;8(3):114–21. Therapy NOT AVAILABLE in the U.S. [PubMed: 11879771]
  29. Ahlstedt S, Belin L, Eriksson NE, Hanson LA. Quantity and avidity of antibodies against birch pollen in atopic patients during hyposensitization. A preliminary study. Int Arch Allergy Appl Immunol. 75; 48(5):632–41. It does not meet ALL the inclusion criteriaOther reason for exclusion (specify):comparison group has not the same allergy. [PubMed: 1132912]
  30. Ajduk J, Marinic I, Aberle N, Rabatic S, Gagro A. Effect of house dust mite immunotherapy on transforming growth factor beta1-producing T cells in asthmatic children. Ann Allergy Asthma Immunol. 2008;100(4):314–22. It does not meet ALL the inclusion criteriaOther reason for exclusion (specify):no harms. [PubMed: 18450115]
  31. Akbas Y, Saatci MR. Monitoring the efficacy of immunotherapy by symptom scores and the skin prick test in patients with allergic rhinitis. Kulak Burun Bogaz Ihtis Derg. 2003;10(6):221–5. Not an RCT. [PubMed: 13679688]
  32. Akcakaya N, Hassanzadeh A, Camcioglu Y, Cokugras H. Local and systemic reactions during immunotherapy with adsorbed extracts of house dust mite in children. Ann Allergy Asthma Immunol. 2000;85(4):317–21. Observational case series. [PubMed: 11061476]
  33. Akdis CA, Barlan IB, Bahceciler N, Akdis M. Immunological mechanisms of sublingual immunotherapy. Allergy. 2006;61 Suppl 81:11–4. No original data. [PubMed: 16792600]
  34. Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol. 2005;116(5):961–8. quiz 969. No original data. [PubMed: 16275361]
  35. Alemany-Vall R. Sensitization against mould fungi. Allerg Asthma (Leipz). 68; 14(3):84–9. No original data. [PubMed: 5728388]
  36. Alfaro V. Juan Manuel Eficacia de la inmunoterapia subcutbnea en el manejo de la rinitis alqrgica al polvo y/o acaro. CES med. 92; 6(2):149–157. Not an RCT.
  37. Ali I, Goksal K, Ozan B, Gulsen D. Long-term allergen-specific immunotherapy correlates with long-term allergen-specific immunological tolerance. Adv Ther. 2008;25(1):29–36. It does not meet ALL the inclusion criteriaOther reason for exclusion (specify):no doses. [PubMed: 18224290]
  38. Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2003;90(1 Suppl 1):1–40. No original data. [PubMed: 12542071]
  39. Allergen-specific low-dose immunotherapy in perennial allergic rhinitis: a double-blind placebo-controlled crossover study. Excluded at data abstraction. [PubMed: 8844501]
  40. Allergen-specific sublingual immunotherapy for patients with grass pollen induced respiratory disease. Meeting abstract\.
  41. Allergen-specific sublingual immunotherapy in patients season respiratory allergy symptoms. Meeting abstract.
  42. Allergic rhinitis and quality of life after one year of allergen immunotherapy Abstract. Abstract only.
  43. Allergic rhinitis to ragweed pollen. I. Reassessment of the effects of immunotherapy on cellular and humoral responses. Oral IT. [PubMed: 1370510]
  44. Allergic rhinitis. Treating symptoms or desensitization? MMW Fortschr Med. 2003;145(5):52. No original data. [PubMed: 12619217]
  45. Almagro E, Asensio O, Bartolome JM, Bosque M, de la Hoz B, Dolz I, Elorza J, Ferreiro M, Garcia JM, Losada E, et al. Multicenter drug surveillance of sublingual immunotherapy in allergic patients. Allergol Immunopathol (Madr). 95; 23(4):153–9. It does not meet ALL the inclusion criteria. [PubMed: 8553989]
  46. Al-Nahdi MS. Effect of immunotherapy in allergic bronchial asthma. Allerg Immunol (Paris). 96; 28(1):4–6. It does not meet ALL the inclusion criteria Method of asthma diagnosis not addressed.
  47. Alonso A, Albonico JF, Mouchian K, Scavini LM, Iraneta SG, Pionetti CH. Immunological changes during cockroach immunotherapy. J Investig Allergol Clin Immunol. 99; 9(5):299–304. Observational case series. [PubMed: 10582198]
  48. Alvarez JMN. Costs of specific immunotherapy (Brief record). Journal of Investigational Allergology and Clinical Immunology. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions No SITNo original data.
  49. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol. 2006;117(1):169–75. Not an RCT. [PubMed: 16387602]
  50. Anaphylaxis-rhinitis-hyposensitization. Hautarzt. 97; 48(8 Suppl):4–6. No original data. [PubMed: 9378646]
  51. Anderson JA, Lane SR, Howard WA, Leiken S, Oppenheim JJ. The effect of hyposensitization on alternaria-induced lymphocyte blastogenesis. Cell Immunol. 74; 10(3):442–9. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 4477050]
  52. Andre C, Fadel R. Anaphylaxis caused by allergen sublingual immunotherapy? Allergy. 2007;62(10):1220–1. Therapy NOT AVAILABLE in the U.S. [PubMed: 17845597]
  53. Andre C, Perrin-Fayolle M, Grosclaude M, Couturier P, Basset D, Cornillon J, Piperno D, Girodet B, Sanchez R, Vallon C, Bellier P, Nasr M. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol. 2003;131(2):111–8. Other reason for exclusion (specify):SLIT oral (aqueous arm) vs SLIT (Tablet) [PubMed: 12811019]
  54. Andre C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol. 2000;121(3):229–34. It does not meet ALL the inclusion criteria. [PubMed: 10729782]
  55. Andri L, Falagiani P. Symptomatic relief after grass nasal immunotherapy: lasting efficacy after 4–5 years. J Investig Allergol Clin Immunol. 2003;13(4):228–31. Therapy NOT AVAILABLE in the U.S. [PubMed: 14989110]
  56. Andri L, Senna G, Mezzelani P. Safety of specific immunotherapy. Ann Allergy. 94; 72(3):285–6. It does not meet ALL the inclusion criteria-allergic asthma not confirmed by pulm lung function per article.
  57. Anonymous. Homoeopathy ineffective for treating asthma triggered by dust-mite allergy. Pharmaceutical Journal. No SIT.
  58. Ansari AA, Killoran EA, Marsh DG. An investigation of human immune response to perennial ryegrass (Lolium perenne) pollen cytochrome c (Lol p X). J Allergy Clin Immunol. 87; 80(2):229–35. Study evaluates outcomes in animals only or in vitro. [PubMed: 3038988]
  59. Anthracopoulos MB, Mantzouranis E, Paliatsos AG, Tzavelas G, Lagona E, Nicolaidou P, Priftis KN. Different effects of sensitization to mites and pollens on asthma symptoms and spirometric indices in children: a population-based Cohort study. Ann Allergy Asthma Immunol. 2007;99(2):122–9. No SIT. [PubMed: 17718099]
  60. APPELMAN HB. UNTOWARD REACTIONS TO EMULSION THERAPY OF POLLENOSIS REPORT OF TWO CASES. JAMA. 64; 187:1030–1. Therapy NOT AVAILABLE in the U.S. [PubMed: 14102944]
  61. ARBESMAN CE, REISMAN RE. HYPOSENSITIZATION THERAPY INCLUDING REPOSITORY: A DOUBLE-BLIND STUDY. J Allergy Clin Immunol. 64; 35:12–7. Observational case series. [PubMed: 14104249]
  62. ARGABRITE JW, MORROW MB, MEYER GH. ALLERGIC BRONCHIAL ASTHMA AND PULMONARY INFECTION DUE TO ASPERGILLUS FUMIGATUS TREATED BY INJECTIONS OF EMULSIFIED ALLERGEN. Ann Allergy. 63; 21:583–7. Therapy NOT AVAILABLE in the U.S. [PubMed: 14070817]
  63. Ariano R, Incorvaia C, La Grutta S, Marcucci F, Pajno G, Sensi L, Di Cara G, Sieber J, Yacoub MR, Frati F. Safety of sublingual immunotherapy started during the pollen season. Curr Med Res Opin. 2009;25(1):103–7. It does not meet ALL the inclusion criteriaNot an RCT. [PubMed: 19210143]
  64. Ariano R, Kroon AM, Augeri G, Canonica GW, Passalacqua G. Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial. Allergy. 99; 54(4):313–9. Therapy NOT AVAILABLE in the U.S. [PubMed: 10371089]
  65. Ariano R, Spadolini I, Panzani RC. Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study. Allergol Immunopathol (Madr). 2001;29(6):238–44. Not an RCT. [PubMed: 11834182]
  66. Arifhodzic N, Behbehani N, Duwaisan AR, Al-Mosawi M, Khan M. Safety of subcutaneous specific immunotherapy with pollen allergen extracts for respiratory allergy. Int Arch Allergy Immunol. 2003;132(3):258–62. Observational case series. [PubMed: 14646387]
  67. Arikan C, Bahceciler NN, Deniz G, Akdis M, Akkoc T, Akdis CA, Barlan IB. Bacillus Calmette-Guerin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy. Clin Exp Allergy. 2004;34(3):398–405. Other reason for exclusion (specify):compares BCG. [PubMed: 15005733]
  68. Armentia A, Fernandez A, Tapias JA, Mendez J, de la Fuente R, Sanchez-Palla P, Sanchis E. Immunotherapy with allergenic extracts in geriatric patients: evaluation of effectiveness and safety. Allergol Immunopathol (Madr). 93; 21(5):193–6. It does not meet ALL the inclusion criteria. [PubMed: 8160564]
  69. Armentia-Medina A, Blanco-Quiros A, Martin-Santos JM, Alvarez-Cuesta E, Moneo-Goiri I, Carreira P, Losada-Cosmes E. Rush immunotherapy with a standardized Bermuda grass pollen extract. Ann Allergy. 89; 63(2):127–35. No SIT. [PubMed: 2669567]
  70. Asai S. Effect of hyposensitization therapy on nasal allergy (author’s transl). Nippon Jibiinkoka Gakkai Kaiho. 76; 79(8):850–61. It does not meet ALL the inclusion criteriaOther reason for exclusion (specify):no control group.
  71. Asaoku Y. Clinical study of immunotherapy for bronchial asthma using purified mite feces antigen. Nihon Kokyuki Gakkai Zasshi. 2000;38(2):92–9. Other reason for exclusion (specify):no cotnrol groupNot an RCT. [PubMed: 10774166]
  72. Asaoku Y, Jyo T, Mochiduki N, Kodomari Y, Kuwabara M, Yoshizane T, Shigeta S, Ono K, Tsuboi S, Ootsuka T, et al. Desensitization immunotherapy on patients with mite-positive bronchial asthma using purified mite feces antigen fractions. Arerugi. 95; 44(7):692–700. Not an RCT. [PubMed: 7575135]
  73. Aschan G, Irander K, Olofsson J. Hyposensitization in allergic rhinitis--a comparison of aqueous extracts and Allpyral by means of rhinomanometry. J Otolaryngol. 78; 7(5):444–9. It does not meet ALL the inclusion criteriaOther reason for exclusion (specify):no dose. [PubMed: 739576]
  74. Ascione E, De Lucia A, Imperiali M, Varricchio A, Motta G. Nasal application of immunotherapy. Chem Immunol Allergy. 2003;82:89–98. Therapy NOT AVAILABLE in the U.S. [PubMed: 12947995]
  75. Asero R. Efficacy of injection immunotherapy with ragweed and birch pollen in elderly patients. Int Arch Allergy Immunol. 2004;135(4):332–5. It does not meet ALL the inclusion criteria. dose is half a vial. [PubMed: 15564775]
  76. Asero R. Pollen specific immunotherapy is not a risk factor for de novo sensitization to cross-reacting allergens in monosensitized subjects. J Investig Allergol Clin Immunol. 2006;16(4):253–7. No SIT. [PubMed: 16889283]
  77. Assem ES, McAllen MK. Changes in challenge tests following hyposensitization with mite extract. Clin Allergy. 73; 3(2):161–75. It does not meet ALL the inclusion criteria. [PubMed: 4131251]
  78. Atwater JS Jr. Allergen immunotherapy. Ann Allergy Asthma Immunol. 2003;91(1):97. author reply 97–8. No original data. [PubMed: 12877460]
  79. Avila Castanon L, Lerma-Ortiz L, Velazquez Armenta Y, del Rio Navarro BE, Sienra Monge JJ. Adverse reactions to immunotherapy in pediatric patients. Rev Alerg Mex. 2003;50(5):182–6. Not an RCT. [PubMed: 14631589]
  80. Aydogan M, Keles S, Eifan A, Akkoc T, Yildiz A, Gursoy MA, Bahceciler N, Barlan I. Impact of sublingual immunotherapy on development of asthma in children with allergic rhinitis sensitised to house-dust-mite: A double blind placebo controlled study; Abstracts of the XXVI Congress of the European Academy of Allergology and Clinical Immunology (EAACI); It does not meet ALL the inclusion criteria.
  81. Bachert C. Allergic rhinitis and its impact on asthma (ARIA)--what does it mean for the future of SIT? Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2003;(94):229–35. No original data. [PubMed: 15119043]
  82. Badan M, Fasel-Felley J, Kolly M, Frei PC, Pecoud A. Prospective study of the undesirable effects of allergic desensitization. Schweiz Med Wochenschr. 86; 116(8):243–5. It does not meet ALL the inclusion criteriaOther reason for exclusion (specify):no dose.
  83. BAGRATUNI L. A comparative study of topical steroids, antihistamines and pollen vaccine in the treatment of hay fever and hay asthma. Ann Allergy. 60; 18:859–65. It does not meet ALL the inclusion criteriaNo SITOther reason for exclusion (specify):no concentration. [PubMed: 13685883]
  84. Bahceciler NN, Arikan C, Taylor A, Akdis M, Blaser K, Barlan IB, Akdis CA. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol. 2005;136(3):287–94. It does not meet ALL the inclusion criteriaOther reason for exclusion (specify):control group is healthy. [PubMed: 15722639]
  85. Bakanov MI. Development of bronchial asthma attacks in children under the effect of prophylactic immunization. Vopr Okhr Materin Det. 68; 13(4):78–9. Non-English article: Russian- Not and RCT. [PubMed: 5705691]
  86. Bakulin MP. Several problems in specific desensitization in children with bronchial asthma. Vopr Okhr Materin Det. 70; 15(7):52–5. Non-English article: Russian - Not and RCT. [PubMed: 5480056]
  87. Balabolkin II, Botvin’eva VV, Abdyldaev TT, Imanalieva ChA, Ryleeva NV, Ivanov VG. Bronchial asthma in children with sensitization to mites. Pediatriia. 92(3):22–6. Non-English article: Russian – Not original data. [PubMed: 1513646]
  88. Balabolkin II, Stasii ED, Dzhunelov AB, Abdyldaev TT, Imanalieva ChA, Guseva NV, Babaeva SB, Strigan VA. Use of anti-allergic immunoglobulin in children with allergic diseases. Pediatriia. 92(1):76–8. No SIT Other reason for exclusion (specify):it is about use o IG not allergen Non-English article. [PubMed: 1614810]
  89. Balli F, Bergamini BM, Marcolini C, De Palma M, Marchioni CF, Baldini EV. Asthma due to Dermatophagoides in children. Peroral desensitization. Pediatr Med Chir. 92; 14(5):523–7. It does not meet ALL the inclusion criteriaOther reason for exclusion (specify): no control group. [PubMed: 1488311]
  90. Barbero S, Catapane MR, Lorenzi L. Clinical and immunoglobulinic behavior of asthmatic children treated by desensitization with bronchoasthmatic vaccine. Minerva Pediatr. 69; 21(16):665–78. No SIT. [PubMed: 4104218]
  91. Bauer CP. Therapy control of hyposensitization treatment in inhalation allergies. Monatsschr Kinderheilkd. 84; 132(6):488–93. It does not meet ALL the inclusion criteriaNot an RCT.
  92. Bauer P, Schwager R. The effect of hyposensitization in bronchial asthma of childhood with regard to the histamine reactivity of the bronchial tract. Monatsschr Kinderheilkd. 83; 131(3):140–4. It does not meet ALL the inclusion criteria. [PubMed: 6855780]
  93. Baur X. IST DIE HYPOSENSIBILISIERUNG NOCH EIN ADAQUATES VERFAHREN ZUR BEHANDLUNG DES ASTHMA BRONCHIALE? [Is hyposensitization still an adequate treatment of bronchial asthma?]. PNEUMOLOGIE. Non-English article – No original data. [PubMed: 1584737]
  94. Baur X. Hyposensitization in bronchial asthma--still a current therapeutic procedure? Med Klin (Munich). 89; 84(9):439–44. Not an RCT. [PubMed: 2682160]
  95. Baur X. Is hyposensitization still an adequate procedure in treatment of bronchial asthma? Pneumologie. 92; 46(3):89–91. No original data. [PubMed: 1584737]
  96. Beato Martinez A, Ayala Mejias S, Molina Quiros C, Colmenero Ruiz M, Sanz Fernandez R. Sublingual immunotherapy in seasonal allergic rhinitis. Review of 30 cases. Acta Otorrinolaringol Esp. 2005;56(3):112–5. It does not meet ALL the inclusion criteria. [PubMed: 15819518]
  97. Belli E, Riccardino N. Variations in serum immunoglobulins during specific hyposensitization. G Batteriol Virol Immunol. 72; 65(5):178–81. Does not apply to any of the key questions. [PubMed: 4200184]
  98. BELLI N. Further contribution to the therapy of bronchial asthma. Praxis. 52; 41(52):1128–30. No SIT. [PubMed: 13047142]
  99. Bellussi L, Bologna M, Di Stanislao C, Lauriello M, Mezzedimi C, Muzi P, Passali GC, Passali D. Simplified local nasal immunotherapy in mite dust allergic rhinitis. J Investig Allergol Clin Immunol. 2002;12(1):42–7. Therapy NOT AVAILABLE in the U.S. [PubMed: 12109531]
  100. Berbis P, Carena MC, Auffranc JC, Privat Y. Cutaneo-systemic necrotizing vasculitis occurring during desensitization. Ann Dermatol Venereol. 86; 113(9):805–10. It does not meet ALL the inclusion criteria. [PubMed: 2881509]
  101. Berek-Pyzikowa B. Protective vaccinations in children with severe allergic reactions. Przegl Epidemiol. 69; 23(1):135–8. Does not apply to any of the key questions. [PubMed: 5790101]
  102. Berg T, Nordvall SL, Lanner A. Clinical studies of a purified timothy pollen extract. Desensitization therapy with a purified timothy pollen preparation compared to a crude timothy pollen extract. I. Results of tests in vivo. Int Arch Allergy Appl Immunol. 80; 63(3):266–74. It does not meet ALL the inclusion criteria no clinical outcomes. [PubMed: 7419290]
  103. Bernard R, Maurel P, Raquet J, Richez P. Pollinosis in children. Their treatment with delayed allergens. Pediatrie. 70; 25(8):883–6. Therapy NOT AVAILABLE in the U.S. [PubMed: 5494354]
  104. Bernardis P, Agnoletto M, Puccinelli P, Parmiani S, Pozzan M. Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients. J Investig Allergol Clin Immunol. 96; 6(1):55–62. Not an RCT. [PubMed: 8833170]
  105. Bernstein DI, Epstein T, Murphy-Berendts K, Liss GM. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol. 2010;104(6):530–5. It does not meet ALL the inclusion criteria. [PMC free article: PMC8246419] [PubMed: 20568387]
  106. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J Allergy Clin Immunol. 2004;113(6):1129–36. No SIT. [PubMed: 15208595]
  107. Bernstein IL, Michael JG, Malkiel S, Sweet LC, Brackett Immunoregulatory function of specific IgG. II. Clinical evaluation of combined active and passive immunotherapy. Int Arch Allergy Appl Immunol. 79; 58(1):30–7. Therapy NOT AVAILABLE in the U.S. [PubMed: 84797]
  108. Bernstein JA. Pharmacoeconomic considerations for allergen immunotherapy. Clin Allergy Immunol. 2004;18:151–64. It does not meet ALL the inclusion criteria. [PubMed: 15042914]
  109. Berto P, Bassi M, Incorvaia C, Frati F, Puccinelli P, Giaquinto C, Cantarutti L, Ortolani C. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Eur Ann Allergy Clin Immunol. 2005;37(8):303–8. It does not meet ALL the inclusion criteria. [PubMed: 17066648]
  110. Berto P, Frati F, Incorvaia C. Economic studies of immunotherapy: a review. Curr Opin Allergy Clin Immunol. 2008;8(6):585–9. It does not meet ALL the inclusion criteria. [PubMed: 18985948]
  111. Berto P, Frati F, Incorvaia C, Cadario G, Contiguglia R, Di Gioacchino M, Puccinelli P, Senna GE, Valle C. Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study. Curr Med Res Opin. 2008;24(1):261–6. It does not meet ALL the inclusion criteria. [PubMed: 18053319]
  112. Berto P, Passalacqua G, Crimi N, Frati F, Ortolani C, Senna G, Canonica GW. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol. 2006;97(5):615–21. It does not meet ALL the inclusion criteria. [PubMed: 17165269]
  113. Bigoni A. Report of an unusual case of a phenomenom of the Arthus type following specific desensitization. Arcisp S Anna Ferrara. 68; 21 Suppl:901–6. Other reason for exclusion (specify):case report Not an RCT. [PubMed: 4240405]
  114. Blair H. Hyposensitization for hay fever. Clin Allergy. 77; 7(3):291–4. Other reason for exclusion (specify): letter. [PubMed: 908127]
  115. Blaiss MS. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proc. 2010;31(5):375–80. It does not meet ALL the inclusion criteria. [PubMed: 20929603]
  116. Blaiss MS. Important aspects in management of allergic rhinitis: compliance, cost, and quality of life. Allergy Asthma Proc. 2003;24(4):231–8. It does not meet ALL the inclusion criteriaNo original data. [PubMed: 12974189]
  117. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy. 2008;63(3):374. Other reason for exclusion (specify):case report. [PubMed: 18076729]
  118. Bleda C, Soler R, Romaguera A, Mas S, Juan JM. Immunotherapy is effective in the treatment of allergic rhinitis. Retrospective study of 67 cases. Acta Otorrinolaringol Esp. 98; 49(5):369–72. Not an RCT. [PubMed: 9717325]
  119. Bodtger U, Poulsen LK, Malling HJ. Retrospective assessment of seasonal allergic symptoms: over-rating but useful. Clin Exp Allergy. 2003;33(4):496–500. Does not apply to any of the key questions. [PubMed: 12680866]
  120. Bohle B. Immunological mechanisms in sublingual immunotherapy. Drugs Today (Barc). 2008;44 Suppl B:95–6. No original data. [PubMed: 19221631]
  121. Bonifazi F. Immunotherapy in pollen and mould asthma. Monaldi Arch Chest Dis. 94; 49(2):150–3. It does not meet ALL the inclusion criteriaNo original data. [PubMed: 8049700]
  122. Bonneau JC, Drouet M, Le Sellin J, Sabbah A. Type III (Arthus) reaction during desensitization. Allerg Immunol (Paris). 86; 18(4):13–6. Other reason for exclusion (specify): [PubMed: 2969249]
  123. Bonnin AJ, Zacharias DM. Sublingual immunotherapy. N Engl J Med. 2008;359(8):869–70. author reply 870. It does not meet ALL the inclusion criteria. [PubMed: 18716310]
  124. Boquete M, Carballada F, Exposito F, Gonzalez A. Preventive immunotherapy. Allergol Immunopathol (Madr). 2000;28(3):89–93. Other reason for exclusion (specify): review. [PubMed: 10867376]
  125. Borchers AT, Keen CL, Gershwin ME. Fatalities following allergen immunotherapy. Clin Rev Allergy Immunol. 2004;27(2):147–58. No original data. [PubMed: 15576898]
  126. Bordignon V, Burastero SE. Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2006;97(2):158–63. It does not meet ALL the inclusion criteria. [PubMed: 16937744]
  127. Botey J, Eseverri JL, Marin AM. Do nasal and conjunctival provocation tests represent a trustworthy parameter for the follow-up of childhood IgE-dependent bronchial asthma? Allerg Immunol (Paris). 96; 28(2):52–4. It does not meet ALL the inclusion criteria. [PubMed: 8703310]
  128. Bousquet J, Malling HJ. Immunotherapy vs inhaled budesonide in bronchial asthma: an open, parallel comparative trial. Clin Exp Allergy. 98; 28(6):778. No original data. [PubMed: 9677145]
  129. Bousquet J, Braquemond P, Feinberg J, Guerin B, Maasch H, Michel FB. Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy. Ann Allergy. 86; 56(6):456–9. It does not meet ALL the inclusion criteriad. [PubMed: 3717711]
  130. Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol. 89; 83(4):797–802. It does not meet ALL the inclusion criteria. [PubMed: 2708740]
  131. Bousquet J, Hejjaoui A, Skassa-Brociek W, Guerin B, Maasch HJ, Dhivert H, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol. 87; 80(4):591–8. Therapy NOT AVAILABLE in the U.S. [PubMed: 3668124]
  132. Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB, Pauli G, Caillaud D, Dubost R, Leynadier F, Vervloet D, Herman D, Galvain S, Andre C. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy. 99; 54(3):249–60. It does not meet ALL the inclusion criteriaOther reason for exclusion (specify):no lung function. [PubMed: 10321561]
  133. Bowser C, Erstein DP, Silverberg JI, Nowakowski M, Joks R. Correlation of plasma complement split product levels with allergic respiratory disease activity and relation to allergen immunotherapy. Ann Allergy Asthma Immunol. 2010;104(1):42–9. It does not meet ALL the inclusion criteriaOther reason for exclusion (specify):no comp gr. [PubMed: 20143644]
  134. Bradding P. Allergen immunotherapy and mast cells. Clin Exp Allergy. 99; 29(11):1445–8. No original data. [PubMed: 10520069]
  135. Branco Ferreira M, Spinola Santos A, Pereira Santos MC, Palma Carlos ML, Pereira Barbosa MA, Palma Carlos AG. Efficacy and safety of specific immunotherapy with a modified mite extract. Allergol Immunopathol (Madr). 2005;33(2):80–5. Therapy NOT AVAILABLE in the U.S. [PubMed: 15808114]
  136. Branco-Ferreira M, Clode MH, Palma-Carlos AG. Distal digital vasculitis induced by specific immunotherapy. Allergy. 98; 53(1):102–3. Other reason for exclusion (specify):case report. [PubMed: 9491238]
  137. Brechter C, Rorsman H. Basophil leukocytes in hyposensitisation. Int Arch Allergy Appl Immunol. 65; 28(1):35–40. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 5862063]
  138. Bringel H, Vela C, Urena V, Gurbindo D, Garcia R, Lahoz C. IgG antibodies: in vitro blocking activity of IgE mediated reactions. Clin Allergy. 82; 12(1):37–46. It does not meet ALL the inclusion criteria. [PubMed: 6175439]
  139. Broman P, Moller E. Lymphocyte transformation by grass pollen allergens. A study of atopic patients receiving immunotherapy. Allergy. 84; 39(4):297–308. Therapy NOT AVAILABLE in the U.S. [PubMed: 6731755]
  140. Broman P, Moller E. Lymphocyte transformation by grass pollen allergens: a study of atopic patients receiving immunotherapy. Part II. Patients during maintenance treatment. Allergy. 88; 43(5):321–31. Does not apply to any of the key questions Other reason for exclusion (specify):No asthma or rhinitis. [PubMed: 3414911]
  141. Bronchial asthma in children. Sublingual immunotherapy treatment alternative with dermatofhagoides pteronyssinus. Library unable to locate.
  142. Brostoff J, Ganderton MA. Co-seasonal prick desensitization in summer hay fever. Acta Allergol. 68; 23(1):35–8. It does not meet ALL the inclusion criteria. [PubMed: 5694850]
  143. Brostoff J. Cellular and humoral effects of hyposensitization in patients with summer hay fever. Int Arch Allergy Appl Immunol. 73; 45(1):162–9. Does not apply to any of the key questions. [PubMed: 4580371]
  144. BROWN EA. RAGWEED POLLINOSIS. THE TREATMENT OF POLLINOSIS BY MEANS OF EMULSIFIED EXTRACTS XXVII. A STUDY OF 1809 PATIENTS STUDIED FOR THE 1962 RAGWEED POLLEN SEASON. Ann Allergy. 63(21):505–27. Therapy NOT AVAILABLE in the U.S. [PubMed: 14064967]
  145. Bruggenjurgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U, Willich SN. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann Allergy Asthma Immunol. 2008;101(3):316–24. Does not apply to any of the key questions. [PubMed: 18814456]
  146. Brunet C, Bedard PM, Lavoie A, Jobin M, Hebert J. Allergic rhinitis to ragweed pollen. II. Modulation of histamine-releasing factor production by specific immunotherapy. J Allergy Clin Immunol. 92; 89(1 Pt 1):87–94. It does not meet ALL the inclusion criteriadNot an RCT. [PubMed: 1370511]
  147. Brunner FX. Allergic rhinitis in childhood--therapy and therapeutic success in a 5-year observation period. Laryngol Rhinol Otol (Stuttg). 86; 65(5):260–3. It does not meet ALL the inclusion criteria. [PubMed: 3736289]
  148. Bruttmann G, Agnius-Delord C. IgE changes in pollinosis after desensitization. Nouv Presse Med. 76; 5(38):2544–2547. It does not meet ALL the inclusion criteria. [PubMed: 980767]
  149. Bruun E. Treatment of hay fever with an aluminum--precipitated pyridine grass pollen extract ("Allpyral grass mix"). Ugeskr Laeger. 67; 129(26):874–6. Therapy NOT AVAILABLE in the U.S. [PubMed: 5599499]
  150. Buchanan DJ, Hillis A, Williams PN. A double blind controlled trial of Bencard house dust mite (Migen) hyposensitisation in Zambian asthmatics. Med J Zambia. 80–81; 15(1):14–6. It does not meet ALL the inclusion criteria. [PubMed: 6821012]
  151. Buenfil Lopez JA. Immunotherapy in childhood asthma. Rev Alerg Mex. 97; 44(3):67–9. It does not meet ALL the inclusion criteria.
  152. Bulakhova EK. The efficacy of specific hyposensitization in bronchial asthma and pollinosis. Vrach Delo. 91(2):89–91. Other reason for exclusion (specify): [PubMed: 2058136]
  153. Bunnag C, Dhorranintra B. A preliminary study of circulating immune complexes during allergen immunotherapy in Thai patients. Asian Pac J Allergy Immunol. 89; 7(1):15–21. It does not meet ALL the inclusion criteria. [PubMed: 2526632]
  154. Burgi H, Regli J. Experiences with the immunotherapy of chronic asthmatic bronchitis. Schweiz Med Wochenschr. 67; 97(31):1007–8. It does not meet ALL the inclusion criteria. [PubMed: 5593638]
  155. Businco L, Zannino L, Cantani A, Corrias A, Fiocchi A, La Rosa M. Systemic reactions to specific immunotherapy in children with respiratory allergy: a prospective study. Pediatr Allergy Immunol. 95; 6(1):44–7. It does not meet ALL the inclusion criteria. [PubMed: 7550765]
  156. Bystrzanowska T, Majchrzak M, Poplawski B. Results of desensitization treatment in allergic rhinitis. Pol Tyg Lek. 76; 31(21):881–4. Other reason for exclusion (specify): [PubMed: 951244]
  157. Antunez C, Mayorga C, Corzo JL, Jurado A, Torres MJ. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration. Pediatr Allergy Immunol. 2008;19(3):210–8. It does not meet ALL the inclusion criteria. [PubMed: 18399897]
  158. Wen CJ, Zhu MF, Ren WM, Liu XY, Qian H. Clinical efficacy and safety of sublingual immunotherapy using standardized dermatophagoides farinae extract for children with combined allergic rhinitis and asthma syndrome. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011;46(5):393–6. Not an RCT. [PubMed: 21781561]
  159. Naspitz CK, Warner JO. Children are pharmaco-therapeutic orphans. Pediatric Allergy and Immunology. 2010;21(2 PART 1):249–250. Does not apply to any of the key questions No SITOther reason for exclusion (specify):Editorial. [PubMed: 20444165]
  160. Rondon C, Blanca-Lopez N, Aranda A, Herrera R, Rodriguez-Bada JL, Canto G, Mayorga C, Torres MJ, Campo P, Blanca M. Local allergic rhinitis: Allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen. Journal of Allergy and Clinical Immunology. 2011;127(4):1069–1071. Other reason for exclusion (specify):correspondence with pilot observational dataNot an RCT. [PubMed: 21277626]
  161. Hankin CS, Lockey RF. Patient characteristics associated with allergen immunotherapy initiation and adherence. Journal of Allergy and Clinical Immunology. 2011;127(1):46–48. e3. Not an RCT. [PubMed: 21093021]
  162. Wang CS, Zhang W, Wang XD, Xi L, Ouyang YH, Zhao Y, Wang Y, Zhang L. Clinical efficacy and immunological changes in children with allergic rhinitis receiving specific immunotherapy with Dermatophagoides pteronyssinus. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011;46(1):36–9. Other reason for exclusion (specify):chinese. [PubMed: 21429334]
  163. Vidal C, Tabar AI, Figueroa J, Navarro JA, Sanchez C, Orovitg A, Armisen M, Echechipia S, Joral A, Lizarza S, Lizaso MT, Rodriguez V, de la Torre F. Assessment of short-term changes induced by a Dermatophagoides pteronyssinus extract on asthmatic patients. Randomised, double-blind, placebo-controlled trial. Current drug delivery. 2011;8(2):152–158. It does not meet ALL the inclusion criteria. [PubMed: 21235477]
  164. Cabrera GE, Citera G, Gutierrez M, Scopelitis E, Espinoza LR. Digital vasculitis following allergic desensitization treatment. J Rheumatol. 93; 20(11):1970–2. It does not meet ALL the inclusion criteria. [PubMed: 8308789]
  165. Calvo M, Marin F, Grob K, Sanhueza M, Kylling L, Albornoz C, Strickler A. Ten-year follow-up in pediatric patients with allergic bronchial asthma: evaluation of specific immunotherapy. J Investig Allergol Clin Immunol. 94; 4(3):126–31. It does not meet ALL the inclusion criteria. [PubMed: 7981882]
  166. Cambri S, Tarantino G, Cambri V. Is the diagnostic differentiation between Parietaria officinalis and Parietaria judaica important for the specific immunotherapy? Clin Ter. 86; 119(4):269–73. It does not meet ALL the inclusion criteria. [PubMed: 3802737]
  167. Campbell JD, Buchmann P, Kesting S, Cunningham CR, Coffman RL, Hessel EM. Allergen-specific T cell responses to immunotherapy monitored by CD154 and intracellular cytokine expression. Clin Exp Allergy. 2010;40(7):1025–35. Does not apply to any of the key questionsStudy evaluates outcomes in animals only or in vitro. [PubMed: 20412135]
  168. Can allergy shots provide relief from hay fever even after the shots are discontinued? Mayo Clin Health Lett. 2000;18(6):8. No original data. [PubMed: 10868134]
  169. Can nasal ECP help to predict clinical outcome of specific immunotherapy in mite-allergic rhinitis patients? Library unable to locate.
  170. Can serum specific IgE/total IgE ratio predict clinical response to allergenspecific immunotherapy in children monosensitised to house dust mite? Meeting abstract. [PMC free article: PMC3321312] [PubMed: 22536274]
  171. Can D, Demir E, Tanac R, Gulen F, Yenigun A. Immediate adverse reactions to immunotherapy. J Investig Allergol Clin Immunol. 2003;13(3):177–80. Not an RCT. [PubMed: 14635467]
  172. Can D, Tanac R, Demir E, Gulen F, Veral A. Efficacy of pollen immunotherapy in seasonal allergic rhinitis. Pediatr Int. 2007;49(1):64–9. It does not meet ALL the inclusion criteria. [PubMed: 17250508]
  173. Canonica GW, Mingari MC, Melioli G, Colombatti M, Moretta L. Imbalances of T cell subpopulations in patients with atopic diseases and effect of specific immunotherapy. J Immunol. 79; 123(6):2669–72. Therapy NOT AVAILABLE in the U.S. [PubMed: 315429]
  174. Canos Molinos J, Munoz-Lopez F. Value of serum IgG subclasses in the prognosis of asthma in children with immunotherapy treatment. Allergol Immunopathol (Madr). 97; 25(1):10–7. Does not apply to any of the key questions. [PubMed: 9111871]
  175. Cantani A, Ciaschi V. Epidemiology of alternaria alternata allergy: a prospective study in 6840 Italian asthmatic children. Eur Rev Med Pharmacol Sci. 2004;8(6):289–94. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 15745389]
  176. Cantani A, Micera M. A prospective study of asthma desensitization in 1182 children, 592 asthmatic children and 590 nonatopic controls. Eur Rev Med Pharmacol Sci. 2005;9(6):325–9. Does not apply to any of the key questions. [PubMed: 16479736]
  177. Cantani A, Micera M. Is specific immunotherapy safe and effective in children? Eur Rev Med Pharmacol Sci. 2000;4(5–6):139–43. No original data. [PubMed: 11710512]
  178. Cantani A, Micera M. Significant decrease of IgE antibodies after a three-year controlled study of specific immunotherapy to pollen allergens in children with allergic asthma. Eur Rev Med Pharmacol Sci. 2005;9(2):103–11. It does not meet ALL the inclusion criteria. [PubMed: 15945499]
  179. Cantani A, Arcese G, Di Rienzo A, Lucenti P. Immunotherapy for asthma. Ann Allergy Asthma Immunol. 98; 80(2):213–4. No original data. [PubMed: 9494457]
  180. Cantani A, Arcese G, Gagliesi D, Lucenti P. Specific immunotherapy in children is safe and effective. Eur Rev Med Pharmacol Sci. 98; 2(1):41–4. No original data. [PubMed: 9825570]
  181. Cantani A, Businco E, Maglio A. Alternaria allergy: a three-year controlled study in children treated with immunotherapy. Allergol Immunopathol (Madr). 88; 16(1):1–4. It does not meet ALL the inclusion criteria. [PubMed: 3381709]
  182. Cantani A, Businco E, Benincori N, de Angelis M, di Fazio A, Businco L. A three year controlled study in children with pollinosis treated with immunotherapy. Ann Allergy. 84; 53(1):79–84. Therapy NOT AVAILABLE in the U.S. [PubMed: 6377983]
  183. Cao LF, Lu Q, Gu HL, Chen YP, Zhang Y, Lu M, Qian YQ, Li L, Xu YP. Clinical evaluation for sublingual immunotherapy of allergic asthma and atopic rhinitis with Dermatophagoides Farinae Drops. Zhonghua Er Ke Za Zhi. 2007;45(10):736–41. Non-English article. [PubMed: 18211754]
  184. Capristo A, Comune V, Maiello N, Miraglia Del Giudice M. Long-term studies of respiratory function during hyposensitization therapy of childhood asthma. Pediatria (Napoli). 79; 87(2):183–95. No original data. [PubMed: 548913]
  185. Capristo A, Maiello N, Barra R, Salzano V, Miraglia Del Giudice M. Long-term clinical and laboratory findings in a group of asthmatic children treated for 3 years with a specific desensitizing therapy. Pediatria (Napoli). 80; 88(2):171–87. It does not meet ALL the inclusion criteria. [PubMed: 7243516]
  186. Carbone R, Luppi F, Monselise A, Bottino G. Bronchial hyperresponsiveness in asthmatic adults--a long-term correlation study. Eur Rev Med Pharmacol Sci. 2005;9(2):125–31. It does not meet ALL the inclusion criteria. [PubMed: 15945502]
  187. Carnimeo N, Valerio G, Resta O, Lopez M. Computerized analysis of methodological data and clinical reports concerning a group of 400 asthmatic patients undergoing immunotherapy. Arch Monaldi. 79; 34(1–2):42–8. It does not meet ALL the inclusion criteria. [PubMed: 400094]
  188. Carron R, Tuaillon C, Brodschi M, Chalamelle MJ. Allergic asthma in children treated by desensitization: 12 years experience; results, considerations. Lyon Med. 70; 223(2):111–25. It does not meet ALL the inclusion criteria. [PubMed: 5434511]
  189. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117(1):134–40. Does not apply to any of the key questions. [PubMed: 16387596]
  190. Casgrain G, Leger J, Leger F. A slowly absorbed pollen extract: follow-up of a clinical study. Union Med Can. 65; 94(6):808–10. It does not meet ALL the inclusion criteria. [PubMed: 5836074]
  191. CASGRAIN G, LEGER J, LEGER F. CLINICAL STUDY OF A NEW POLLEN EXTRACT OF SLOW ABSORPTION. Union Med Can. 64; 93:302–4. It does not meet ALL the inclusion criteria. [PubMed: 14142342]
  192. Castell M, Castellote C, Barbera G. Detection of blocking antibodies after hyposensitization. Immunobiology. 85; 169(1):30–6. It does not meet ALL the inclusion criteria. [PubMed: 3988313]
  193. Castellote MC, Duran N, Barbera G, Torralba A. Levels of complement factors and immunoglobulins in asthmatic children undergoing hyposensitization. Allergol Immunopathol (Madr). 84; 12(4):259–66. Does not apply to any of the key questions. [PubMed: 6507222]
  194. Castellote MC, Munoz Lopez F, Barbera G, Torralba A. Urinary excretion of cyclic-AMP and cyclic-GMP in allergic children throughout seven months of hyposensitization treatment. Ann Allergy. 81; 46(5):281–3. It does not meet ALL the inclusion criteria, C, D. [PubMed: 6263134]
  195. Castracane JM, Rocklin RE. Detection of human auto-anti-idiotypic antibodies (Ab2). II. Generation of Ab2 in atopic patients undergoing allergen immunotherapy. Int Arch Allergy Appl Immunol. 88; 86(3):295–302. It does not meet ALL the inclusion criteria. [PubMed: 3261276]
  196. Cengizlier R, Saraclar Y, Adalioglu C, Tuncer A. Changes in nasal metachromatic cells during allergen immunotherapy in children. Allergol Immunopathol (Madr). 95; 23(3):111–6. It does not meet ALL the inclusion criteria. [PubMed: 7572539]
  197. Cengizlier R, Saraclar Y, Tomac N. Evaluation of immunotherapy by nasal antigen challenge. J Otolaryngol. 99; 28(4):185–8. [PubMed: 10461254]
  198. Centanni G. Comparison of the therapeutic results obtained with alum-pyridine pollen extracts and aqeuous extracts. Folia Allergol (Roma). 70; 17(3):309–26. Therapy NOT AVAILABLE in the U.S. [PubMed: 5517222]
  199. Cernelc D, Cernelc M. Prognosis of bronchial asthma in children after specific subcutaneous hyposensitization (SSH) and nonspecific treatment (NT). Allerg Immunol (Leipz). 72; 18(3):167–76. It does not meet ALL the inclusion criteria. [PubMed: 4269349]
  200. Cernelc D, Bohinjec M, Cernelc P. Some results of various methods of specific hyposensitization in asthmatic children. Monatsschr Kinderheilkd. 76; 124(5):250–1. It does not meet ALL the inclusion criteria. [PubMed: 934082]
  201. Cernelc D, Vozelj M, Wraber T. Immunotherapy of pollinosis caused by Ambrosia artemisiifolia (author’s transl). Plucne Bolesti Tuberk. 78; 30(1–2):70–6. Non-English article: serb. [PubMed: 97693]
  202. Cernelc VD, Bobinjec M, Cernelc S. Epidemiology, diagnosis and treatment of the house-dust-mite allergy in asthmatic children. Allerg Immunol (Leipz). 74–75; 20–21(1):1–6. It does not meet ALL the inclusion criteria. [PubMed: 4282821]
  203. Cevit O, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Specific allergen immunotherapy: effect on immunologic markers and clinical parameters in asthmatic children. J Investig Allergol Clin Immunol. 2007;17(5):286–91. It does not meet ALL the inclusion criteria. [PubMed: 17982919]
  204. Chang H, Han DH, Mo JH, Kim JW, Kim DY, Lee CH, Min YG, Rhee CS. Early compliance and efficacy of sublingual immunotherapy in patients with allergic rhinitis for house dust mites. Clin Exp Otorhinolaryngol. 2009;2(3):136–40. obs case series. [PMC free article: PMC2751878] [PubMed: 19784406]
  205. Chang J, Hong CS. The effect of immunotherapy on nonspecific bronchial hyperresponsiveness in bronchial asthma and allergic rhinitis. Yonsei Med J. 2001;42(1):106–13. It does not meet ALL the inclusion criteria. [PubMed: 11293488]
  206. Changes in bronchial reactivity to histamine in the course of allergen immunotherapy in seasonal allergic rhinitis patients -are they really caused by the treatment? Comparison of two schedules, Maintenance versus pre-seasonal. Meeting abstract.
  207. CHARPIN J, ROCCA-SERRA JP. Vaccinations in the asthmatic patient. J Fr Med Chir Thorac. 61; 15:667–71. No SIT. [PubMed: 13878330]
  208. Charpin J, Aubert J, Roccaserra JP, Zafiropoulo A. Treatment of Graminaceae pollinosis by Allpyral. Mars Med. 66; 103(12):967–70. Therapy NOT AVAILABLE in the U.S. [PubMed: 5991240]
  209. CHARPIN J, ZAFIROPOULO A, AUBERT J. SPECIFIC DESENSITIZATION IN THE TREATMENT OF BRONCHIAL ASTHMA. Minerva Med. 64; 55:1243–6. No original data. [PubMed: 14144104]
  210. Check WA. Modified antigen therapy aids allergy victims. JAMA. 82; 247(16):2202–3. No original data. [PubMed: 7069868]
  211. Chen LL, Li AS, Tao JN, Chen WX, Tang RF. Clinical and experimental studies on preventing and treating anaphylactic asthma with Zusanli(ST36) point immunotherapy. Journal of Integrated Traditional and Western Medicine / Zhongguo Zhong Xi Yi Jie He Za Zhi. Does not apply to any of the key questions. [PubMed: 9772584]
  212. Chen J, Kong W, Xiang J, Lu Z, Zhou Y. Compliance analysis of sublingual immunotherapy and countermeasures. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010;24(5):203–6. It does not meet ALL the inclusion criteriad. [PubMed: 20464985]
  213. Chen J, Kong W, Xiang J, Shu H, Shi Q, Tan H, Lu Z, Zhou Y, Zhang X. Efficacy evaluation of specific immunotherapy with standardized dermatophagoides pteronyssinus extract for allergic rhinitis accompanied with asthma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010;24(2):57–9. Not an RCT. [PubMed: 20306851]
  214. Chen WY, Yu J, Wang JY. Decreased production of endothelin-1 in asthmatic children after immunotherapy. J Asthma. 95; 32(1):29–35. It does not meet ALL the inclusion criteriad. [PubMed: 7844086]
  215. Chen WY, Yu J, Wang JY. The effect of immunotherapy on bronchial hyperresponsiveness in asthmatic children. Asian Pac J Allergy Immunol. 94; 12(1):15–20. Does not apply to any of the key questions. [PubMed: 7872988]
  216. Chen ZG, Chen YF, Li M, Ji JZ, Chen FH, Chen H. Effects of Dermatophagoides pteronyssinus allergen-specific immunotherapy on the prognosis of asthmatic children. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29(6):1179–81. Not an RCT. [PubMed: 19726355]
  217. Chen ZG, Li M, Chen YF, Ji JZ, Li YT, Chen W, Chen FH, Chen H. Effects of dermatophagoides pteronyssinus allergen-specific immunotherapy on the serum interleukin-13 and pulmonary functions in asthmatic children. Chin Med J (Engl). 2009;122(10):1157–61. It does not meet ALL the inclusion criteria. [PubMed: 19493463]
  218. Cheng L, Li HB. Specific immunotherapy of allergic rhinitis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2008;43(1):73–6. Non-English article. [PubMed: 18357723]
  219. Cheng Z, Wang X, Wang G, Shu C, Cheng Y. An experimental study on the regulation of expression of Thq/Th2 cytokines by allergen vaccine atomization inhalation in patients with asthma. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006;20(17):790–2. Does not apply to any of the key questions. [PubMed: 17087116]
  220. Chernokhvostova EV, Kotova TS, Atovmian OI, Arsen’eva EL, Bogacheva GT, Rokhlin OV. Immunoenzyme test system with monoclonal antibodies to human IgG4 in the determination of allergen-specific antibodies in pollinosis. Biull Eksp Biol Med. 89; 108(11):574–7. Does not apply to any of the key questions. [PubMed: 2633822]
  221. Chiang BL, Lu FM, Chuang YH, Chou CC, Hsieh KH. Change of chemokines during immunotherapy in asthmatic children. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 96; 37(5):324–32. Number of subjects in study is 6 or fewer on active treatment (Unless it reports harms) [PubMed: 8942025]
  222. Chiang BL, Tsai MJ, Chou CC, Hsieh KH. In vitro production of cytokines and allergen-specific IgE in bronchial asthmatic children with different disease activity. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 98; 39(3):173–9. Does not apply to any of the key questionsStudy evaluates outcomes in animals only or in vitro. [PubMed: 9684522]
  223. Chien YK, Anfosso F, Charpin J. IgE and IgG1, 2, 4 in desensitization of pollen asthma. Hawaii Med J. 84; 43(11):410–412. It does not meet ALL the inclusion criteria. [PubMed: 6511391]
  224. Chien YK, Yang WP, Xue ZL, Massey DG. House dust mite asthma in China: a review. Ann Allergy. 87; 59(2):147–8. No original data. [PubMed: 3304031]
  225. Chikamatsu K, Sakakura K, Matsuoka T, Endo S, Takahashi G, Matsuzaki Z, Masuyama K. Analysis of T-helper responses and FOXP3 gene expression in patients with Japanese cedar pollinosis. Am J Rhinol. 2008;22(6):582–8. Does not apply to any of the key questions Not an RCT. [PubMed: 19178794]
  226. Choi IS, Koh YI, Chung SW, Wi JO, Sim DS. Late local urticaria as a long-term sequela of allergen-specific immunotherapy. Korean J Intern Med. 2004;19(3):202–4. It does not meet ALL the inclusion criteria. [PMC free article: PMC4531568] [PubMed: 15481615]
  227. Choovoravech P. Effect of immunotherapy: treatment with mite and other aeroallergens in Thai allergic patients. J Med Assoc Thai. 80; 63(9):506–11. Does not apply to any of the key questions. [PubMed: 7420002]
  228. Choovoravech P. Effects of immunotherapy on Thai asthmatic children. Asian Pac J Allergy Immunol. 84; 2(1):32–6. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 6529481]
  229. Choquet PH, Nguyen B, Vai F, Guerin B, Sauvaget J. Accelerated desensitization in asthma caused by cat fur. Presse Med. 87; 16(3):126–7. It does not meet ALL the inclusion criteria. [PubMed: 2950435]
  230. Chowdhury I, Chatterjee B. The immunological and clinical effects of immunotherapy in patients suffering from house dust allergy. Ann Agric Environ Med. 99; 6(2):91–7. It does not meet ALL the inclusion criteria. [PubMed: 10607989]
  231. Chu JC, Wun TH, Chen XJ. Treatment of asthmatic patients sensitive to mites (Dermatophagoides farinae); a four-year study of immunotherapy with an extract of Dermatophagoides farinae. Ann Allergy. 81; 47(2):107–9. It does not meet ALL the inclusion criteria. [PubMed: 7258740]
  232. Chuchalin AG, Raudla LA, Tatarskii AR, Shurkalin BK, Evseev NG. Extracorporeal specific immunosorption in the complex treatment of patients with bronchial asthma and hypersensitivity to house dust allergen. Ter Arkh. 84; 56(6):24–8. Does not apply to any of the key questions. [PubMed: 6474372]
  233. Cingi C, Aynaci S, Cakli H, Cingi E, Ozudogru E, Kecik C, Altin F, Bal C. Efficacy of long-term sublingual-oral immunotherapy in allergic rhinitis. Acta Otorhinolaryngol Ital. 2005;25(4):214–9. It does not meet ALL the inclusion criteria. [PMC free article: PMC2639887] [PubMed: 16482978]
  234. Ciprandi G, Cadario G, Di Gioacchino GM, Gangemi S, Gasparini A, Isola S, Marengo F, Minelli S, Ricciardi L, Ridolo E, Pravettoni V, Valle C, Verini M, Zambito M, Incorvaia C, Puccinelli P, Scurati S, Frati F, Simonetta M. Sublingual immunotherapy in children with allergic polysensitization. Allergy Asthma Proc. 2010;31(3):227–31. It does not meet ALL the inclusion criteria. [PubMed: 20615323]
  235. Ciprandi G, Cadario G, Di Gioacchino M, Gangemi S, Minelli M, Ridolo E, Valle C, Verini M, Boccardo R, Incorvaia C, Puccinelli P, Scurati S, Frati F. Sublingual immunotherapy in polysensitized allergic patients with rhinitis and/or asthma: allergist choices and treatment efficacy. J Biol Regul Homeost Agents. 2009;23(3):165–71. It does not meet ALL the inclusion criteria. [PubMed: 19828093]
  236. Ciprandi G, Cadario G, Valle C, Ridolo E, Verini M, Di Gioacchino M, Minelli M, Gangemi S, Sillano V, Colangelo C, Pravettoni V, Pellegrino R, Borrelli P, Fiorina A, Carosso A, Gasparini A, Riario-Sforza GG, Incorvaia C, Puccinelli P, Scurati S, Frati F. Sublingual immunotherapy in polysensitized patients: effect on quality of life. J Investig Allergol Clin Immunol. 2010;20(4):274–9. It does not meet ALL the inclusion criteria. [PubMed: 20815304]
  237. Ciprandi G, Cirillo I, Fenoglio D, Marseglia G, Tosca MA. Sublingual immunotherapy induces spirometric improvement associated with IL-10 production: preliminary reports. Int Immunopharmacol. 2006;6(8):1370–3. Therapy NOT AVAILABLE in the U.S. [PubMed: 16782551]
  238. Ciprandi G, Cirillo I, Tosca MA, Marseglia G, Fenoglio D. Sublingual immunotherapy-induced IL-10 production is associated with changed response to the decongestion test: preliminary results. Allergy Asthma Proc. 2007;28(5):574–7. It does not meet ALL the inclusion criteria. [PubMed: 18034978]
  239. Ciprandi G, Colombo BM, Murdaca G, De Amici M. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy. 2008;63(7):945–6. It does not meet ALL the inclusion criteria. [PubMed: 18588566]
  240. Ciprandi G, Contini P, Pistorio A, Murdaca G, Puppo F. Sublingual immunotherapy reduces soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis. Int Immunopharmacol. 2009;9(2):253–7. It does not meet ALL the inclusion criteria; control healthy. [PubMed: 19100344]
  241. Ciprandi G, Continia P, Fenoglio D, Sormani MP, Negrini S, Puppo F, Indiveri F. Relationship between soluble HLA-G and HLA-A,-B,-C serum levels, and interferon-gamma production after sublingual immunotherapy in patients with allergic rhinitis. Hum Immunol. 2008;69(7):409–13. Does not apply to any of the key questions. [PubMed: 18573288]
  242. Ciprandi G, De Amici M, Marseglia G. Serum adipsin levels in patients with seasonal allergic rhinitis: preliminary data. Int Immunopharmacol. 2009;9(12):1460–3. It does not meet ALL the inclusion criteria. [PubMed: 19699327]
  243. Ciprandi G, De Amici M, Murdaca G, Colombo BM, Quaglini S, Marseglia G, Di Gioacchino M. Serum IL-4 as a marker of immunological response to sublingual immunotherapy. J Biol Regul Homeost Agents. 2008;22(2):117–23. It does not meet ALL the inclusion criteria. [PubMed: 18597704]
  244. Ciprandi G, De Amici M, Murdaca G, Filaci G, Fenoglio D, Marseglia GL. Adipokines and sublingual immunotherapy: preliminary report. Hum Immunol. 2009;70(1):73–8. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 19028536]
  245. Ciprandi G, De Amici M, Negrini S, Marseglia G, Tosca MA. TGF-beta and IL-17 serum levels and specific immunotherapy. Int Immunopharmacol. 2009;9(10):1247–9. Does not apply to any of the key questions. [PubMed: 19622397]
  246. Ciprandi G, De Amici M, Tosca MA, Pistorio A, Marseglia GL. Sublingual immunotherapy affects specific antibody and TGF-beta serum levels in patients with allergic rhinitis. Int J Immunopathol Pharmacol. 2009;22(4):1089–96. Does not apply to any of the key questions. [PubMed: 20074473]
  247. Ciprandi G, De Amici M, Tosca M, Marseglia G. Serum transforming growth factor-beta levels depend on allergen exposure in allergic rhinitis. Int Arch Allergy Immunol. 2010;152(1):66–70. Does not apply to any of the key questions. [PubMed: 19940507]
  248. Ciprandi G, De Amici M, Tosca M, Negrini S, Murdaca G, Marseglia GL. Two year sublingual immunotherapy affects serum leptin. Int Immunopharmacol. 2009;9(10):1244–6. It does not meet ALL the inclusion criteria. [PubMed: 19497390]
  249. Ciprandi G, Fenoglio D, Cirillo I, Vizzaccaro A, Ferrera A, Tosca MA, Puppo F. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol. 2005;95(1):38–44. Does not apply to any of the key questions. [PubMed: 16095140]
  250. Ciprandi G, Fenoglio D, Di Gioacchino M, Ferrera A, Ferrera F, Sormani MP, Marseglia GL. Sublingual immunotherapy provides an early increase of interferon-gamma production. J Biol Regul Homeost Agents. 2008;22(3):169–73. Does not apply to any of the key questions. [PubMed: 18842170]
  251. Ciprandi G, Incorvaia C, Puccinelli P, Scurati S, Masieri S, Frati F. The POLISMAIL lesson: sublingual immunotherapy may be prescribed also in polysensitized patients. Int J Immunopathol Pharmacol. 2010;23(2):637–40. It does not meet ALL the inclusion criteria. [PubMed: 20646360]
  252. Ciprandi G, Murdaca G, Colombo BM, De Amici M, Marseglia GL. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum Immunol. 2008;69(8):510–2. It does not meet ALL the inclusion criteria. [PubMed: 18577409]
  253. Ciprandi G, Sormani MP, Cirillo I, Tosca M. Upper respiratory tract infections and sublingual immunotherapy: preliminary evidence. Ann Allergy Asthma Immunol. 2009;102(3):262–3. It does not meet ALL the inclusion criteria. [PubMed: 19354079]
  254. Ciprandi G, Sormani MP, Filaci G, Fenoglio D. Carry-over effect on IFN-gamma production induced by allergen-specific immunotherapy. Int Immunopharmacol. 2008;8(12):1622–5. It does not meet ALL the inclusion criteria. [PubMed: 18691675]
  255. Cirla AM, Cirla PE, Parmiani S, Pecora S. A pre-seasonal birch/hazel sublingual immunotherapy can improve the outcome of grass pollen injective treatment in bisensitized individuals. A case-referent, two-year controlled study. Allergol Immunopathol (Madr). 2003;31(1):31–43. It does not meet ALL the inclusion criteria. [PubMed: 12573207]
  256. Citron KM. Hyposensitization: assessment of results. Br J Dis Chest. 77; 71(4):241–2. Does not apply to any of the key questions. [PubMed: 338007]
  257. Citron KM. Injection treatment for desensitization in asthma, hay fever, and allergic rhinitis. Br J Dis Chest. 66; 60(1):1–9. No original data. [PubMed: 5920505]
  258. Clark J, Schall R. Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials. Allergy. 2007;62(9):1023–8. Does not apply to any of the key questions. [PubMed: 17686105]
  259. Clark RB, Burdett BR. Allergy immunotherapy. Am Fam Physician. 82; 26(5):219–23. No original data. [PubMed: 7148631]
  260. Clark TJ. Efficacy and safety of anti-asthma treatment. Allergy. 88; 43 Suppl 8:32–5. No original data. [PubMed: 3202280]
  261. Clarke PS. Dangers of immunotherapy for the treatment of asthma in children. Med J Aust. 90; 153(11–12):744. No original data. [PubMed: 2247014]
  262. Clarke PS. Immunotherapy in allergic asthma. Med J Aust. 81; 1(8):432. No original data. [PubMed: 7254097]
  263. Clarke PS. Improved diagnosis and treatment of allergic rhinitis by the use of nasal provocation tests. Ann Allergy. 88; 60(1):57–60. It does not meet ALL the inclusion criteria. [PubMed: 3337397]
  264. Clarke PS. Titration of immunotherapy by periodical nasal allergic challenges in the treatment of allergic rhinitis. Med J Aust. 92; 157(1):11–3. Does not apply to any of the key questions. [PubMed: 1640882]
  265. Clarke PS. Titration of immunotherapy. Med J Aust. 93; 158(2):142. No original data. [PubMed: 8419771]
  266. Clasen I, Wuthrich B. Recent results of peroral hyposensitization in infantile bronchial asthma. Monatsschr Kinderheilkd. 76; 124(5):248. It does not meet ALL the inclusion criteria. [PubMed: 934080]
  267. Clemmensen O, Knudsen HE. Contact sensitivity to aluminium in a patient hyposensitized with aluminium precipitated grass pollen. Contact Dermatitis. 80; 6(5):305–8. It does not meet ALL the inclusion criteria,d. [PubMed: 7418388]
  268. CLINICAL AND IMMUNOLOGIC EVALUATION OF A PURIFIED FRACTION OF RAGWEED POLLEN (DELTA). A DOUBLE-BLIND STUDY. Excluded at data abstraction. [PubMed: 14320908]
  269. Clinical data and inflammation parameters in patients with cypress allergy treated with sublingual swallow therapy and subcutaneous immunotherapy. Excluded at abstract level. [PubMed: 19505393]
  270. Clinical effect of sublingual immunotherapy in allergic rhinitis patients. Meeting abstract.
  271. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Duplicate. [PubMed: 20100188]
  272. Clinical efficacy and side effects of sublingual immunotherapy versus placebo in children with perennial allergic rhinitis and asthma, sensitised to house dust mites. Abstract only.
  273. Clinical efficacy of grass-pollen immunotherapy. Duplicate.
  274. Clinical efficacy of house dust mite-specific immunotherapy in asthmatic children. Excluded at data abstraction. [PubMed: 20225533]
  275. Clinical efficacy of sublingual immunotherapy in seasonal allergic asthma. Meeting abstract.
  276. Clinical efficacy of sublingual immunotherapy in patients with grass pollen induced respiratory allergy symptoms. Meeting abstract.
  277. Clinical outcome and IL-17, IL-23, IL-27 and FOXP3 expression in peripheral blood mononuclear cells of pollen-allergic children during sublingual immunotherapy. Part of 5734. [PubMed: 19566585]
  278. Cloninger PN, Stein HL, Nagy SM, Kemp JP, Turk A. The role of immunotherapy in asthma. Am Rev Respir Dis. 78; 118(2):447–8. No original data. [PubMed: 697196]
  279. Cochard MM, Eigenmann PA. Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy. J Allergy Clin Immunol. 2009;124(2):378–9. Other reason for exclusion (specify):case report. [PubMed: 19541352]
  280. Cohen GN. Asthma management includes desensitization injections. Am J Med. 95; 98(5):517–8. It does not meet ALL the inclusion criteriaNo original data. [PubMed: 7605455]
  281. Cohen SG. Lowell and Franklin on double-blind hyposensitization therapy for ragweed hay fever: the people. J Allergy Clin Immunol. 2004;113(6):1227–31. Does not apply to any of the key questions. [PubMed: 15208609]
  282. Cohen SG, Frankland AW, Dworetzky M. Noon and Freeman on prophylactic inoculation against hay fever. J Allergy Clin Immunol. 2003;111(5):1142–50. No original data. [PubMed: 12743591]
  283. Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol. 93; 91(3):734–7. It does not meet ALL the inclusion criteria. [PubMed: 8454795]
  284. Cohon A, Arruda LK, Martins MA, Guilherme L, Kalil J. Evaluation of BCG administration as an adjuvant to specific immunotherapy in asthmatic children with mite allergy. J Allergy Clin Immunol. 2007;120(1):210–3. Therapy NOT AVAILABLE in the U.S. [PubMed: 17531299]
  285. Coifman RE, Cox LS. 2006 American Academy of Allergy, Asthma & Immunology member immunotherapy practice patterns and concerns. J Allergy Clin Immunol. 2007;119(4):1012–3. Does not apply to any of the key questions. [PubMed: 17418663]
  286. Collins-Williams C. Non-allergic bronchial hyperreactivity in asthmatic children decreases with age and increases with mite immunotherapy. Ann Allergy. 86; 56(2):190–1. Other reason for exclusion (specify): letter. [PubMed: 3946852]
  287. Combination of immunotherapy and inhaled steroid therapy increase efficacy of the treatment in patient with allergic asthma to house dust mites. Library unable to locate.
  288. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy. 2009;64(11):1570–9. Other reason for exclusion (specify):meta-analysis. [PubMed: 19796205]
  289. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Library unable to locate. [PubMed: 22142341]
  290. Comparative Efficacy of Subcutaneous Immunotherapy, Sublingual Immunotherapy and Combined Subcutaneous and Sublingual Immunotherapy in Patients with Seasonal Allergic Rhinitis and Cross-Reactive Food Allergy Abstract. Abstract only.
  291. Comparative study of the effectiveness of 2 methods of specific immunotherapy of pollinoses. Library unable to locate. [PubMed: 2424113]
  292. Comparison of clinical efficacy and preventive role between subcutaneous and sublingual immunotherapy in children with seasonal allergic rhinitis. Meeting abstract.
  293. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Duplicate of 3490. [PubMed: 17523385]
  294. Comparison of nasal immunohistology in patients with seasonal rhinoconjunctivitis treated with topical steroids or specific allergen immunotherapy. Part of 4625. [PubMed: 15813810]
  295. Comparison of specific sublingual immunotherapy to homeopathic therapy in children with allergic rhinitis. Meeting abstract.
  296. Comparisons of alum-precipitated and unprecipitated aqueous ragweed pollen extracts in the treatment of hay fever. Excluded at data abstraction. [PubMed: 659729]
  297. Confino-Cohen R, Goldberg A. Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study. Ann Allergy Asthma Immunol. 2010;104(1):73–8. Not an RCT. [PubMed: 20143649]
  298. Connell JT, Sherman WB. Changes in skin-sensitizing antibody titer after injections of aqueous pollen extract. J Allergy. 69; 43(1):22–32. It does not meet ALL the inclusion criteria. [PubMed: 4973855]
  299. CONNELL JT, SHERMAN WB. SKIN-SENSITIZING ANTIBODY. II. RELATIONSHIP OF HAY FEVER SYMPTOMS TO THE SKIN-SENSITIZING ANTIBODY TITER IN PATIENTS TREATED WITH RAGWEED EMULSION INJECTIONS, AQUEOUS RAGWEED INJECTIONS OR NO INJECTION TREATMENT. J Allergy Clin Immunol. 64; 35:18–26. Therapy NOT AVAILABLE in the U.S. [PubMed: 14104250]
  300. Cook N. Pre-seasonal local nasal desensitization in hay fever. J Laryngol Otol. 74; 88(12):1169–74. It does not meet ALL the inclusion criteria. [PubMed: 4452801]
  301. Cook PR. Allergic rhinitis. Outcomes of immunotherapy on symptom control. Otolaryngol Clin North Am. 98; 31(1):129–40. No original data. [PubMed: 9530682]
  302. Cools M, Van Bever HP, Weyler JJ, Stevens WJ. Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen. Allergy. 2000;55(1):69–73. It does not meet ALL the inclusion criteria. [PubMed: 10696859]
  303. Coop CA, Tankersley MS. Dose adjustment practices among allergists for local reactions to immunotherapy. Ann Allergy Asthma Immunol. 2007;99(1):77–81. Does not apply to any of the key questions. [PubMed: 17650834]
  304. Cooper B. Migen in the treatment of perennial rhinitis. Br J Clin Pract. 79; 33(11–12):323–4. It does not meet ALL the inclusion criteria. [PubMed: 540088]
  305. Cooper PJ, Darbyshire J, Nunn AJ, Warner JO. A controlled trial of oral hyposensitization in pollen asthma and rhinitis in children. Clin Allergy. 84; 14(6):541–50. Therapy NOT AVAILABLE in the U.S. [PubMed: 6391735]
  306. Corbetta L, Pesiri P, Ferro G, Mander A. Improvement of fog and exercise-induced bronchoconstriction after local and subcutaneous immunotherapy in mite asthma. Allergol Immunopathol (Madr). 92; 20(2):61–6. It does not meet ALL the inclusion criteria. [PubMed: 1442451]
  307. Corrigan C. Sublingual immunotherapy. J Allergy Clin Immunol. 2007;119(2):515. author reply 515–7. No original data. [PubMed: 17187850]
  308. Cousergue JL. Results of allergenic desensitization in asthmatics in Morocco. Study of 200 cases. Maroc Med. 70; 537:437–42. Other reason for exclusion (specify):I observational data - Non-English article. [PubMed: 5503092]
  309. Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol. 2006;97(2):126–37. quiz 137–40, 202. No original data. [PubMed: 16937741]
  310. Cox L. Allergen immunotherapy. Ann Allergy Asthma Immunol. 2003;91(1):96–7. author reply 97–8. No original data. [PubMed: 12877459]
  311. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117(5):1021–35. No original data. [PubMed: 16675328]
  312. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol. 2010;125(3):569–74. 574.e1–574.e7. No original data. [PubMed: 20144472]
  313. Craig TJ, Moeckli JK, Donnelly A. Noncompliance with immunotherapy secondary to adverse effects. Ann Allergy Asthma Immunol. 95; 75(3):290. Other reason for exclusion (specify): letter. [PubMed: 7552935]
  314. Creticos PS. Immunotherapy with allergens. JAMA. 92; 268(20):2834–9. No original data. [PubMed: 1433698]
  315. Creticos PS, Adkinson NF Jr, Kagey-Sobotka A, Proud D, Meier HL, Naclerio RM, Lichtenstein LM, Norman PS. Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. J Clin Invest. 85; 76(6):2247–53. It does not meet ALL the inclusion criteria. [PMC free article: PMC424347] [PubMed: 2416777]
  316. Creticos PS, Chen YH, Schroeder JT. New approaches in immunotherapy: allergen vaccination with immunostimulatory DNA. Immunol Allergy Clin North Am. 2004;24(4):569–81. v. No original data. [PubMed: 15474859]
  317. Creticos PS, Marsh DG, Proud D, Kagey-Sobotka A, Adkinson NF Jr, Friedhoff L, Naclerio RM, Lichtenstein LM, Norman PS. Responses to ragweed-pollen nasal challenge before and after immunotherapy. J Allergy Clin Immunol. 89; 84(2):197–205. It does not meet ALL the inclusion criteria. [PubMed: 2668381]
  318. Criado Molina A, Guerra Pasadas F, Daza Munoz JC, Moreno Aguilar C, Almeda Llamas E, Munoz Gomariz E, Font Ugalde P, Alonso Diaz C, German Cardenas M, Sanchez Guijo P. Immunotherapy with an oral Alternaria extract in childhood asthma. Clinical safety and efficacy and effects on in vivo and in vitro parameters. Allergol Immunopathol (Madr). 2002;30(6):319–30. It does not meet ALL the inclusion criteriad. [PubMed: 12464165]
  319. Crifo S, De Seta E, Lucarelli N, Masieri S. Specific local immunotherapy in nasal allergy (preliminary report). Allergol Immunopathol (Madr). 80; 8(1):1–6. Other reason for exclusion (specify):nasal. [PubMed: 7405756]
  320. Crimi E, Voltolini S, Troise C, Gianiorio P, Crimi P, Brusasco V, Negrini AC. Local immunotherapy with Dermatophagoides extract in asthma. J Allergy Clin Immunol. 91; 87(3):721–8. Therapy NOT AVAILABLE in the U.S Other reason for exclusion (specify):local inhalation IT.
  321. Cross-reactivity between deciduous trees during immunotherapy. I. In vivo results. Excluded at data abstraction. [PubMed: 3708791]
  322. Cserhati E, Mezei G. Nasal immunotherapy in pollen-sensitive children. Allergy. 97; 52(33 Suppl):40–4. Therapy NOT AVAILABLE in the U.S. [PubMed: 9188948]
  323. Cvitanovic S. Allergy to Parietaria officinalis pollen. Croat Med J. 99; 40(1):42–8. It does not meet ALL the inclusion criteria. [PubMed: 9933896]
  324. Cvitanovic S, Zekan L, Capkun V, Marusic M. Specific hyposensitization in patients allergic to Parietaria officinalis pollen allergen. J Investig Allergol Clin Immunol. 94; 4(6):283–90. Therapy NOT AVAILABLE in the U.S Other reason for exclusion (specify):allergoid product. [PubMed: 7735515]
  325. Czarnecka-Operacz M, Jenerowicz D, Silny W. Oral allergy syndrome in patients with airborne pollen allergy treated with specific immunotherapy. Acta Dermatovenerol Croat. 2008;16(1):19–24. It does not meet ALL the inclusion criteriaOther reason for exclusion (specify):OAS: food allergy. [PubMed: 18358104]
  326. DAG, Lobefalo G, Liccardi G, Cazzola M. A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaura pollen. Clinical and Experimental Allergy. Other reason for exclusion (specify): LNIT. [PubMed: 7750006]
  327. Price D. Asthma and allergic rhinitis: Linked in treatment and outcomes. Annals of Thoracic Medicine. 2010;5(2):63–64. No original data. [PMC free article: PMC2883199] [PubMed: 20582169]
  328. Srivastava D, Gaur SN, Arora N, Singh BP. Clinico-immunological changes post-immunotherapy with Periplaneta americana. European Journal of Clinical Investigation. 2011;41(8):879–888. Not an RCT. [PubMed: 21323911]
  329. Vita D, Caminiti L, Ruggeri P, Pajno GB. Sublingual immunotherapy: Adherence based on timing and monitoring control visits. Allergy: European Journal of Allergy and Clinical Immunology. 2010;65(5):668–669. No original dataOther reason for exclusion (specify): review. [PubMed: 19845569]
  330. Dal Bo S. On repository therapy of grass hay fever: a seven years’ experience. Acta Allergol. 68; 23(3):252–64. Therapy NOT AVAILABLE in the U.S. [PubMed: 5756009]
  331. DALBO S. EXPERIENCE WITH REPOSITORY THERAPY OF POLLINOSIS IN NORTHERN ITALY. Ann Allergy. 64; 22:670–7. Therapy NOT AVAILABLE in the U.S. [PubMed: 14242087]
  332. Dam Petersen K, Gyrd-Hansen D, Kjaergaard S, Dahl R. Clinical and patient based evaluation of immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr). 2005;33(5):264–9. Other reason for exclusion (specify):retrospective. [PubMed: 16287545]
  333. Damanik MP, Wahab AS. Suminta, Ediyono, and Ismangoen The influence of desensitization on the recovery of allergy, in particular asthma. Paediatr Indones. 84; 24(9–10):203–10. It does not meet ALL the inclusion criteria. [PubMed: 6545916]
  334. Dantzler BS, Tipton WR, Nelson HS, O’Barr TP. Tissue threshold changes during the first months of immunotherapy. Ann Allergy. 80; 45(4):213–6. It does not meet ALL the inclusion criteria. [PubMed: 7425390]
  335. Davis WE, Cook PR, McKinsey JP, Templer JW. Anaphylaxis in immunotherapy. Otolaryngol Head Neck Surg. 92; 107(1):78–83. It does not meet ALL the inclusion criteria. [PubMed: 1528607]
  336. De Amici M, Puggioni F, Casali L, Alesina R. Variations in serum levels of interleukin (IL)-1beta, IL-2, IL-6, and tumor necrosis factor-alpha during specific immunotherapy. Ann Allergy Asthma Immunol. 2001;86(3):311–3. It does not meet ALL the inclusion criteriad. [PubMed: 11289330]
  337. de Bot CM, Moed H, Berger MY, Roder E, de Groot H, de Jongste JC, van Wijk RG, van der Wouden JC. Randomized double-blind placebo-controlled trial of sublingual immunotherapy in children with house dust mite allergy in primary care: study design and recruitment. BMC Fam Pract. 2008;9:59. It does not meet ALL the inclusion criteria. [PMC free article: PMC2577674] [PubMed: 18937864]
  338. de Bot C, Moed H, van der Wouden JC. Sublingual immunotherapy in children. Re: Marcucci et al. Pediatr Allergy Immunol. 2006;17(4):315. author reply 316–7. No original data. [PubMed: 16771788]
  339. de la Cuesta CG, Garcia BE, Sanz ML, Feliu X, Oehling A. The value of total IgE determination in mite allergy. Allergol Immunopathol (Madr). 89; 17(5):233–5. It does not meet ALL the inclusion criteria. [PubMed: 2610185]
  340. DeCastro FJ. Delayed reaction to aqueous hyposensitization material. JAMA. 70; 212(6):1069. Other reason for exclusion (specify):Harms. [PubMed: 5467407]
  341. Degara PF. Clinical study of allergy therapy with alum-precipitated pyridine suspensions. Special usefulness for highly sensitive patients. N Y State J Med. 65; 65(21):2682–4. Therapy NOT AVAILABLE in the U.S. [PubMed: 5213201]
  342. Dehlink E, Eiwegger T, Gerstmayr M, Kampl E, Bohle B, Chen KW, Vrtala S, Urbanek R, Szepfalusi Z. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy. 2006;36(1):32–9. It does not meet ALL the inclusion criteria. [PubMed: 16393263]
  343. Deitmer T. Hyposensitization in allergic rhinoconjunctivitis. HNO. 99; 47(7):601. It does not meet ALL the inclusion criteria.
  344. Del Prete A, Chiosi E, Magli A, Calandriello M, Bernardo B, Bracale G. Surgical treatment and desensitization therapy of giant papillary allergic conjunctivitis. Ophthalmic Surg. 92; 23(11):776–9. It does not meet ALL the inclusion criteria. [PubMed: 1484672]
  345. Del Prete A, Loffredo C, Carderopoli A, Caparello O, Verde R, Sebastiani A. Local specific immunotherapy in allergic conjunctivitis. Acta Ophthalmol (Copenh). 94; 72(5):631–4. It does not meet ALL the inclusion criteria. [PubMed: 7887165]
  346. Delaunois L, Salamon E, Prignot J. Influence of hyposensitization with Dermatophagoides pteronyssinus extract on clinical score, total and specific IgE levels, and skin test in asthmatic patients. Ann Allergy. 85; 55(2):150–2. It does not meet ALL the inclusion criteria. [PubMed: 4025957]
  347. Della Casa R, Di Scianni N. Bronchial asthma in childhood with special reference to vaccine therapy. Minerva Pediatr. 69; 21(34):1598–603. It does not meet ALL the inclusion criteria. [PubMed: 5404712]
  348. Della Volpe A, D’Agostino GW, Varricchio AM, Mansi N. Sublingual allergen-specific immunotherapy in allergic rhinitis and related pathologies: Efficacy in a paediatric population. Int J Immunopathol Pharmacol. 2002;15(1):35–40. It does not meet ALL the inclusion criteriaTu dose is not defined (what is the conc. [PubMed: 12593786]
  349. Delthil P, Cany J. A new trend in the treatment of juvenile asthma: combined crenotherapy, climatotherapy and desensitization. Pediatrie. 66; 21(2):245–50. No original data. [PubMed: 5907092]
  350. Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy. Excluded at data abstraction. [PubMed: 10412677]
  351. Des Roches A, Paradis L, Paradis J. Immunotherapy for asthma. N Engl J Med. 1912;97; 336(26) No original data. [PubMed: 9198750]
  352. Des Roches A, Paradis L, Knani J, Hejjaoui A, Dhivert H, Chanez P, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy. 96; 51(6):430–3. [PubMed: 8837669]
  353. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol. 97; 99(4):450–3. It does not meet ALL the inclusion criteria. [PubMed: 9111487]
  354. Descriptive study of tolerance of two different high dose modified allergen extracts. Meeting abstract.
  355. Desensitization for those afflicted with hay fever. With 4 pricks hyposensitized to pollen. MMW Fortschr Med. 2004;146(11):58. No original data. [PubMed: 15152778]
  356. Detection of human auto-anti-idiotypic antibodies (Ab2). I. Isolation and characterization of Ab2 in the serum of a ragweed immunotherapy-treated patient. Library unable to locate. [PubMed: 3261275]
  357. Devey ME, Wilson DV, Wheeler AW. The IgG subclasses of antibodies to grass pollen allergens produced in hay fever patients during hyposensitization. Clin Allergy. 76; 6(3):227–36. Therapy NOT AVAILABLE in the U.S Other reason for exclusion (specify):modified allergen. [PubMed: 939035]
  358. Di Bernardino C, Di Bernardino F, Colombo R, Angrisano A. A case control study of dermatophagoides immunotherapy in children below 5 years of age. Allerg Immunol (Paris). 2002;34(2):56–9. Therapy NOT AVAILABLE in the U.S. [PubMed: 11933755]
  359. Di Bona D, Plaia A, Scafidi V, Leto-Barone MS, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol. 2010;126(3):558–66. No original data. [PubMed: 20674964]
  360. Di Lorenzo G, Mansueto P, Pacor ML, Rizzo M, Castello F, Martinelli N, Ditta V, Lo Bianco C, Leto-Barone MS, D’Alcamo A, Di Fede G, Rini GB, Ditto AM. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;123(5):1103–10. 1110.e1–4. It does not meet ALL the inclusion criteria. [PubMed: 19356792]
  361. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, Canonica GW, Passalacqua G. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy. 2003;33(2):206–10. It does not meet ALL the inclusion criteria. [PubMed: 12580913]
  362. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy. 99; 54(10):1110–3. Other reason for exclusion (specify):surveillanceNot an RCT. [PubMed: 10536891]
  363. Di Rienzo V, Puccinelli P, Frati F, Parmiani S. Grass pollen specific sublingual/swallow immunotherapy in children: open-controlled comparison among different treatment protocols. Allergol Immunopathol (Madr). 99; 27(3):145–51. It does not meet ALL the inclusion criteria. [PubMed: 10431100]
  364. Di Stanislao C, Angelini F, Gagliardi MC, Di Bernardino L, Fundaro’ C, Galli E, Rossi P. Beta glucuronidase short-term immunotherapy. Allergy. 2003;58(5):459. Therapy NOT AVAILABLE in the U.S. [PubMed: 12752344]
  365. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Abstract only. [PubMed: 9860027]
  366. Diamond MT, Joffe B. Reaction at old vaccination site. JAMA. 65; 194(12):1325–6. No SIT. [PubMed: 5898092]
  367. Dieges PH. A method for demonstration of blocking antibodies in desensitized hay fever patients. Acta Allergol. 72; 27(3):179–85. Does not apply to any of the key questions. [PubMed: 4678804]
  368. Dieges PH. A prospective study on some immunological changes occurring in the first year of grass pollen desensitization. Acta Allergol. 76; 31(2):130–40. It does not meet ALL the inclusion criteriadose not specified. [PubMed: 947137]
  369. Dieges PH. Clinical evaluation of desensitization therapy in hay fever. Acta Otorhinolaryngol Belg. 79; 33(4):522–7. No original data. [PubMed: 395812]
  370. Dieguez I, Sanz ML, Oehling A. Influence of immunotherapy on histamine release and other immunological parameters of immediate hypersensitivity in pollinosis. J Investig Allergol Clin Immunol. 93; 3(2):64–71. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 7506622]
  371. Dinakar C, Van Osdol TJ, Barnes CS, Dowling PJ, Zeigler AW. Changes in exhaled nitric oxide levels with immunotherapy. Allergy Asthma Proc. 2006;27(2):140–4. Does not apply to any of the key questions. [PubMed: 16724633]
  372. Dominguez MA, Sanz ML, Lobera T, Oehling A. T helper and T suppressor subpopulations in pollinosis. Effect of specific immunotherapy. Allergol Immunopathol (Madr). 83; 11(6):415–20. It does not meet ALL the inclusion criteria. [PubMed: 6230904]
  373. Donahue JG, Greineder DK, Connor-Lacke L, Canning CF, Platt R. Utilization and cost of immunotherapy for allergic asthma and rhinitis. Ann Allergy Asthma Immunol. 99; 82(4):339–47. Does not apply to any of the key questions. [PubMed: 10227332]
  374. Donovan JP, Buckeridge DL, Briscoe MP, Clark RH, Day JH. Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Ann Allergy Asthma Immunol. 96; 77(1):74–80. It does not meet ALL the inclusion criteria. [PubMed: 8705641]
  375. Dorward AJ, Waclawski E, Kerr JW. A comparison of the clinical and immunological effects of an alum-precipitated five-grass extract with a conjugated two-grass extract in the desensitization of hay fever. Clin Allergy. 84; 14(6):561–70. Therapy NOT AVAILABLE in the U.S. [PubMed: 6391736]
  376. Double blind placebo controlled study of specific immunotherapy (ITS) with alginate conjugated mite alpha fraction in perennial allergic rhinitis. Library unable to locate.
  377. Double blind trial of hyposensitization to Dermatophagoides farinae and D. pteronyssinus in asthmatic children. Library unable to locate. [PubMed: 1611544]
  378. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. Duplicate of 2999. [PubMed: 10452766]
  379. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Duplicate of 5875. [PubMed: 9700035]
  380. Drachenberg KJ, Pfeiffer P, Urban E. Sublingual immunotherapy - Results from a multi-centre, randomised, double-blind, placebo-controlled study with a standardised birch and grass/rye pollen extract. Allergologie. german. sNon-English article.
  381. Drazhnevskaia LD. Specific hyposensitization of the atopic form of bronchial asthma. Vrach Delo. 74(6):16–7. Not an RCT. [PubMed: 4466079]
  382. Drira I, Belhabib S, Trojjet S, Souissi R, Chebbi ML. Observance in specific desensitization in allergic asthmatics. Tunis Med. 96; 74(10):411–3. It does not meet ALL the inclusion criteria. [PubMed: 9506100]
  383. Droszcz W, Pawlowicz A. Controlled immunotherapy of bronchial asthma. Pol Tyg Lek. 83; 38(27):829–30. Other reason for exclusion (specify): [PubMed: 6657520]
  384. Droszcz W, Lech B, Madalinska M. Results of desensitization with Migen of patients with bronchial asthma caused by hypersensitivity to the mite Dermatophagoides pteronyssinus. Pneumonol Pol. 78; 46(8):613–5. Other reason for exclusion (specify):Not an RCT. [PubMed: 714704]
  385. Droszcz W, Wronska J, Lech B, Madalinska M. 3-year experience with desensitization of paptients with pollenosis using grass pollen extract of depot type. Pol Arch Med Wewn. 77; 58(4):334–8. Therapy NOT AVAILABLE in the U.S Other reason for exclusion (specify): [PubMed: 928171]
  386. Drouet M, Sabbah A, Bonneau JC, Le Sellin J. Renal complications due to desensitization. Allerg Immunol (Paris). 86; 18(4):17–9. Not an RCT. [PubMed: 3453713]
  387. Dubois O, Derambure S. Treatment of bronchial asthma in children by emulsified allergens. Pediatrie. 66; 21(2):219–32. Therapy NOT AVAILABLE in the U.S. [PubMed: 5907089]
  388. Duce Gracia F, Fraj Lazaro J. Desensitizing treatment in bronchial asthma. Arch Bronconeumol. 96; 32(8):414–20. No original data. [PubMed: 8983570]
  389. Ducommun J, Morel V, Ribi C, Hauser C. Localized cold-induced urticaria associated with specific immunotherapy for tree pollen allergy. Allergy. 2008;63(6):789–90. Other reason for exclusion (specify):not significant harm reported. [PubMed: 18445198]
  390. Duflo V. Results of Allerglobulin in asthma or eczema in a group of children. Lyon Med. 71; 226(20):891–3. It does not meet ALL the inclusion criteria. [PubMed: 4111409]
  391. Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy. 2006;61(10):1235. Other reason for exclusion (specify):case report. [PubMed: 16942576]
  392. During nasal challenge test with aqueous phleum pratense, measurements of nasal peakflow and total nasal symptom score are normalised 6 H post challenge. Meeting abstract.
  393. Dursun AB, Sin BA, Oner F, Misirligil Z. The safety of allergen immunotherapy (IT) in Turkey. J Investig Allergol Clin Immunol. 2006;16(2):123–8. Not an RCT. [PubMed: 16689186]
  394. Dworetzky M. Lowell and Franklin on double-blind hyposensitization therapy for ragweed hay fever: the paper. J Allergy Clin Immunol. 2004;113(6):1231–3. No original data. [PubMed: 15208610]
  395. Early effects of rush immunotherapy with Dermatophagoides pteronyssinus in asthmatics. Excluded at data abstraction. [PubMed: 9491200]
  396. Ebner C, Kraft D, Ebner H. Booster immunotherapy (BIT). Allergy. 94; 49(1):38–42. It does not meet ALL the inclusion criteria.
  397. Ebner H, Neuchrist C, Havelec L, Kraft D. Comparative studies of the effectiveness of specific immunotherapy in house dust mite allergy. Wien Klin Wochenschr. 89; 101(15):504–11. Therapy NOT AVAILABLE in the U.S. [PubMed: 2672610]
  398. Echechipia S, Tabar AI, Lobera T, Munoz D, Rodriguez A, Blasco A, Olaguibel JM, Casanovas M, Fernandez de Corres L. Immunotherapy with a standardized Dermatophagoides pteronyssinus glutaraldehyde-modified extract against an unmodified extract: a comparative study of efficacy, tolerance and in vivo and in vitro modification of parameters. J Investig Allergol Clin Immunol. 95; 5(6):325–32. Therapy NOT AVAILABLE in the U.S. [PubMed: 8653220]
  399. Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma. Excluded at data abstraction. [PubMed: 19788024]
  400. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy. Excluded at data abstraction. [PubMed: 18517082]
  401. Effect of allergen specific immunotherapy (IT) on natural killer cell activity (NK), IgE, IFN-gamma levels and clinical response in patients with allergic rhinitis and asthma. Excluded at data abstraction. [PubMed: 9015776]
  402. Effect of grass pollen immunotherapy on asthma quality of life Abstract. Meeting abstract.
  403. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. Part of 1840. [PubMed: 17714551]
  404. Effect of immunotherapy in bronchial asthma: treatment with extracts of house dust and mite. Excluded at data abstraction. [PubMed: 4418497]
  405. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: A randomized, placebo-controlled, double-blind, double-dummy study. Duplicate of 10246. [PubMed: 22041501]
  406. Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. Excluded at data abstraction. [PubMed: 16680932]
  407. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. Excluded at data abstraction. [PubMed: 20159249]
  408. Effect of subcutaneous and sublingual immunotherapy on clinical improvement and quality of life in children with rhinitis and asthma monosensitised to house dust mite: a randomised, placebo-controlled, double-blind, double-dummy study. Library unable to locate.
  409. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Part of 3525. [PubMed: 3069238]
  410. Effectiveness of hyposensitization therapy in ragweed hay-fever in children. Excluded at data abstraction. [PubMed: 5952104]
  411. Effects of allergen specific immunotherapy on functions of Th and Treg cells in patients with seasonal allergic rhinitis. Meeting abstract. [PubMed: 21421451]
  412. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. Part of 3835. [PubMed: 2013680]
  413. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Duplicate of 3403. [PubMed: 17378260]
  414. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Excluded at data abstraction. [PubMed: 19134016]
  415. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. Part of 10070. [PubMed: 16461133]
  416. Efficacy and safety of sublingual immunotherapy in adults with allergic rhinoconjunctivitis: results after 2 years of a controlled trial. Library unable to locate.
  417. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis. Duplicate. [PubMed: 17274520]
  418. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Duplicate. [PubMed: 19076534]
  419. Efficacy of grass-maize pollen oral immunotherapy in patients with seasonal hay-fever: a double-blind study. Oral IT. [PubMed: 3436031]
  420. Efficacy of specific desensitization with mites standartization extract in asthma. Library unable to locate.
  421. Efficacy of sublingual specific immunotherapy drops in patients with respiratory allergy to Alternaria alternata: A randomised, Assessor-blinded, Patientreported outcome, Controlled 3-year trial. Duplicate of 10483. [PubMed: 21050060]
  422. Egeskjold EM, Permin H, Nielsen I, Sorensen HJ, Osterballe O, Kallerup HE. Anti-IgG antibodies and antinuclear antibodies in allergic patients. Allergy. 81; 36(8):573–81. It does not meet ALL the inclusion criteria. [PubMed: 6978090]
  423. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy. 2007;62(5):567–8. Not an RCT. [PubMed: 17313400]
  424. Einecke D. Minor rhinitis. Consequent therapy protects against asthma. MMW Fortschr Med. 2002;144(13):14. No original data. [PubMed: 12001581]
  425. Einecke U. From wheezing to anaphylactic shock: allergology for your practice. MMW Fortschr Med. 2008;150(13):12–4. 16. No original data. [PubMed: 18522349]
  426. El Jundi O, Karakaya G, Fuat Kalyoncu A. Sarcoidosis following specific immunotherapy: more than just coincidence? Allergol Immunopathol (Madr). 2007;35(1):32–4. Other reason for exclusion (specify):harmsNot an RCT. [PubMed: 17338900]
  427. el-Hefny A. Hyposensitization therapy in asthmatic children. J Egypt Med Assoc. 66; 49(11):728–35. Not an RCT. [PubMed: 5965037]
  428. el-Hefny A. Hyposensitization therapy in asthmatic children. J Egypt Med Assoc. 66; 49(11):728–35. Not an RCT. [PubMed: 5965037]
  429. El-Mehairy MM, el-Tarabishi MM. House dust sensitivity in respiratory allergy and the effect of its treatment by desensitization. Allerg Asthma (Leipz). 67; 13(1):19–25. It does not meet ALL the inclusion criteria. [PubMed: 5582397]
  430. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy. 2006;61(2):198–201. Therapy NOT AVAILABLE in the U.S. [PubMed: 16409196]
  431. Eng PA,, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy. 2002;57(4):306–12. Therapy NOT AVAILABLE in the U.S. [PubMed: 11906360]
  432. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy. 2002;57(4):306–12. Therapy NOT AVAILABLE in the U.S. [PubMed: 11906360]
  433. Engel P, Malet A, Sanosa J, Fajas L, Garcia-Calderon PA. The histamine liberation test as a diagnostic parameter and its possible modification following specific immunotherapy. Allergol Immunopathol (Madr). 85; 13(2):93–100. It does not meet ALL the inclusion criteria. [PubMed: 2408457]
  434. Enzyme potentiated hyposensitization: IV. effect of protamine on the immunological behavior of beta glucuronidase in mice and patients with hay fever. Kirwan/Cochrane 2009. [PubMed: 1124865]
  435. Eriksson NE. Allergy diagnosis and specific therapy in asthma--when, where and how? Eur J Respir Dis Suppl. 84; 136:139–59. No original data. [PubMed: 6587982]
  436. Eriksson NE, Ahlstedt S, Lovhagen O. Immunotherapy in spring-time hay fever. A clinical and immunological study comparing two different treatment extract compositions. Allergy. 79; 34(4):233–47. Therapy NOT AVAILABLE in the U.S. [PubMed: 92897]
  437. Eriksson NE, Ahlstedt S, Lovhagen O. Immunotherapy in spring-time hay fever. A clinical and immunological study comparing two different treatment extract compositions. Allergy. 79; 34(4):233–47. It does not meet ALL the inclusion criteria. [PubMed: 92897]
  438. Esch RE, Bush RK, Peden D, Lockey RF. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Ann Allergy Asthma Immunol. 2008;100(5):475–81. It does not meet ALL the inclusion criteria. [PubMed: 18517081]
  439. Eusebius NP, Papalia L, Suphioglu C, McLellan SC, Varney M, Rolland JM, O’Hehir RE. Oligoclonal analysis of the atopic T cell response to the group 1 allergen of Cynodon dactylon (bermuda grass) pollen: pre- and post-allergen-specific immunotherapy. Int Arch Allergy Immunol. 2002;127(3):234–44. It does not meet ALL the inclusion criteria. [PubMed: 11979049]
  440. Evans R, Pence H, Kaplan H, Rocklin RE. The effect of immunotherapy on humoral and cellular responses in ragweed hayfever. J Clin Invest. 76; 57(5):1378–85. Does not apply to any of the key questions Not an RCT. [PMC free article: PMC436791] [PubMed: 57122]
  441. Evans R, Pence H, Kaplan H, Rocklin RE. The effect of immunotherapy on humoral and cellular responses in ragweed hayfever. J Clin Invest. 76; 57(5):1378–85. Does not apply to any of the key questions Not an RCT. [PMC free article: PMC436791] [PubMed: 57122]
  442. Ewan PW. Anaphylactic reaction to desensitisation. Br Med J. 80; 281(6247):1069. No original data. [PMC free article: PMC1714402] [PubMed: 7427578]
  443. Ewan PW. Anaphylactic reaction to desensitisation. Br Med J. 80; 281(6247):1069. No original data. [PMC free article: PMC1714402] [PubMed: 7427578]
  444. Angelini F, Pacciani V, Corrente S, Silenzi R, Di Pede A, Polito A, Riccardi C, Di Cesare S, Yammine ML, Rossi P, Moschese V, Chini L. Dendritic cells modification during sublingual immunotherapy in children with allergic symptoms to house dust mites. World Journal of Pediatrics. 2011;7(1):24–30. Not an RCT. [PubMed: 21191773]
  445. Lowell FC, Franklin W. A double-blind study of the effectiveness and specificity of injecton therapy in ragweed hay fever. N Engl J Med. 1965;273(13):675–9. It does not meet ALL the inclusion criteriano dose. [PubMed: 5318212]
  446. Fadal RG, Nalebuff DJ. A study of optimum dose immunotherapy in pharmacological treatment failures. Arch Otolaryngol. 80; 106(1):38–43. It does not meet ALL the inclusion criteria no comparison. [PubMed: 7352893]
  447. Fadel R. Report of the Stallergenes symposium. Eur Ann Allergy Clin Immunol. 2004;36(3):104. It does not meet ALL the inclusion criteria. [PubMed: 15137482]
  448. Fagerberg E, Nilzen A, Wiholm S. Studies in hyposensitisation with Allpyral. Objective evaluation of the results. Acta Allergol. 72; 27(1):1–14. Therapy NOT AVAILABLE in the U.S Other reason for exclusion (specify):Allpyral. [PubMed: 5067419]
  449. Failure hyposensitisation in treatment of children with grass-pollen asthma. Br Med J (Clin Res Ed). 82; 284(6326):1402–3. No original data. [PMC free article: PMC1498296] [PubMed: 6803994]
  450. Fargetton B, Blandin G, Latil F. Hyposensitization by oral administration of aqueous pollen extracts. Allerg Immunol (Paris). 87; 19(4):165–6. It does not meet ALL the inclusion criteria. [PubMed: 3453133]
  451. Farid R, Ghasemi R, Baradaran-Rahimi M, Jabbari F, Ghaffari J, Rafatpanah H. Evaluation of six years allergen immunotherapy in allergic rhinitis and allergic asthma. Iran J Allergy Asthma Immunol. 2006;5(1):29–31. It does not meet ALL the inclusion criteria no comparator drug. [PubMed: 17242501]
  452. Farrerons-Co FJ, Echevarne F, Velasco MF. The role of cyclic amp in the process of specific hyposensitization. Ann Allergy. 80; 45(3):180–4. It does not meet ALL the inclusion criteria,dNot an RCT. [PubMed: 6251739]
  453. Feliziani V, Marfisi RM, Parmiani S. Rush immunotherapy with sublingual administration of grass allergen extract. Allergol Immunopathol (Madr). 93; 21(5):173–8. It does not meet ALL the inclusion criteria. [PubMed: 8160561]
  454. Fell P, Brostoff J. A single dose desensitization for summer hay fever. Results of a double blind study-1988. Eur J Clin Pharmacol. 90; 38(1):77–9. Therapy NOT AVAILABLE in the U.S. [PubMed: 2328752]
  455. Fell P, Brostoff J. A single dose desensitization for summer hay fever. Results of a double blind study-1988. Eur J Clin Pharmacol. 90; 38(1):77–9. Therapy NOT AVAILABLE in the U.S. [PubMed: 2328752]
  456. Feng H, Xiang L, Shen KL. Dynamical changes of lung function and immunologic markers in asthmatic children receiving specific immunotherapy with standardized house dust mite extract. Zhongguo Dang Dai Er Ke Za Zhi. 2010;12(9):715–9. Not an RCT. [PubMed: 20849721]
  457. Fennerty AG, Jones KP, Davies BH, Fifield R, Edwards J. Immunological changes associated with a successful outcome of pollen immunotherapy. Allergy. 88; 43(6):415–9. Not an RCT. [PubMed: 2973256]
  458. Fenton MM. Critical evaluation of optimal dosage in pollen therapy in children. J Asthma Res. 66; 4(1):53–6. It does not meet ALL the inclusion criteria. [PubMed: 5957547]
  459. Fernandez de Corres L, Oehling A. Specific hyposensitization using inhalation antigens. Allerg Immunol (Leipz). 71; 17(2):111–6. It does not meet ALL the inclusion criteria. [PubMed: 4261235]
  460. Fernandez-Tavora L, Rico P, Martin S. Clinical experience with specific immunotherapy to horse dander. J Investig Allergol Clin Immunol. 2002;12(1):29–33. It does not meet ALL the inclusion criteria. [PubMed: 12109529]
  461. Ferreira MB, Santos AS, Santos MC, Carlos ML, Barbosa MA, Carlos AG. Nasal ECP patterns and specific immunotherapy in mite-allergic rhinitis patients. Eur Ann Allergy Clin Immunol. 2005;37(3):96–102. It does not meet ALL the inclusion criteriamodified extractTherapy NOT AVAILABLE in the U.S. [PubMed: 15918296]
  462. Ferreira MB, Santos MC, Pregal AL, Alonso E, Santos AS, Palma-Carlos ML, Palma-Carlos AG. Effect of specific immunotherapy versus loratadine on serum adhesion molecules. Allerg Immunol (Paris). 2001;33(8):319–22. It does not meet ALL the inclusion criteriaiomarker study w/out cxNot an RCT. [PubMed: 11763722]
  463. Ferreira N, Trindade JC. Specific immunotherapy 3 years follow-up in asthmatic children. Allergol Immunopathol (Madr). 93; 21(5):185–92. It does not meet ALL the inclusion criteria. [PubMed: 8160563]
  464. Ferrer A, Garcia-Selles J. Significant improvement in symptoms, skin test, and specific bronchial reactivity after 6 months of treatment with a depigmented, polymerized extract of Dermatophagoides pteronyssinus and D. farinae. J Investig Allergol Clin Immunol. 2003;13(4):244–51. It does not meet ALL the inclusion criteriamodified allergenTherapy NOT AVAILABLE in the U.S. [PubMed: 14989113]
  465. Ferrer A, Garcia-Selles J. SIT with a depigmented, polymerized mite extract. Allergy. 2002;57(8):754–5. It does not meet ALL the inclusion criteriamodified allergenTherapy NOT AVAILABLE in the U.S. [PubMed: 12121200]
  466. Ferres J, Justicia JL, Garcia MP, Munoz-Tuduri M, Alva V. Efficacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice. Allergol Immunopathol (Madr). 2010. It does not meet ALL the inclusion criteria. [PubMed: 20570032]
  467. Filiaci F, Di Filippo S, Lucarelli N, Zambetti G. Specific local immunotherapy in the treatment of hay fever. Rhinology. 84; 22(4):261–8. It does not meet ALL the inclusion criteria. [PubMed: 6522976]
  468. Filiaci F, Zambetti G, Romeo R, Ciofalo A, Luce M, Germano F. Non-specific hyperreactivity before and after nasal specific immunotherapy. Allergol Immunopathol (Madr). 99; 27(1):24–8. No SIT. [PubMed: 10217669]
  469. Filiaci F, Zambetti G, Romeo R, Ciofalo A, Luce M, Germano F. Non-specific hyperreactivity before and after nasal specific immunotherapy. Allergol Immunopathol (Madr). 99; 27(1):24–8. It does not meet ALL the inclusion criteriano comparator. [PubMed: 10217669]
  470. Fiocchi A, Pajno G, La Grutta S, Pezzuto F, Incorvaia C, Sensi L, Marcucci F, Frati F. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol. 2005;95(3):254–8. It does not meet ALL the inclusion criteria. [PubMed: 16200816]
  471. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Part of 2555. [PubMed: 16792584]
  472. Foucard T, Johansson SG. Allergen-specific IgE and IgG antibodies in pollenallergic children given immunotherapy for 2–6 years. Clin Allergy. 78; 8(3):249–57. Other reason for exclusion (specify):allpyral. [PubMed: 668098]
  473. Foucard T, Johansson SG. Immunological studies in vitro and in vivo of children with pollenosis given immunotherapy with an aqueous and a glutaraldehyde-treated tyrosine-absorbed grass pollen extract. Clin Allergy. 76; 6(5):429–39. It does not meet ALL the inclusion criteria. [PubMed: 61825]
  474. Francis JN, Lloyd CM, Sabroe I, Durham SR, Till SJ. T lymphocytes expressing CCR3 are increased in allergic rhinitis compared with non-allergic controls and following allergen immunotherapy. Allergy. 2007;62(1):59–65. It does not meet ALL the inclusion criteria. [PMC free article: PMC3385351] [PubMed: 17156343]
  475. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 2003;111(6):1255–61. It does not meet ALL the inclusion criteria. [PubMed: 12789226]
  476. Franco C, Barbadori S, Freshwater LL, Kordash TR. A double-blind, placebo controlled study of Alpare mite D. pteronyssinus immunotherapy in asthmatic patients. Allergol Immunopathol (Madr). 95; 23(2):58–66. It does not meet ALL the inclusion criteria. [PubMed: 8526168]
  477. Frank A. Perennial coseasonal hyposensitisation (author’s transl). Wien Med Wochenschr. 80; 130(8):270–4. It does not meet ALL the inclusion criteria. [PubMed: 7395258]
  478. Frank MO. Skin testing and immunotherapy in children. J Allergy Clin Immunol. 95; 96(1):138. No original data. [PubMed: 7662022]
  479. Frank MO. Skin testing and immunotherapy in children. J Allergy Clin Immunol. 95; 96(1):138. No original data. [PubMed: 7662022]
  480. Frankland AW. Preseasonal injection treatment in hay fever using aqueous extracts. Int Arch Allergy Appl Immunol. 65; 28(1):1–11. It does not meet ALL the inclusion criteria. [PubMed: 5324221]
  481. Freedman SS, Boyd GK. Pollen hyposensitization: interval between maintenance injections. J Asthma Res. 67; 5(2):133–8. It does not meet ALL the inclusion criteria. [PubMed: 6079836]
  482. Freedman SS, Pelletier GA. Asthma in childhood: treatment of 1070 cases. Ann Allergy. 70; 28(4):133–41. Does not apply to any of the key questions. [PubMed: 5526419]
  483. Frew A, Dubuske L, Amersdorffer J, Holdich T. Significant benefits of combined symptom and medication scores for ultra short course subcutaneous immunotherapy compared with placebo in patients with grass pollen allergic rhinoconjunctivitis. Allergy. Other reason for exclusion (specify): poster.
  484. Frostad AB. Immunotherapy with major allergens of timothy grass pollen. Allergy. 81; 36(5):345–7. No original data. [PubMed: 7316105]
  485. Frostad AB, Grimmer O, Sandvik L, Aas K. Hyposensitization. Comparing a purified (refined) allergen preparation and a crude aqueous extract from timothy pollen. Allergy. 80; 35(2):81–95. It does not meet ALL the inclusion criteria. [PubMed: 7386802]
  486. Frostad AB, Grimmer O, Sandvik L, Aas K. Hyposensitization. Comparing a purified (refined) allergen preparation and a crude aqueous extract from timothy pollen. Allergy. 80; 35(2):81–95. obs case series. [PubMed: 7386802]
  487. Fu CL, Ye YL, Lee YL, Chiang BL. Both allergen-specific CD4 and CD8 Type 2 T cells decreased in asthmatic children with immunotherapy. Pediatr Allergy Immunol. 2003;14(4):284–91. It does not meet ALL the inclusion criteria. [PubMed: 12911506]
  488. Fuchs E. Allergic bronchial asthma; diagnosis and desensitization (author’s transl). Prax Pneumol. 74; 28(2):78–84. No original data. [PubMed: 4598946]
  489. Fuchs E. Specific desensitization with inhalation antigens. Dtsch Med Wochenschr. 66; 91(19):904–6. No original data. [PubMed: 5910731]
  490. Fujimura T, Yonekura S, Taniguchi Y, Horiguchi S, Saito A, Yasueda H, Nakayama T, Takemori T, Taniguchi M, Sakaguchi M, Okamoto Y. The Induced Regulatory T Cell Level, Defined as the Proportion of IL-10Foxp3(+) Cells among CD25(+)CD4(+) Leukocytes, Is a Potential Therapeutic Biomarker for Sublingual Immunotherapy: A Preliminary Report. Int Arch Allergy Immunol. 2010;153(4):378–387. Does not apply to any of the key questions. [PubMed: 20559004]
  491. Fujimura T, Yonekura S, Taniguchi Y, Horiguchi S, Saito A, Yasueda H, Nakayama T, Takemori T, Taniguchi M, Sakaguchi M, Okamoto Y. The Induced Regulatory T Cell Level, Defined as the Proportion of IL-10Foxp3(+) Cells among CD25(+)CD4(+) Leukocytes, Is a Potential Therapeutic Biomarker for Sublingual Immunotherapy: A Preliminary Report. Int Arch Allergy Immunol. 2010;153(4):378–387. It does not meet ALL the inclusion criteria. [PubMed: 20559004]
  492. Furin MJ, Norman PS, Creticos PS, Proud D, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol. 91; 88(1):27–32. It does not meet ALL the inclusion criteria. [PubMed: 2071783]
  493. Furin MJ, Norman PS, Creticos PS, Proud D, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol. 91; 88(1):27–32. It does not meet ALL the inclusion criteria. [PubMed: 2071783]
  494. Furin MJ, Norman PS, Creticos PS, Proud D, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol. 91; 88(1):27–32. Not an RCT. [PubMed: 2071783]
  495. Blumberga G, Groes L, Dahl R. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma. 2011;(2):178–85. Does not apply to any of the key questions. [PMC free article: PMC3039748] [PubMed: 20883456]
  496. Ciprandi G, Morandi F, Olcese R, Silvestri M, Tosca MA. Subcutaneous and sublingual immunotherapy and T regulatory cells: There is clinical relevance. Clinical and Experimental Allergy. 2010;40(10):1578–1579. No original dataOther reason for exclusion (specify):correspondenceNot an RCT. [PubMed: 20937063]
  497. Senti G, Von Moos S, Tay F, Graf N, Sonderegger T, Johansen P, Kundig TM. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. Journal of Allergy and Clinical Immunology. 2012;129(1):128–135. Therapy NOT AVAILABLE in the U.S. [PubMed: 21996342]
  498. Xu G, Li HB. Evaluation of therapeutic effect of allergen specific immunological treatment. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011;46(1):19–20. No original data. [PubMed: 21429328]
  499. Gadermaier E, Flicker S, Aberer W, Egger C, Reider N, Focke M, Vrtala S, Kundi M, Valenta R. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide. Int Arch Allergy Immunol. 2010;151(1):17–27. It does not meet ALL the inclusion criteria. [PubMed: 19672093]
  500. Gagro A, Rabatic S, Trescec A, Dekaris D, Medar-Lasic M. Expression of lymphocytes Fc epsilon RII/CD23 in allergic children undergoing hyposensitization. Int Arch Allergy Immunol. 93; 101(2):203–8. Does not apply to any of the key questions. [PubMed: 7685220]
  501. Gallesio MT, Furno F. Specific hyposensitizing therapy. Considerations on its effectiveness and validity. Minerva Med. 79; 70(18):1299–303. It does not meet ALL the inclusion criteria. [PubMed: 450269]
  502. Galli E, Chini L, Nardi S, Benincori N, Panei P, Fraioli G, Moschese V, Rossi P. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergol Immunopathol (Madr). 94; 22(1):18–22. Does not apply to any of the key questions. [PubMed: 8030579]
  503. Gamboa PM, Castillo JG, Wong E, de la Cuesta CG, Oehling A. Variations of histamine release in an atopic population. II. Clinical situation according to age and duration of immunotherapy. Allergol Immunopathol (Madr). 89; 17(6):279–83. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 2483969]
  504. Gamboa P, Gonzalez G, Jauregui I, Jorro G, Molero I, Eseverri JL, Gonzalez R, Luna I, Marcos C, Miro J, Pulido Z, Gracia T, Iriarte P, Carreno A, Navarro JA, Rocafort S, Garcia-Robaina JC, Souto I, Casas R, Lleonart R, Nevot S, Asensio O, Bosque M, Blasco A, de la Torre F. A prospective and multicenter safety-monitoring study of a short up-dosing schedule of immunotherapy with a mass-units-standardized extract of mites. Allergol Immunopathol (Madr). 2004;32(1):13–7. It does not meet ALL the inclusion criteria no comparator group. [PubMed: 14980190]
  505. Gammeri E, Arena A, D’Anneo R, La Grutta S. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol Immunopathol (Madr). 2005;33(4):221–3. Therapy NOT AVAILABLE in the U.S. [PubMed: 16045861]
  506. Gamzatova AA, Gadzhimirzaev GA. The treatment of atopic rhinitis in children with an accelerated variant of specific immunotherapy. Vestn Otorinolaringol. 94(5–6):33–7. Not an RCT. [PubMed: 7856017]
  507. Gamzatova AA, Gadzhimirzaev GA. The treatment of atopic rhinitis in children with an accelerated variant of specific immunotherapy. Vestn Otorinolaringol. 94(5–6):33–7. Not an RCT. [PubMed: 7856017]
  508. Gandarias B, Alonso MD, Fernandez Rivas M, Fernandez-Tavora L, Miranda P, Munoz Lejarazu D, Sotillo M, Tejero J, Rico P. Retrospective study of tolerance to short initiation schedules in subcutaneous immunotherapy. J Investig Allergol Clin Immunol. 2005;15(4):242–8. It does not meet ALL the inclusion criteria. [PubMed: 16433204]
  509. Garcia BE, Sanz ML, Dieguez I, de las Marinas MD, Oehling A. Specific IgG subclasses in pollinosis. J Investig Allergol Clin Immunol. 92; 2(6):300–6. Does not apply to any of the key questions. [PubMed: 1342913]
  510. Garcia BE, Sanz ML, Wong E, Oehling A. Effect of immunotherapy on antigen-specific IgG4 in asthmatics sensitive to D. pteronyssinus. Allergol Immunopathol (Madr). 88; 16(6):379–83. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 3242375]
  511. Garcia F, Blanco J, Perez R, Alonso L, Marcos M, Carretero P, Juste S, Garces M. Localized cold urticaria associated with immunotherapy. Allergy. 98; 53(1):110–1. Not an RCT. [PubMed: 9491244]
  512. Garcia-Marcos L, Carvajal Uruena I, Escribano Montaner A, Fernandez Benitez M, Garcia de la Rubia S, Tauler Toro E, Perez Fernandez V, Barcina Sanchez C. Seasons and other factors affecting the quality of life of asthmatic children. J Investig Allergol Clin Immunol. 2007;17(4):249–56. No SITNot an RCT. [PubMed: 17694697]
  513. Garcia-Robaina JC, Sanchez I, de la Torre F, Fernandez-Caldas E, Casanovas M. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol. 2006;118(5):1026–32. Therapy NOT AVAILABLE in the U.S. [PubMed: 17088125]
  514. Garde J, Ferrer A, Jover V, Pagan JA, Andreu C, Abellan A, Felix R, Milan JM, Pajaron M, Huertas AJ, Lavin JR, de la Torre F. Tolerance of a Salsola kali extract standardized in biological units administered by subcutaneous route. Multicenter study. Allergol Immunopathol (Madr). 2005;33(2):100–4. It does not meet ALL the inclusion criteria. [PubMed: 15808117]
  515. GEFFRIAUD M. PRACTICAL REFLECTIONS ON ALLERGOLOGICAL INVESTIGATION IN TRUE ASTHMA OF THE YOUNG ADULT. CONDUCTION OF SPECIFIC DESENSITIZATION TREATMENT AT INCREASING DOSES VIA THE CUTANEOUS ROUTE. Clinique (Paris). 63; 58:463–8. No original data. [PubMed: 14092138]
  516. GEFFRIAUD M. PRACTICAL REFLECTIONS ON ALLERGOLOGICAL INVESTIGATION IN TRUE ASTHMA OF THE YOUNG ADULT. CONDUCTION OF SPECIFIC DESENSITIZATION TREATMENT AT INCREASING DOSES VIA THE CUTANEOUS ROUTE. Clinique (Paris). 63; 58:463–8. No original data. [PubMed: 14092138]
  517. Geller-Bernstein C, Waisel Y, Lahoz C. Environment and sensitization to cypress in Israel. Allerg Immunol (Paris). 2000;32(3):92–3. No SITNo original data. [PubMed: 10815232]
  518. Gietkiewicz K, Fal AM, Matolepszy J. Evaluation of effectiveness and safety of three-year-long immunotherapy with mixed grass pollen allergens. Polskie Archiwum Medycyny Wewnetrznej. -Therapy NOT AVAILABLE in the U.S Non-English article: polish. [PubMed: 12026536]
  519. Gietkiewicz K, Fal AM, Malolepszy J. Evaluation of effectiveness and safety of three year immunotherapy with mixed grass pollen allergens. Pol Arch Med Wewn. 2001;106(6):1163–8. Non-English article: polish. [PubMed: 12026536]
  520. Gillissen A, Bergmann KC, Kleine-Tebbe J, Schultze-Werninghaus G, Virchow JC Jr, Wahn U, Graf von der Schulenburg JM. Specific immunotherapy in allergic asthma. Dtsch Med Wochenschr. 2003;128(5):204–9. No original data. [PubMed: 12557113]
  521. Giron-Caro F, Munoz-Hoyos A, Ruiz-Cosano C, Bonillo-Perales A, Molina-Carballo A, Escames G, Macias M, Acuna-Castroviejo D. Melatonin and beta-endorphin changes in children sensitized to olive and grass pollen after treatment with specific immunotherapy. Int Arch Allergy Immunol. 2001;126(1):91–6. Does not apply to any of the key questions. [PubMed: 11641610]
  522. Giusan AO, Raikis BN. Comparative characteristics of the effectiveness of specific treatment methods in seasonal allergic rhinosinusitis. Vestn Otorinolaringol. 80(3):50–2. No SIT. [PubMed: 6992395]
  523. Glaser J. Immunological effects of injection therapy. Pediatrics. 72; 50(5):826–7. No original data. [PubMed: 5084194]
  524. Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol. 82; 70(4):261–71. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 6811645]
  525. Gluck J, Rogala B, Rogala E, Oles E. Allergen immunotherapy in intermittent allergic rhinitis reduces the intracellular expression of IL-4 by CD8+ T cells. Vaccine. 2007;26(1):77–81. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 18054415]
  526. Gniazdowska B, Gniazdowski R. Desensitization at the first stage of IGE-mediated response as hay fever prophylaxis. Pol Tyg Lek. 90; 45(42–44):869–72. Not an RCT. [PubMed: 2098734]
  527. Gniazdowski R, Martynowski A. Results of specific desensitization with grass allergens in patients with pollenosis. Pediatr Pol. 77; 52(9):1005–11. Non-English article. [PubMed: 917618]
  528. Gniazdowski R. Treatment of hay fever with "Pollinex". Otolaryngol Pol. 78; 32(4):435–40. Therapy NOT AVAILABLE in the U.S. [PubMed: 101956]
  529. Golbert TM. Sublingual desensitization. JAMA. 71; 217(12):1703–4. No original data. [PubMed: 5109826]
  530. Goldstein GL, Chai H. Efficacy of rush immunotherapy in decreasing bronchial sensitivity to inhaled antigens in perennial childhood asthma. Ann Allergy. 81; 47(5 Pt 1):333–7. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 7316248]
  531. Golysheva MA, Berzhets VM, Pakhomova LA, Emel’ianova OIu. The diagnosis and treatment of allergic diseases caused by sensitization to the Dermatophagoides farinae mite. Ter Arkh. 89; 61(10):130–1. Non-English article. [PubMed: 2609258]
  532. Gondoh A. Desensitization in type I skin hypersensitivity. Neutralization method (Miller)--relation of its effect to the immediate allergic test. Nippon Hifuka Gakkai Zasshi. 83; 93(10):1075–89. No SIT. [PubMed: 6663793]
  533. Gonzalez de la Cuesta C, Feijoo R, Rico P. A prospective safety-monitoring study of immunotherapy in mite-allergy patients with mass-units-standardized extract. Allergy. 97; 52(5):580–3. It does not meet ALL the inclusion criteria. [PubMed: 9201372]
  534. Gonzalez de la Cuesta C, Feijoo R, Rico P. A prospective safety-monitoring study of immunotherapy in mite-allergy patients with mass-units-standardized extract. Allergy. 97; 52(5):580–3. obs case series. [PubMed: 9201372]
  535. Gonzalez P, Florido F, Saenz de San Pedro B, de la Torre F, Rico P, Martin S. Immunotherapy with an extract of Olea europaea quantified in mass units. Evaluation of the safety and efficacy after one year of treatment. J Investig Allergol Clin Immunol. 2002;12(4):263–71. It does not meet ALL the inclusion criteria. [PubMed: 12926186]
  536. Gordon VH, Rountree HP, Matthews JW, Feldman G, Thompson C, Brewster MA. Relationships of foreign protein injections (hyposensitization) in atopic children to serum lipids and lipoproteins. Ann Allergy. 76; 36(1):1–9. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 174460]
  537. Gorokhov AA. Effectiveness of specific treatment of patients with seasonal rhinosinusopathy caused by ambrosia pollen. Vestn Otorinolaringol. 75(3):54–6. It does not meet ALL the inclusion criteria. [PubMed: 1146113]
  538. Goto S, Kawakami Y, Miyamoto T, Katsunuma H, Eto T. Evaluation of Broncasma berna therapy in bronchial asthma by double blind test. Arerugi. 70; 19(9):668–75. No SIT. [PubMed: 4919761]
  539. Gotz M, Haber P, Jarisch R. Specific bronchial reactivity following long-term specific immunotherapy in children and adults. Prax Klin Pneumol. 84; 38(7):263–6. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 6483765]
  540. Gotz M, Jarisch R, Popow C. Results of hyposensitization in children (author’s transl). Wien Klin Wochenschr. 79; 91(5):155–7. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions.
  541. Gozalo F, Martin S, Rico P, Alvarez E, Cortes C. Clinical efficacy and tolerance of two year Lolium perenne sublingual immunotherapy. Allergol Immunopathol (Madr). 97; 25(5):219–27. It does not meet ALL the inclusion criteria. [PubMed: 9395005]
  542. Gozalo F, Martin S, Rico P, Alvarez E, Cortes C. Clinical efficacy and tolerance of two year Lolium perenne sublingual immunotherapy. Allergol Immunopathol (Madr). 97; 25(5):219–27. It does not meet ALL the inclusion criteria. [PubMed: 9395005]
  543. Gozde Kanmaz H, Harmanci K, Razi C, Kose G, Cengizlier MR. Specific immunotherapy improves asthma related quality of life in childhood. Allergol Immunopathol (Madr). 2010. It does not meet ALL the inclusion criteria. [PubMed: 20888114]
  544. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. Part of 5794. [PubMed: 8648033]
  545. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Duplicate of 3165. [PubMed: 11972594]
  546. Greenberger PA. Rush injection therapy for asthma and allergic rhinitis. Ann Allergy. 94; 73(5):378–80. No original data. [PubMed: 7978528]
  547. Greineder DK. Risk management in allergen immunotherapy. J Allergy Clin Immunol. 96; 98(6 Pt 3):S330–4. No original data. [PubMed: 8977545]
  548. Grella G, de Carolis A. Respiratory asthmatic syndromes in the aspect of social diseases: etiopathogenic considerations and possibilities of treatment with panvalent desensitizing extracts. Clin Ter. 65; 34(3):229–46. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 5849858]
  549. Grembiale RD, Camporota L, Naty S, Tranfa CM, Djukanovic R, Marsico SA. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. Am J Respir Crit Care Med. 2000;162(6):2048–52. Therapy NOT AVAILABLE in the U.S. [PubMed: 11112112]
  550. GRONEMEYER W. SPECIFIC DESENSITIZATION THERAPY OF BRONCHIAL ASTHMA. Therapiewoche. 64; 14:200–3. No original data. [PubMed: 14134294]
  551. Grosclaude M, Bouillot P, Alt R, Leynadier F, Scheinmann P, Rufin P, Basset D, Fadel R, Andre C. Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int Arch Allergy Immunol. 2002;129(3):248–53. Therapy NOT AVAILABLE in the U.S. [PubMed: 12444323]
  552. Gruber W, Eber E, Mileder P, Modl M, Weinhandl E, Zach MS. Effect of specific immunotherapy with house dust mite extract on the bronchial responsiveness of paediatric asthma patients. Clin Exp Allergy. 99; 29(2):176–81. Therapy NOT AVAILABLE in the U.S. [PubMed: 10051720]
  553. Guardia P, Moreno C, Justicia JL, Conde J, Cimarra M, Diaz M, Guerra F, Martinez-Cocera C, Gonzalo-Garijo MA, Perez-Calderon R, Gonzalez-Quevedo T, Sanchez-Cano M, Vigaray J, Acero S, Blanco R, Martin S, de la Torre F. Tolerance and short-term effect of a cluster schedule with pollen-extracts quantified in mass-units. Allergol Immunopathol (Madr). 2004;32(5):271–7. Therapy NOT AVAILABLE in the U.S. [PubMed: 15456623]
  554. Gudkova RG. On specific desensitization therapy of bronchial asthma. Klin Med (Mosk). 67; 45(5):55–60. Does not apply to any of the key questions No SIT. [PubMed: 5607525]
  555. Guerra L, Compalati E, Rogkakou A, Pecora S, Passalacqua G, Canonica GW. Randomized open comparison of the safety of SLIT in a no-updosing and traditional updosing schedule in patients with Parietaria allergy. Allergol Immunopathol (Madr). 2006;34(2):82–3. It does not meet ALL the inclusion criteria. [PubMed: 16808019]
  556. Guiang SF. Ragweed treatment problems. Ann Allergy. 70; 28(1):31–2. [PubMed: 5526411]
  557. Guillevin L, Guittard T, Bletry O, Godeau P, Rosenthal P. Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung. 87; 165(3):165–72. It does not meet ALL the inclusion criteria. [PubMed: 3108593]
  558. Guillevin L, Guittard T, Bletry O, Godeau P, Rosenthal P. Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung. 87; 165(3):165–72. It does not meet ALL the inclusion criteriaNot an RCT. [PubMed: 3108593]
  559. Gulen F, Zeyrek D, Can D, Altinoz S, Koksoy H, Demir E, Tanac R. Development of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. Asian Pac J Allergy Immunol. 2007;25(1):7–11. It does not meet ALL the inclusion criteria. [PubMed: 17891916]
  560. Gulen F, Zeyrek D, Can D, Altinoz S, Koksoy H, Demir E, Tanac R. Development of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. Asian Pac J Allergy Immunol. 2007;25(1):7–11. non random trial. [PubMed: 17891916]
  561. Gumowski P, Lech B, Chaves I, Girard JP. Chronic asthma and rhinitis due to Candida albicans, epidermophyton, and trichophyton. Ann Allergy. 87; 59(1):48–51. It does not meet ALL the inclusion criteria. [PubMed: 3605797]
  562. Gushchin IS, Leskov VP, Chitaeva VG, Polsacheva OV, Poroshina IuA. Correlation between the T, K and NK cell count and the IgE level in patients with atopy (pollinosis). Vutr Boles. 83; 22(1):50–8. Does not apply to any of the key questions Not an RCT. [PubMed: 6605625]
  563. Gushchin IS, Leskov VP, Chitaeva VG, Polsacheva OV, Poroshina IuA. Correlation between the T, K and NK cell count and the IgE level in patients with atopy (pollinosis). Vutr Boles. 83; 22(1):50–8. It does not meet ALL the inclusion criteria. [PubMed: 6605625]
  564. Gozde Kanmaz H, Harmanci K, Razi C, Kose G, Cengizlier MR. Specific immunotherapy improves asthma related quality of life in childhood. Allergologia et Immunopathologia. 2011;39(2):68–72. Not an RCT. [PubMed: 20888114]
  565. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. Journal of Allergy and Clinical Immunology. 2011;127(1):64–71. e4. Therapy NOT AVAILABLE in the U.S. [PubMed: 21211643]
  566. Haahtela T, Wihl JA, Munch E, Vilkka V, Hagelund CH, Watson HK. Hyposensitization in hay fever with grass pollen extracts: a three-year study comparing a dialysed alum adsorbed extract with allpyral. Ann Allergy. 84; 52(5):355–62. Therapy NOT AVAILABLE in the U.S. [PubMed: 6721260]
  567. Hacarova M, Vlckova I, Chlumecka L. Personal experience with parenteral hyposensitization therapy in allergic rhinitis. Acta Univ Palacki Olomuc Fac Med. 91; 129:113–8. It does not meet ALL the inclusion criteria. [PubMed: 1837652]
  568. Hajos K. 10 years of asthma therapy. Allerg Asthma (Leipz). 66; 12(2):92–102. No original data. [PubMed: 5983710]
  569. Hakansson L, Heinrich C, Rak S, Venge P. Priming of eosinophil adhesion in patients with birch pollen allergy during pollen season: effect of immunotherapy. J Allergy Clin Immunol. 97; 99(4):551–62. It does not meet ALL the inclusion criteria. [PubMed: 9111502]
  570. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol. 97; 99(2):254–60. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 9042055]
  571. Hanasz-Jarzynska T, Kostanska H. The behaviour of immunoglobulins in children and adolescents hyposensitized for pollinosis and pollen asthma. Allergol Immunopathol (Madr). 82; 10(1):11–6. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 7080992]
  572. Hankin CS, Cox L, Lang D, Bronstone A, Fass P, Leatherman B, Wang Z. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched Cohort study. Ann Allergy Asthma Immunol. 2010;104(1):79–85. It does not meet ALL the inclusion criteria. [PubMed: 20143650]
  573. HARLEY D. THE COSEASONAL TREATMENT OF HAY FEVER. Int Arch Allergy Appl Immunol. 64; 25:1–10. No original data. [PubMed: 14206398]
  574. HARLEY D. THE COSEASONAL TREATMENT OF HAY FEVER. Int Arch Allergy Appl Immunol. 64; 25:1–10. No original data. [PubMed: 14206398]
  575. Harmanci K, Razi CH, Toyran M, Kanmaz G, Cengizlier MR. Evaluation of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. Asian Pac J Allergy Immunol. 2010;28(1):7–13. Not an RCT. [PubMed: 20527510]
  576. Harvey SM, Laurie S, Hilton K, Khan DA. Safety of rush immunotherapy to multiple aeroallergens in an adult population. Ann Allergy Asthma Immunol. 2004;92(4):414–9. It does not meet ALL the inclusion criteria. [PubMed: 15104192]
  577. Haugaard L, Dahl R. Immunotherapy in patients allergic to cat and dog dander. I. Clinical results. Allergy. 92; 47(3):249–54. It does not meet ALL the inclusion criteria. [PubMed: 1510237]
  578. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol. 93; 91(3):709–22. It does not meet ALL the inclusion criteria. [PubMed: 8454793]
  579. Haugaard L, Mosbech H, Heinig JH, Ostergaard PA. Treatment of patients allergic to house dust mites. Allergy. 91; 46 Suppl 11:26–32. No original dataOther reason for exclusion (specify): review of published HDM cx trials. [PubMed: 1897698]
  580. Haugaard L, Mosbech H, Heinig JH, Ostergaard PA. Treatment of patients allergic to house dust mites. Allergy. 91; 46(Suppl 11):26–32. No original data. [PubMed: 1897698]
  581. Hayashi M, Ohashi Y, Tanaka A, Kakinoki Y, Nakai Y. Suppression of seasonal increase in serum interleukin-5 is linked to the clinical efficacy of immunotherapy for seasonal allergic rhinitis. Acta Otolaryngol Suppl. 98; 538:133–42. It does not meet ALL the inclusion criteria. [PubMed: 9879413]
  582. Heale R. Short term coseasonal sublingual immunotherapy reduced the development of asthma in children with hay fever. Evid Based Nurs. 2005;8(2):44. Other reason for exclusion (specify): letter. [PubMed: 15830417]
  583. Hebert J, Bedard PM. Comparison of 3 types of immunotherapy for treating grass pollen-induced allergic rhinitis. Allerg Immunol (Paris). 86; 18(7):19–23. It does not meet ALL the inclusion criteria. [PubMed: 3453720]
  584. Hedlin G. Treatment with cat allergy vaccines. Clin Exp Allergy. 91; 21 Suppl 1:211–5. Other reason for exclusion (specify): review. [PubMed: 2032148]
  585. Hedlin G. Treatment with cat allergy vaccines. Clin Exp Allergy. 91; 21 Suppl 1:211–5. No original data. [PubMed: 2032148]
  586. Hedlin G, Graff-Lonnevig V, Heilborn H, Lilja G, Norrlind K, Pegelow K, Sundin B, Lowenstein H. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol. 91; 87(5):955–64. Not an RCT. [PubMed: 2026846]
  587. Hedlin G, Heilborn H, Lilja G, Norrlind K, Pegelow KO, Schou C, Lowenstein H. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol. 95; 96(6 Pt 1):879–85. It does not meet ALL the inclusion criteria. [PubMed: 8543744]
  588. Hedlin G, Silber G, Naclerio R, Proud D, Lamas AM, Eggleston P, Adkinson NF Jr. Comparison of the in-vivo and in-vitro response to ragweed immunotherapy in children and adults with ragweed-induced rhinitis. Clin Exp Allergy. 90; 20(5):491–500. obs case series. [PubMed: 2253080]
  589. Heijer A, Goransson K. The significance of testing and hyposensitization with several grass pollens for hay fever. Acta Allergol. 68; 23(2):146–60. It does not meet ALL the inclusion criteria Can’t decifer what 1/100 to 1/10k means w/respect to allergen conc (?) [PubMed: 5755560]
  590. Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol. 90; 85(2):473–9. It does not meet ALL the inclusion criteria. [PubMed: 2406324]
  591. Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol. 90; 85(2):473–9. obs case series. [PubMed: 2406324]
  592. Hejjaoui A, Ferrando R, Dhivert H, Michel FB, Bousquet J. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol. 92; 89(5):925–33. It does not meet ALL the inclusion criteria. [PubMed: 1583250]
  593. Henzgen M, Wenz W, Strumpfel R. Experiences with desensitization of early spring pollen allergy using 2 tree pollen extracts. Z Gesamte Inn Med. 89; 44(22):691–3. Non-English article. [PubMed: 2626850]
  594. High-dose sublingual immunotherapy in children at 8-year follow-up. Part of 2999. [PubMed: 19354077]
  595. Hill DJ, Smart IJ, Hosking CS. Specific cellular and humoral immunity in children with grass pollen asthma. Clin Allergy. 82; 12(1):83–9. It does not meet ALL the inclusion criteria. [PubMed: 7067069]
  596. Hirokawa Y, Kondo T, Kobayashi I, Ohta Y. Rush immunotherapy with house dust extract in patients with mild extrinsic asthma. Tohoku J Exp Med. 96; 178(4):371–80. It does not meet ALL the inclusion criteria. [PubMed: 8804154]
  597. Hirsch SR, Kalbfleisch JH, Cohen SH. Comparison of Rinkel injection therapy with standard immunotherapy. J Allergy Clin Immunol. 82; 70(3):183–90. Other reason for exclusion (specify):epicutan. [PubMed: 7108070]
  598. Hirsch SR, Kalbfleisch JH, Golbert TM, Josephson BM, McConnell LH, Scanlon R, Kniker WT, Fink JN, Murphree JJ, Cohen SH. Rinkel injection therapy: a multicenter controlled study. J Allergy Clin Immunol. 81; 68(2):133–55. Other reason for exclusion (specify):epicutan. [PubMed: 7019293]
  599. Hofman J, Botulinska E, Tobolczyk J. Subclasses of immunoglobulin G in children with atopic bronchial asthma. Pol Merkur Lekarski. 2004;16(92):108–10. Does not apply to any of the key questions. [PubMed: 15176290]
  600. Hoiby AS, Strand V, Robinson DS, Sager A, Rak S. Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy. 2010;40(7):1062–70. Therapy NOT AVAILABLE in the U.S. [PubMed: 20642579]
  601. Hollins FR, Whittles JH. Hay fever--consideration and possible dangers in the large scale desensitisation of secondary school children. Public Health. 74; 88(3):121–9. Does not apply to any of the key questions. [PubMed: 4449976]
  602. Holt PG. Primary prevention by early intervention with specific immunotherapy. Drugs Today (Barc). 2008;44 Suppl B:75–7. No original data. [PubMed: 19221625]
  603. Hommers L, Ellert U, Scheidt-Nave C, Langen U. Factors contributing to conductance and outcome of specific immunotherapy: data from the German National Health Interview and Examination Survey 1998. Eur J Public Health. 2007;17(3):278–84. Does not apply to any of the key questions. [PubMed: 17060335]
  604. Horak F, Watson K. A comparison of two grass pollen extracts in the treatment of hay fever. Allergol Immunopathol (Madr). 87; 15(2):59–64. Therapy NOT AVAILABLE in the U.S. [PubMed: 3618442]
  605. Horak F. Costs of allergy therapy. Wien Med Wochenschr. 99; 149(14–15):444–6. No original data. [PubMed: 10584291]
  606. Horak F, Jager S, Skoda-Turk R. Reduced allergen immunotherapy of grass pollinosis (author’s transl). Wien Klin Wochenschr Suppl. 80; 117:36–8. Therapy NOT AVAILABLE in the U.S. [PubMed: 6936982]
  607. Horak F, Jager S, Skoda-Turk R. Reduced allergen immunotherapy of grass pollinosis (author’s transl). Wien Klin Wochenschr Suppl. 80; 117:36–8. Therapy NOT AVAILABLE in the U.S. [PubMed: 6936982]
  608. Horak F, Jager S, Turk R. Assessment of therapeutic success of a specific immunotherapy of grass pollen allergy. Laryngol Rhinol Otol (Stuttg). 83; 62(9):416–8. Does not apply to any of the key questions. [PubMed: 6355717]
  609. Horak F, Jager S, Turk R. Assessment of therapeutic success of a specific immunotherapy of grass pollen allergy. Laryngol Rhinol Otol (Stuttg). 83; 62(9):416–8. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 6355717]
  610. House dust mite specific sublingual immunotherapy in children with asthma and rhinitis; A long term follow-up after cessation of treatment. Meeting abstract.
  611. Hurst DS, Gordon BR, Fornadley JA, Hunsaker DH. Safety of home-based and office allergy immunotherapy: A multicenter prospective study. Otolaryngol Head Neck Surg. 99; 121(5):553–61. It does not meet ALL the inclusion criteria. [PubMed: 10547469]
  612. Hyposensitisation to house dust mites. Br Med J. 80; 280(6214):589–90. No original data. [PMC free article: PMC1600738] [PubMed: 7370597]
  613. Hyposensitization in childhood asthma. Br Med J. 68; 2(5603):478–9. No original data. [PMC free article: PMC1991877] [PubMed: 5648295]
  614. Hyposensitization in childhood hay fever. A comparison of refined and whole timothy extracts. Excluded at data abstraction. [PubMed: 6108724]
  615. Hyposensitization with Dermatophagoides pteronyssinus antigen: trial in asthma induced by house dust. Excluded at data abstraction. [PMC free article: PMC1799252] [PubMed: 4940158]
  616. Hyposensitization with Dermatophagoides pteronyssinus in house dust allergy: a controlled study of clinical and immunological effects. Excluded at data abstraction. [PubMed: 4131252]
  617. Hyposensitization with extracts of Dermatophagoides pteronyssinus and house dust. Excluded at data abstraction. [PubMed: 4643787]
  618. Ibero M, Castillo MJ. Significant improvement of specific bronchial hyperreactivity in asthmatic children after 4 months of treatment with a modified extract of dermatophagoides pteronyssinus. J Investig Allergol Clin Immunol. 2006;16(3):194–202. Therapy NOT AVAILABLE in the U.S. [PubMed: 16784014]
  619. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. Excluded at data abstraction. [PMC free article: PMC302277] [PubMed: 4119162]
  620. Iglesias-Cadarso A, Hernandez-Weigand P, Reano M, Herrera I, Sanchez-Morillas L, Perez-Pimiento A. A prospective safety study of allergen immunotherapy in daily clinical practice. Allergol Immunopathol (Madr). 2004;32(5):278–83. It does not meet ALL the inclusion criteria. [PubMed: 15456624]
  621. Iikura Y, Otuka T, Sakamoto Y, Kimata M, Akasawa A, Uekusa T, Saito H, Sakaguchi N, Koya N, Matsumoto K. Study of clinical effects of immunotherapy in childhood asthma. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 97(91):45–55. It does not meet ALL the inclusion criteria. [PubMed: 9383891]
  622. Immunotherapy as a method of causal treatment of atopic bronchial asthma. Library unable to locate. [PubMed: 1114118]
  623. Immunotherapy in allergy to dog: a double-blind clinical study. Part of 5737. [PubMed: 6742528]
  624. Immunotherapy in bronchial asthma sensitive to pollens. Study of its efficacy. Library unable to locate.
  625. Immunotherapy in hay fever with two major allergens 19, 25 and partially purified extract of timothy grass pollen. A controlled double blind study. In vivo variables, season I. Part of 4181. [PubMed: 7008640]
  626. Immunotherapy is allergen-specific: A double-blind trial of mite or timothy extract in mite and grass dual-allergic patients. Library unable to locate. [PubMed: 22212720]
  627. Immunotherapy of hay fever with ragweed antigen E: comparisons with whole pollen extract and placebos. Excluded at data abstraction. [PubMed: 4873833]
  628. Immunotherapy vs inhaled budesonide in bronchial asthma: an open, parallel, comparative trial. Excluded at data abstraction. [PubMed: 9420131]
  629. Immunotherapy with a fast updosed hypoallergenic SCIT formulation: A retrospective study on tolerability in children and adolescents. Meeting abstract.
  630. Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment. Excluded at abstract level. [PubMed: 2913138]
  631. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. Duplicate. [PubMed: 3950252]
  632. Immunotherapy with partially purified ansd standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. Excluded at data abstraction. [PubMed: 3950252]
  633. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. Excluded at data abstraction. [PubMed: 9684190]
  634. Immunotherapy. CMAJ. 2005;173(6 Suppl):S46–50. No original data. [PMC free article: PMC1329954] [PubMed: 16157737]
  635. Immunotherapy: new guidelines suggest a ‘window’ for prevention. Dis Manag Advis. 2003;9(4):59–61. 50. No original data. [PubMed: 12751144]
  636. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Duplicate. [PubMed: 14656349]
  637. Imperial College London. Randomized double blind placebo controlled trial of grass pollen immunotherapy using a cluster regime completed. ClinicalTrials.gov. [accessed 31 Jul 2008]. Does not apply to any of the key questions No original data.
  638. Imunoterapia com extrato de Dermatophagoides pteronyssinus em pacientes asmbticos. Library unable to locate.
  639. Imuunotherapy administered under the tongue to treat dust mite allergy. Library unable to locate.
  640. In ‘t Veen JC, Sterk PJ, Bel EH. Alternative strategies in the treatment of bronchial asthma. Clin Exp Allergy. 2000;30(1):16–33. No original data. [PubMed: 10606927]
  641. Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir Y. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol. 2007;17(2):85–91. It does not meet ALL the inclusion criteria. [PubMed: 17460946]
  642. Inci D, Altintas DU, Kendirli SG, Yilmaz M, Karakoc GB. The effect of specific immunotherapy on exhaled breath condensate nitrite levels. Allergy. 2006;61(7):899–900. It does not meet ALL the inclusion criteria. [PubMed: 16792595]
  643. Increasing long-term safety of seasonal grass pollen sublingual immunotherapy: The ECRIT study. Library unable to locate. [PubMed: 21980934]
  644. Influence of early specific immunotherapy by house dust mite allergens on development of asthma in children with atopic dermatitis. Library unable to locate.
  645. Initial results of specific desensitization of seasonal allergic rhinitis in the Otolaryngologic Clinic of the I.P. Pavlov Medical Institute in Plovdiv, Bulgaria. Library unable to locate. [PubMed: 5376713]
  646. Injection of low-dose antigen attenuates the response to subsequent bronchoprovocative challenge. Excluded at data abstraction. [PubMed: 3138609]
  647. Inmunoterapia alergqnica en asma bronquial. Library unable to locate.
  648. Intraseasonal short-time updosing with SQ-standardised subcutaneous immunotherapy in patients with intermittent allergic rhinitis: a new therapeutic option. Meeting abstract.
  649. Investigation of asthma prevention by specific immunotherapy in children. Library unable to locate.
  650. Investigation of the immunologic basis of clinical improvement by immunotherapy (IT) with grass pollen and dermatophagoides pteronyssinus (Der p) extracts in asthma abstract. Abstract only.
  651. Ishimova LM, Sokolova TS, Khutueva SKh. Clinical aspects, specific diagnosis and hyposensitization in pollinosis in children. Pediatriia. 70; 49(4):27–31. RussianNon-English article. [PubMed: 5533279]
  652. Ishizaki T, Kawakami Y. Effect of Broncasma Berna on bronchial asthma. A double blind study. Schweiz Med Wochenschr. 73; 103(12):455–9. No SIT. [PubMed: 4572552]
  653. Isotypic and antigenic restriction of the blocking antibody response to ryegrass pollen: correlation of rye group I antigen-specific IgG1 with clinical response. Part of 4861. [PubMed: 3819220]
  654. Ito H, Nishimura J, Mamiya S, Suzuki M, Yokota A, Baba S. A study of the changes in the level of serum IgG4 antibody and soluble CD23 (s-CD23) in nasal allergy patients with immunotherapy. Auris Nasus Larynx. 93; 20(3):185–96. Therapy NOT AVAILABLE in the U.S. [PubMed: 8297266]
  655. Ito K. Clinical study on hyposensitization therapy of bronchial asthma. Arerugi. 68; 17(3):164–78. Other reason for exclusion (specify):chinese. [PubMed: 5677704]
  656. Ito K. Clinical study on pollenosis. Nippon Naika Gakkai Zasshi. 92; 81(9):1502–8. Therapy NOT AVAILABLE in the U.S. [PubMed: 1280671]
  657. Ito K. Clinical study on pollenosis. Nippon Naika Gakkai Zasshi. 92; 81(9):1502–8. Therapy NOT AVAILABLE in the U.S. [PubMed: 1280671]
  658. Ito Y, Takahashi Y, Fujita T, Fukuyama S. Clinical effects of immunotherapy on Japanese cedar pollinosis in the season of cedar and cypress pollination. Auris Nasus Larynx. 97; 24(2):163–70. It does not meet ALL the inclusion criteria. [PubMed: 9134139]
  659. Ito Y, Takahashi Y, Fujita T, Fukuyama S. Clinical effects of immunotherapy on Japanese cedar pollinosis in the season of cedar and cypress pollination. Auris Nasus Larynx. 97; 24(2):163–70. It does not meet ALL the inclusion criteria. [PubMed: 9134139]
  660. Iusuf-zade LI. Effect of specific hyposensitization on the general and antigen-specific IgE content in the atopic form of bronchial asthma in children. Vopr Okhr Materin Det. 80; 25(3):11–3. Not an RCT. [PubMed: 6155732]
  661. Iusuf-zade LI. Effect of specific hyposensitization on the general and antigen-specific IgE content in the atopic form of bronchial asthma in children. Vopr Okhr Materin Det. 80; 25(3):11–3. Not an RCT. [PubMed: 6155732]
  662. Bird JA, Abramson S. Pediatric asthma and allergy. Journal of Asthma and Allergy Educators. 2011;2(5):253–254. It does not meet ALL the inclusion criteria.
  663. Bucur J, Dreborg S, Einarsson R, Ljungstedt-Pahlman I, Nilsson JE, Persson G. Immunotherapy with dog and cat allergen preparations in dog-sensitive and cat-sensitive asthmatics. Ann Allergy. 1989;62(4):355–61. Not an RCT. [PubMed: 2705663]
  664. Lee JE, Choi YS, Kim MS, Han DH, Rhee CS, Lee CH, Kim DY. Efficacy of sublingual immunotherapy with house dust mite extract in polyallergen sensitized patients with allergic rhinitis. 2011;(1):79–84. Not an RCT. [PubMed: 21704889]
  665. Warner JO. Immunotherapy in asthma. Paediatrics and Child Health. 2011;21(7):329–330. Not an RCT.
  666. Panasoff J. Slit vs. Slipt. Pediatric Allergy and Immunology. 2011;22(8):876. It does not meet ALL the inclusion criteria. [PubMed: 22122791]
  667. Jablonski K, Tronnier H. Tinnitus as a side effect of hyposensitization treatment. Case report. Derm Beruf Umwelt. 86; 34(2):39–41. It does not meet ALL the inclusion criteriadOther reason for exclusion (specify):case report. [PubMed: 3698835]
  668. Jacobsen L. Immunotherapy for the prevention of allergic diseases. Clin Allergy Immunol. 2004;18:529–40. No original data. [PubMed: 15042933]
  669. Jacquemin MG, Saint-Remy JM. Epitope-specific down-regulation of anti-allergen antibodies following injection of allergen-antibody complexes in hypersensitive patients. Int Arch Allergy Immunol. 95; 107(1–3):313–5. It does not meet ALL the inclusion criteria. [PubMed: 7542082]
  670. JAGGI OP, VISWANATHAN R. EVALUATION OF HYPOSENSITISATION IN CASES OF SEASONAL ASTHMA. J Indian Med Assoc. 64; 43:107–11. It does not meet ALL the inclusion criteriadose unclear. [PubMed: 14197938]
  671. Jahnz-Rozyk K, Glodzinska-Wyszogrodzka E, Rozynska-Polanska R, Paluchowska E, Zabielski LS. The effect of specific immunotherapy on serum eotaxin level in patients with pollinosis: preliminary studies. Pol Merkur Lekarski. 2001;11(63):244–6. Other reason for exclusion (specify): [PubMed: 11761820]
  672. Jahnz-Rozyk K, Kuna P, Pojda Z, Pirozynska E. The effect of specific immunotherapy on the concentration of some chemokines in BALF in patients with atopic bronchial asthma. Pol Merkur Lekarski. 96; 1(4):223–6. Other reason for exclusion (specify): [PubMed: 9156928]
  673. Jahnz-Rozyk K, Targowski T, Glodzinska-Wyszogrodzka E, Plusa T. Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis. Allergy. 2003;58(7):595–601. Therapy NOT AVAILABLE in the U.S. [PubMed: 12823117]
  674. Jarisch R. Specific immune therapy. Padiatr Padol. 90; 25(6):405–7. It does not meet ALL the inclusion criteria.
  675. Jarisch R. Specific immune therapy. Padiatr Padol. 90; 25(6):405–7. It does not meet ALL the inclusion criteria.
  676. Jarisch R, Sandor I, Gotz M, Kummer F. Immunotherapy of allergic disease. Studies on 460 patients. Hautarzt. 79; 30(7):365–70. Therapy NOT AVAILABLE in the U.S. [PubMed: 478857]
  677. Jarisch R, Sandor I, Gotz M, Popow C. Specific immunotherapy of allergic diseases: application, effect and side-effects (author’s transl). Wien Klin Wochenschr Suppl. 80; 117:15–8. No original data. [PubMed: 6936976]
  678. Jarisch R, Sandor I, Gotz M, Popow C. Specific immunotherapy of allergic diseases: application, effect and side-effects (author’s transl). Wien Klin Wochenschr Suppl. 80; 117:15–8. No original dataOther reason for exclusion (specify):venom. [PubMed: 6936976]
  679. Jerzynska J, Stelmach W, Majak P, Brzozowska A, Sobocinska A, Stelmach I. Effect of specific immunotherapy on serum levels of tumor necrosis factor alpha in asthmatic children. Allergy Asthma Proc. 2008;29(3):274–9. It does not meet ALL the inclusion criteria. [PubMed: 18534085]
  680. Jo T, Kikuchi H, Hamaguchi Y, Orita R, Komoto K. Relationship between the specificity of the antigen used and its therapeutic effect in the hyposensitization therapy. Arerugi. 70; 19(9):718–22. Non-English article. [PubMed: 5473925]
  681. Johnson KH, Millard PS. Desensitization therapy for asthma in allergic children. J Fam Pract. 97; 44(5):439–40. No original data. [PubMed: 9152253]
  682. Johnstone DE. Immunotherapy in children: past, present, and future. (Part I). Ann Allergy. 81; 46(1):1–7. No original data. [PubMed: 6161571]
  683. Johnstone DE. Immunotherapy in children: past, present, and future. (Part II). Ann Allergy. 81; 46(2):59–66. No original data. [PubMed: 7008661]
  684. Johnstone DE. Uses and abuses of hyposensitization in children. Am J Dis Child. 72; 123(1):78–83. Other reason for exclusion (specify): review. [PubMed: 4258718]
  685. Jones SK, Lovell CR, Peachey RD. Delayed onset of inflammatory nodules following hay fever desensitization injections. Clin Exp Dermatol. 88; 13(6):376–8. Therapy NOT AVAILABLE in the U.S. [PubMed: 3256456]
  686. Jorde W, Kersten W. Allergic pulmonary diseases in childhood. Diagnostic and therapeutic results. Med Klin. 73; 68(29):961–5. No original data. [PubMed: 4146865]
  687. Joshi SV, Tripathi DM, Dhar HL. Allergen specific immunotherapy in nasobronchial allergy. Indian J Med Sci. 2003;57(12):527–34. It does not meet ALL the inclusion criteriano controls. [PubMed: 14701944]
  688. Jung CM, Prinz JC, Rieber EP, Ring J. A reduction in allergen-induced Fc epsilon R2/CD23 expression on peripheral B cells correlates with successful hyposensitization in grass pollinosis. J Allergy Clin Immunol. 95; 95(1 Pt 1):77–87. It does not meet ALL the inclusion criteria. [PubMed: 7822667]
  689. Jung CM, Prinz JC, Rieber EP, Ring J. A reduction in allergen-induced Fc epsilon R2/CD23 expression on peripheral B cells correlates with successful hyposensitization in grass pollinosis. J Allergy Clin Immunol. 95; 95(1 Pt 1):77–87. It does not meet ALL the inclusion criteriaTherapy NOT AVAILABLE in the U.S. [PubMed: 7822667]
  690. Juniper EF, Kline PA, Ramsdale EH, Hargreave FE. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 90; 85(3):606–11. No SIT. [PubMed: 2107241]
  691. Juniper E. In re: Van Bever HP, Stevens WJ. (JACI 1990;86:141–6). J Allergy Clin Immunol. 91; 88(2):283–4. No original data. [PubMed: 1880332]
  692. Juniper E. In re: Van Bever HP, Stevens WJ. (JACI 1990;86:141–6). J Allergy Clin Immunol. 91; 88(2):283–4. No original data. [PubMed: 1880332]
  693. Just J, Bodart E, Pothel E, Boule M, Grimfeld A, Tournier G. Value of accelerated hyposensitization with mixed allergens in severe childhood asthma. Ann Pediatr (Paris). 92; 39(4):236–40. It does not meet ALL the inclusion criteriano controls. [PubMed: 1616237]
  694. Justicia JL, Mullol J. Higher evidence for specific immunotherapy than reported in the ARIA update. J Allergy Clin Immunol. 2008;121(2):536. author reply 536. No original data. [PubMed: 18061656]
  695. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003;33(5):1205–14. It does not meet ALL the inclusion criteria. [PubMed: 12731045]
  696. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003;33(5):1205–14. It does not meet ALL the inclusion criteria. [PubMed: 12731045]
  697. Aas K. Hyposensitization in house dust allergy asthma. A double-blind controlled study with evaluation of the effect on bronchial sensitivity to house dust. Acta Paediatr Scand. 1971;60(3):264–8. Other reason for exclusion (specify):house dust. [PubMed: 4931556]
  698. Nieminen K, Valovirta E, Savolainen J. Clinical outcome and IL-17, IL-23, IL-27 and FOXP3 expression in peripheral blood mononuclear cells of pollen-allergic children during sublingual immunotherapy. 2010;(1 Pt 2):e174–84. Does not apply to any of the key questions Not an RCT. [PubMed: 19566585]
  699. Kaad PH, Ostergaard PA. The hazard of mould hyposensitization in children with asthma. Clin Allergy. 82; 12(3):317–20. Other reason for exclusion (specify):ALUTARD--? depot prep. [PubMed: 7105396]
  700. Kaita T. Studies on bronchial asthma in children. 3. Hyposensitization therapy of bronchial asthma in children. Hiroshima J Med Sci. 67; 16(3):177–84. It does not meet ALL the inclusion criteriahouse dust IT. [PubMed: 5602849]
  701. Kakinoki Y, Ohashi Y, Nakai Y, Tanaka A, Washio Y. Pollen immunotherapy inhibits T helper 1 and 2 cell responses, but suppression of T helper 2 cell response is a more important mechanism related to the clinical efficacy. Arch Otolaryngol Head Neck Surg. 2000;126(1):63–70. It does not meet ALL the inclusion criteria no controls. [PubMed: 10628713]
  702. Kakinoki Y, Ohashi Y, Nakai Y, Washio Y, Nasako Y, Tanaka A, Nakai Y. Allergen induced mRNA expression of interleukin-5, but not of interleukin-4 and interferon-gamma, in peripheral blood mononuclear cells obtained before the pollen season predicts the clinical efficacy of immunotherapy for seasonal allergic rhinitis. Scand J Immunol. 2000;51(2):202–8. It does not meet ALL the inclusion criteria no controls. [PubMed: 10652165]
  703. Kaliner M, Lemanske R. Rhinitis and asthma. JAMA. 92; 268(20):2807–29. No original data. [PubMed: 1433696]
  704. Kalla M, Rozniecki J, Polanska Z, Swatko A. Evaluation of the effectiveness of desensitization in bronchial asthma caused by house dust mites or grass pollen in the light of clinical results and the histamine and polymyxin inhalation test. Pol Tyg Lek. 79; 34(22):865–8. Therapy NOT AVAILABLE in the U.S Other reason for exclusion (specify): [PubMed: 482149]
  705. Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. 2009. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 19732370]
  706. Kammoun R, Yousfi H, Najah S. 200 cases of allergic asthma treated with specific desensitization. Tunis Med. 84; 62(3):217–20. It does not meet ALL the inclusion criteriano controlsTherapy NOT AVAILABLE in the U.S. [PubMed: 6528399]
  707. Kandil AA, Hasan A, Taha O, El-Mesallamy H. Eosinophil cationic protein as a diagnostic marker for asthmatic children treated by immunotherapy. Egypt J Immunol. 2003;10(1):67–76. It does not meet ALL the inclusion criteriahomemade extractsDoes not apply to any of the key questions. [PubMed: 15719624]
  708. Kane PA, Ayad M, Hane A, Wane S. Specific desensitization, basic treatment of asthma. Our experience in Dakar apropos of 56 cases. Dakar Med. 80; 25(1):51–8. It does not meet ALL the inclusion criteriano controls. [PubMed: 7460738]
  709. Kang BC, Johnson J, Morgan C, Chang JL. The role of immunotherapy in cockroach asthma. J Asthma. 88; 25(4):205–18. It does not meet ALL the inclusion criteria. [PubMed: 2460431]
  710. KAPLAN MA, SPITZER RH, GUTMAN AA, KALAYIL PK. HYPOSENSITIZATION STUDIES WITH A PURIFIED DWARF RAGWEED FRACTION. Ann Allergy. 63; 21:494–504. It does not meet ALL the inclusion criteriano controlsTherapy NOT AVAILABLE in the U.S. [PubMed: 14062371]
  711. Karaayvaz M, Ozanguc N. Recall urticaria: a case report. J Allergy Clin Immunol. 96; 97(6):1419–20. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 8648043]
  712. Karaayvaz M, Erel F, Caliskaner Z, Ozanguc N. Systemic reactions due to allergen immunotherapy. J Investig Allergol Clin Immunol. 99; 9(1):39–44. It does not meet ALL the inclusion criteria. [PubMed: 10212856]
  713. Karakaya G, Sahin S, Fuat Kalyoncu A. Erythema multiforme: As a complication of allergen-specific immunotherapy. Allergol Immunopathol (Madr). 2001;29(6):276–8. Other reason for exclusion (specify):case report. [PubMed: 11834187]
  714. Karl S, Rakoski J. Hyposensitization with cross-reacting pollen allergens. Z Hautkr. 88; 63(Suppl 4):55–7. Non-English article. [PubMed: 3252627]
  715. Karlsson R, Agrell B, Dreborg S, Foucard T, Kjellman NI, Koivikko A, Einarsson R. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. II. In vitro results. Allergy. 86; 41(2):141–50. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 3518527]
  716. Katelaris CH. Modern management of allergic rhinitis. Adv Otorhinolaryngol. 97; 51:68–71. No original dataOther reason for exclusion (specify): review. [PubMed: 9017073]
  717. Kato S, Nakai Y, Ohashi Y, Kato M. RAST in diagnosis and therapy of allergic rhinitis. Acta Otolaryngol Suppl. 91; 486:209–16. It does not meet ALL the inclusion criteriano controlsDoes not apply to any of the key questions. [PubMed: 1842868]
  718. Kats PD, Ostroumov AI, Ametov AS, Iusuf-Zade LI, Toritsina LK. Clinico-immunological characteristics of peroral specific hyposensitization in hay fevers in children. Pediatriia. 85(8):18–21. Other reason for exclusion (specify): Oral ITnot SLIT. [PubMed: 4069876]
  719. Kawakami A, Koketsu R, Suzukawa M, Nagao M, Hiraguchi Y, Tokuda R, Fujisawa T, Nagase H, Ohta K, Yamamoto K, Yamaguchi M. Blocking antibody is generated in allergic rhinitis patients during specific immunotherapy using standardized Japanese cedar pollen extract. Int Arch Allergy Immunol. 2008;146 Suppl 1:54–60. It does not meet ALL the inclusion criteriano controls. [PubMed: 18504408]
  720. Kawakami A, Koketsu R, Suzukawa M, Nagao M, Hiraguchi Y, Tokuda R, Fujisawa T, Nagase H, Ohta K, Yamamoto K, Yamaguchi M. Blocking antibody is generated in allergic rhinitis patients during specific immunotherapy using standardized Japanese cedar pollen extract. Int Arch Allergy Immunol. 2008;146 Suppl 1:54–60. It does not meet ALL the inclusion criteria. [PubMed: 18504408]
  721. Kelso JM, Jones RT, Tellez R, Yunginger JW. Oral allergy syndrome successfully treated with pollen immunotherapy. Ann Allergy Asthma Immunol. 95; 74(5):391–6. It does not meet ALL the inclusion criteria Number of subjects in study is 6 or fewer on active treatment (Unless it reports harms)
  722. KERR JW, MURCHISON LE. A CONTROLLED TRIAL OF POLLEN ADSORBATE IN THE TREATMENT OF HAY FEVER. Scott Med J. 63; 8:484–8. Therapy NOT AVAILABLE in the U.S. [PubMed: 14089225]
  723. Kerr JW. Does immunotherapy have a role in the treatment of asthma? Clin Allergy. 86; 16(2):179–80. No original dataOther reason for exclusion (specify): letter. [PubMed: 3708792]
  724. Kersten W. How and when is immunotherapy for pollen allergy carried out? Med Klin. 80; 75(21):751–4. It does not meet ALL the inclusion criteriano controls. [PubMed: 7453622]
  725. Keskin O, Tuncer A, Yildirim S, Bursali B, Adalioglu G, Sekerel BE. Does specific immunotherapy injection cause an increase in bronchial reactivity? J Asthma. 2005;42(9):765–8. It does not meet ALL the inclusion criteriano rel outcomesDoes not apply to any of the key questions. [PubMed: 16316871]
  726. Kim HB, Jin HS, Lee SY, Kim JH, Kim BS, Park SJ, Hong SJ. The effect of rush immunotherapy with house dust mite in the production of IL-5 and IFN-gamma from the peripheral blood T cells of asthmatic children. J Korean Med Sci. 2009;24(3):392–7. It does not meet ALL the inclusion criteria. [PMC free article: PMC2698182] [PubMed: 19543499]
  727. Kim ST, Han DH, Moon IJ, Lee CH, Min YG, Rhee CS. Clinical and immunologic effects of sublingual immunotherapy on patients with allergic rhinitis to house-dust mites: 1-year follow-up results. Am J Rhinol Allergy. 2010;24(4):271–5. It does not meet ALL the inclusion criteriano controls. [PubMed: 20819465]
  728. Kim ST, Han DH, Moon IJ, Lee CH, Min YG, Rhee CS. Clinical and immunologic effects of sublingual immunotherapy on patients with allergic rhinitis to house-dust mites: 1-year follow-up results. Am J Rhinol Allergy. 2010;24(4):271–5. It does not meet ALL the inclusion criteria. [PubMed: 20819465]
  729. Kimura I, Tanizaki Y, Goda Y, Komagoe H, Kitani H. Decrease in reactivity of basophils by immunotherapy with housedust extract. Clin Allergy. 85; 15(1):1–7. It does not meet ALL the inclusion criteria. [PubMed: 3872183]
  730. King TP, Norman PS. Standardized extracts, weeds. Clin Rev Allergy. 86; 4(4):425–33. No original data. [PubMed: 2433014]
  731. Kitao Y. Investigation of specific immunotherapy in patients with nasal allergy to housedust and mite: histamine release assay from their peripheral leukocytes. Nippon Jibiinkoka Gakkai Kaiho. 87; 90(6):896–902. Does not apply to any of the key questions. [PubMed: 2444684]
  732. Klein GL, Ziering RW. Diagnosis and treatment of allergic rhinitis and asthma in infancy and childhood. Compr Ther. 84; 10(3):26–30. No original data. [PubMed: 6201318]
  733. Klein GL, Ziering RW. Diagnosis and treatment of allergic rhinitis and asthma in infancy and childhood. Compr Ther. 84; 10(3):26–30. No original data. [PubMed: 6201318]
  734. Klein JS. Ragweed immunotherapy in adult asthma. N Engl J Med. 96; 335(3):204. author reply 205–6. No original data. [PubMed: 8657224]
  735. Klein-Tebbe J, Kunkel G. Current status of specific hyposensitization in the treatment of bronchial asthma. Pneumologie. 91; 45(8):630–2. No original data. [PubMed: 1946261]
  736. Kljaic-Turkalj M, Cvoriscec B, Tudoric N, Stipic-Markovic A, Rabatic S, Trescec A, Gagro A, Dekaris D. Decrease in CD23+ B lymphocytes and clinical outcome in asthmatic patients receiving specific rush immunotherapy. Int Arch Allergy Immunol. 96; 111(2):188–94. It does not meet ALL the inclusion criteria. [PubMed: 8859229]
  737. Koker O, Guneser S, Altintas D, Kozanoglu M. Effect of specific immunotherapy in Dermatophagoides pteronyssinus allergic children. Acta Paediatr Jpn. 94; 36(2):150–2. It does not meet ALL the inclusion criteria. [PubMed: 8203258]
  738. Komagoe H, Sudo M, Tanizaki Y, Kitani H, Goda Y, Sasaki Y, Tada S, Takahashi K, Kimura I. Changes in basophil reactivity during immunotherapy with house dust. Arerugi. 84; 33(3):131–4. Non-English article: japanese. [PubMed: 6466101]
  739. Kopitowski Karin. Inmunoterapia con alergenos para el asma. Evid. actual. prbct. ambul. 2004;7(1):26–27. Other reason for exclusion (specify):case report.
  740. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009;39(2):271–9. Therapy NOT AVAILABLE in the U.S. [PubMed: 19016798]
  741. Kopp MV, Stenglein S, Kamin W, Friedrichs F, von Berg A, Zielen S, Hamelmann E, Wahn U, Kuehr J. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. Pediatr Allergy Immunol. 2007;18(6):523–7. It does not meet ALL the inclusion criteria. [PubMed: 17680911]
  742. Korzeniowska-Zuk E, Romanski B. Studies on the possibility of desensitizing patients sensitive to plant pollens and house dust by an oral route. Pneumonol Alergol Pol. 92; 60(7–8):32–8. Other reason for exclusion (specify): oral IT. [PubMed: 1493516]
  743. Kossowski S, Gieldanowski J, Greczek-Harkawy J, Ziemski ZL. Clinical and immunologic studies on fetid atrophic rhinitis (ozena) of the nasopharyngeal cavity treated with a specific vaccine. Arch Immunol Ther Exp (Warsz). 73; 21(5):715–20. It does not meet ALL the inclusion criteria. [PubMed: 4771981]
  744. Kossowski S, Gieldanowski J, Greczek-Harkawy J, Ziemski ZL. Clinical and immunologic studies on fetid atrophic rhinitis (ozena) of the nasopharyngeal cavity treated with a specific vaccine. Arch Immunol Ther Exp (Warsz). 73; 21(5):715–20. It does not meet ALL the inclusion criteriaNo SIT. [PubMed: 4771981]
  745. Kowal K, Nolte H, Skov PS, DuBuske LM. Effect of allergen-specific immunotherapy on recombinant human interleukin 3-mediated amplification of allergen-induced basophil histamine release. Allergy Asthma Proc. 2005;26(6):456–62. It does not meet ALL the inclusion criteria. [PubMed: 16541969]
  746. Kowal K, Nolte H, Skov PS, DuBuske LM. Effect of allergen-specific immunotherapy on recombinant human interleukin 3-mediated amplification of allergen-induced basophil histamine release. Allergy Asthma Proc. 2005;26(6):456–62. It does not meet ALL the inclusion criteria. [PubMed: 16541969]
  747. Kowal K, Osada J, Zukowski S, Dabrowska M, Dubuske L, Bodzenta-Lukaszyk A. Expression of interleukin 4 receptors in bronchial asthma patients who underwent specific immunotherapy. Ann Allergy Asthma Immunol. 2004;93(1):68–75. It does not meet ALL the inclusion criteria. [PubMed: 15281474]
  748. Kowal K, Osada J, Zukowski S, Dabrowska M, Dubuske L, Bodzenta-Lukaszyk A. Expression of interleukin 4 receptors in bronchial asthma patients who underwent specific immunotherapy. Ann Allergy Asthma Immunol. 2004;93(1):68–75. patient preference. [PubMed: 15281474]
  749. Krouse JH, Krouse HJ. Efficacy of immunotherapy based on skin end-point titration. Otolaryngol Head Neck Surg. 2000;123(3):183–7. It does not meet ALL the inclusion criteria Dose not specified. [PubMed: 10964288]
  750. Kruszewski J, Raczka A. Allergen-specific IgG-4 in patients with atopic diseases of the respiratory tract. Arch Immunol Ther Exp (Warsz). 93; 41(2):115–9. It does not meet ALL the inclusion criteria. [PubMed: 7694562]
  751. Kruszewski J, Makowska U, Wasek Z, Plusa T. Changes in various immunobiochemical parameters in patients with bronchial asthma during specific desensitization. Pneumonol Pol. 84; 52(2):77–81. Polish Non-English article. [PubMed: 6201833]
  752. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann KC, Rolinck-Werninghaus C, Grave M, Hultsch T, Wahn U. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(2):274–80. No SIT. [PubMed: 11842297]
  753. Kumar R. Evaluation of skin tests and desensitization in allergic rhinitis. J Laryngol Otol. 77; 91(9):795–803. It does not meet ALL the inclusion criteria Dose not specified. [PubMed: 335006]
  754. Kumar R. Evaluation of skin tests and desensitization in allergic rhinitis. J Laryngol Otol. 77; 91(9):795–803. It does not meet ALL the inclusion criteria. [PubMed: 335006]
  755. Kuna P, Alam R, Kuzminska B, Rozniecki J. The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled, randomized study. J Allergy Clin Immunol. 89; 83(4):816–24. Therapy NOT AVAILABLE in the U.S. [PubMed: 2468702]
  756. Kuna P, Alam R, Kuzminska B, Rozniecki J. The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled, randomized study. J Allergy Clin Immunol. 89; 83(4):816–24. Therapy NOT AVAILABLE in the U.S. [PubMed: 2468702]
  757. Kuznetsova NI, Molotilov BA, Balabolkin II, Paziuk EA. Clinico-immunological evaluation of the effectiveness of specific hyposensitization in children with allergic diseases. Pediatriia. 82(2):35–7. polishNon-English article. [PubMed: 7041076]
  758. Grammer LC, Shaughnessy MA, Suszko IM, Shaughnessy JJ, Patterson R. Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. J Allergy Clin Immunol. 1984;73(4):484–9. Not an RCT. [PubMed: 6707391]
  759. Dubuske LM, Frew AJ, Horak F, Keith PK, Corrigan CJ, Aberer W, Holdich T, von Weikersthal-Drachenberg KJ. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. 2011;(3):239–47. Does not apply to any of the key questions. [PubMed: 21535913]
  760. Zhang L, Wang CS, Han DM. Indication and safety of immunological treatment in pediatric allergic rhinitis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011;46(1):17–8. No original data. [PubMed: 21429327]
  761. Laaksonen K, Junikka M, Lahesmaa R, Terho EO, Savolainen J. In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy. J Allergy Clin Immunol. 2003;112(6):1171–7. It does not meet ALL the inclusion criteria. [PubMed: 14657878]
  762. Lack G, Nelson HS, Amran D, Oshiba A, Jung T, Bradley KL, Giclas PC, Gelfand EW. Rush immunotherapy results in allergen-specific alterations in lymphocyte function and interferon-gamma production in CD4+ T cells. J Allergy Clin Immunol. 97; 99(4):530–8. It does not meet ALL the inclusion criteria. [PubMed: 9111499]
  763. Laetsch C, Wuthrich B. Peroral desensitization of inhalation allergies in childhood: treatment results. Schweiz Med Wochenschr. 73; 103(9):342–7. It does not meet ALL the inclusion criteria. [PubMed: 4144381]
  764. Lahoz F, Ruiz Ocana FM, Marin Nunez F, Perez Guerrero J, Sastre Castillo A. Behavior of cutaneous sensitivity in allergic asthma under specific treatment. Allerg Asthma (Leipz). 68; 14(3):122–35. It does not meet ALL the inclusion criteria.
  765. Lalek N, Kosnik M, Silar M, Korosec P. Immunoglobulin G-dependent changes in basophil allergen threshold sensitivity during birch pollen immunotherapy. Clin Exp Allergy. 2010;40(8):1186–93. Therapy NOT AVAILABLE in the U.S. [PubMed: 20528883]
  766. Lawrence AW. Clinical aspects of respiratory tract allergic diseases in Jamaica, West Indies. Ann Allergy. 82; 49(4):225–8. No SIT. [PubMed: 7125308]
  767. Le Roux P, Briquet MT, Boulloche J, Le Luyer B. Accelerated desensitization in asthma. 2-year evaluations follow-up of 16 children. Arch Fr Pediatr. 91; 48(5):374–5. It does not meet ALL the inclusion criteria,d. [PubMed: 1859246]
  768. Lee HB, Adkinson NF Jr. Measurement of IgG blocking antibody in human serum: comparison of ELISA with monoclonal antibody and fluorogenic substrate and Staphylococcus protein A solid-phase RIA. J Allergy Clin Immunol. 88; 82(1):11–9. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 3392361]
  769. Leng X, Ye ST. One year observation of immunotherapy for Artemisia hay fever in China: a clinical and immunological study. Asian Pac J Allergy Immunol. 87; 5(2):167–72. It does not meet ALL the inclusion criteria. [PubMed: 2452642]
  770. Levy DA, Lichtenstein LM, Goldstein EO, Ishizaka K. Immunologic and cellular changes accompanying the therapy of pollen allergy. J Clin Invest. 71; 50(2):360–9. It does not meet ALL the inclusion criteriano control 2nd yrDoes not apply to any of the key questions. [PMC free article: PMC291932] [PubMed: 4099843]
  771. Lewith GT, Watkins AD, Hyland ME, Shaw S, Broomfield JA, Dolan G, Holgate ST. Use of ultramolecular potencies of allergen to treat asthmatic people allergic to house dust mite: double blind randomised controlled clinical trial. BMJ. 2002;324(7336):520. It does not meet ALL the inclusion criteria. [PMC free article: PMC67767] [PubMed: 11872551]
  772. Leynadier F, Lambin P, Murrieta M, Dry J. Blocking antibodies to inhalant allergens and asthma. Allerg Immunol (Paris). 91; 23(8):341–7. No original data. [PubMed: 1723276]
  773. Li J. Specific immunotherapy of bronchial asthma. Zhonghua Jie He He Hu Xi Za Zhi. 2007;30(7):487–9. Other reason for exclusion (specify):chinese. [PubMed: 17961400]
  774. Liao TN, Hsieh KH. Altered production of histamine-releasing factor (HRF) activity and responsiveness to HRF after immunotherapy in children with asthma. J Allergy Clin Immunol. 90; 86(6 Pt 1):894–901. It does not meet ALL the inclusion criteria,d. [PubMed: 1702128]
  775. Liao TN, Hsieh KH. Altered production of histamine-releasing factor (HRF) activity and responsiveness to HRF after immunotherapy in children with asthma. J Allergy Clin Immunol. 90; 86(6 Pt 1):894–901. It does not meet ALL the inclusion criteria,d. [PubMed: 1702128]
  776. Lichtenstein LM. An evaluation of the role of immunotherapy in asthma. Am Rev Respir Dis. 78; 117(2):191–7. Other reason for exclusion (specify):Editorial. [PubMed: 637403]
  777. Lichtenstein LM. An evaluation of the role of immunotherapy in asthma. Am Rev Respir Dis. 78; 117(2):191–7. No original data. [PubMed: 637403]
  778. Lichtenstein LM, Levy DA. Is desensitization’ for ragweed hay fever immunologically specific? Int Arch Allergy Appl Immunol. 72; 42(4):615–26. It does not meet ALL the inclusion criteria. [PubMed: 4113011]
  779. Lichtenstein LM, Norman PS, Winkenwerder WL. Antibody response following immunotherapy in ragweed hay fever: Allpyral vs. whole ragweed extract. J Allergy. 68; 41(1):49–57. It does not meet ALL the inclusion criteriano cx outcomesTherapy NOT AVAILABLE in the U.S Not an RCT. [PubMed: 4169345]
  780. Lichtenstein LM, Norman PS, Winkenwerder WL. Antibody response following immunotherapy in ragweed hay fever: Allpyral vs. whole ragweed extract. J Allergy. 68; 41(1):49–57. It does not meet ALL the inclusion criteriaTherapy NOT AVAILABLE in the U.S Not an RCT. [PubMed: 4169345]
  781. Limb SL, Brown KC, Wood RA, Wise RA, Eggleston PA, Tonascia J, Hamilton RG, Adkinson NF Jr. Adult asthma severity in individuals with a history of childhood asthma. J Allergy Clin Immunol. 2005;115(1):61–6. It does not meet ALL the inclusion criteria. [PubMed: 15637548]
  782. Lin KL, Wang SY, Hsieh KH. Analysis of house dust mite-specific IgE, IgG4, and IgG antibodies during immunotherapy in asthmatic children. Ann Allergy. 91; 67(1):63–9. It does not meet ALL the inclusion criteria. [PubMed: 1859043]
  783. Lin YL, Shieh CC, Wang JY. The functional insufficiency of human CD4+CD25 high T-regulatory cells in allergic asthma is subjected to TNF-alpha modulation. Allergy. 2008;63(1):67–74. Does not apply to any of the key questions. [PubMed: 18053016]
  784. Linneberg A, Bodtger U. The use of grass pollen-specific immunotherapy among grass pollen allergic rhinitis in the general population. Allergy. 2007;62(7):825–6. It does not meet ALL the inclusion criteria. [PubMed: 17573735]
  785. Linneberg A, Bodtger U. The use of grass pollen-specific immunotherapy among grass pollen allergic rhinitis in the general population. Allergy. 2007;62(7):825–6. No original data. [PubMed: 17573735]
  786. Lipkowitz MA, Schatz M, Cook TJ, Ford L, Frankel SJ, Gluck J, Leibner D, Leija JG, Luskin A, Ortega-Carr D, Spector SL. When allergies and asthma complicate pregnancy. Ann Allergy Asthma Immunol. 98; 81(1):30–4. No original data. [PubMed: 9690570]
  787. Litwin A, Flanagan M, Entis G, Gottschlich G, Esch R, Gartside P, Michael JG. Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral immunotherapy. Ann Allergy Asthma Immunol. 96; 77(2):132–8. Therapy NOT AVAILABLE in the U.S. [PubMed: 8760779]
  788. Litwin A, Flanagan M, Entis G, Gottschlich G, Esch R, Gartside P, Michael JG. Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral immunotherapy. Ann Allergy Asthma Immunol. 96; 77(2):132–8. It does not meet ALL the inclusion criteria microencaplsulated ragweed for Oral ITTherapy NOT AVAILABLE in the U.S. [PubMed: 8760779]
  789. Litwin A, Flanagan M, Entis G, Gottschlich G, Esch R, Gartside P, Michael JG. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J Allergy Clin Immunol. 97; 100(1):30–8. Does not apply to any of the key questions. [PubMed: 9257784]
  790. Litwin M, Materna B, Grenda R, Grzesiowski P, Pilecki O, Reszczynska Z, Wozniewicz B, Kluge P, Iwanicka K. Tubulointerstitial nephritis related to immunotherapy and immunostimulation: a report of two cases. Pol Merkur Lekarski. 2001;11(63):254–8. Not an RCT. [PubMed: 11761823]
  791. Lizaso MT, Tabar AI, Garcia BE, Gomez B, Algorta J, Asturias JA, Martinez A. Double-blind, placebo-controlled Alternaria alternata immunotherapy: in vivo and in vitro parameters. Pediatr Allergy Immunol. 2008;19(1):76–81. Does not apply to any of the key questions. [PubMed: 17662037]
  792. Ljaljevic J, Ljaljevic M. Changes in humoral reactivity in pollinosis before, during, and after the completion of specific hyposensitization. Glas Srp Akad Nauka Med. 79(31):71–80. Does not apply to any of the key questions. [PubMed: 544344]
  793. Local nasal immunotherapy; Proceedings of a satellite symposium to the XVI Congress of European Academy of Allergology and Clinical Immunology; Allergy; Madrid. June 1995; pp. 5–44. No original data. [PubMed: 9254578]
  794. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 87; 79(4):660–77. Not an RCT. [PubMed: 3559001]
  795. Loechel I, Kern A. Desensitization therapy with aqueous pollen extracts in pollinosis. Dermatol Monatsschr. 70; 156(6):602–7. No original data. [PubMed: 5515612]
  796. Lofkvist T, Agrell B, Dreborg S, Svensson G. Effects of immunotherapy with a purified standardized allergen preparation of Dermatophagoides farinae in adults with perennial allergic rhinoconjunctivitis. Allergy. 94; 49(2):100–7. It does not meet ALL the inclusion criteria. [PubMed: 8172356]
  797. Lokar R, Kolbas V, Sabioncello A, Rabatic S. T-lymphocyte subpopulations in children’s atopic asthma. Allerg Immunol (Leipz). 90; 36(2):87–94. It does not meet ALL the inclusion criteria. [PubMed: 2392959]
  798. Lombardi C, Gani F, Landi M, Falagiani P, Bruno M, Canonica GW, Passalacqua G. Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol. 2004;113(6):1219–20. Therapy NOT AVAILABLE in the U.S. [PubMed: 15214362]
  799. Long-term immunologic effects of broad-spectrum aeroallergen immunotherapy. Part of 136. [PubMed: 16691031]
  800. Loren ML. Treatment of seasonal allergic rhinitis: useless versus helpful allergy therapy. BMJ. 2003;327(7425):1229. No original data. [PMC free article: PMC274099] [PubMed: 14630781]
  801. Loureiro G, Tavares B, Chieira C, Pereira C. Effect of Dermatophagoides specific immunotherapy on cutaneous reactivity. Eur Ann Allergy Clin Immunol. 2007;39(1):5–8. It does not meet ALL the inclusion criteria. [PubMed: 17375734]
  802. Loveless MH, Yost WL, Lazarus J. Safety and effectiveness of 7-n-hexyloctadecane as a vehicle in pollen repositories against hay fever. Ann Allergy. 68; 26(2):70–9. It does not meet ALL the inclusion criteria. [PubMed: 5638512]
  803. Lowance MI. Emulsified extract: 1967 report. South Med J. 68; 61(9):990–2. It does not meet ALL the inclusion criteriaTherapy NOT AVAILABLE in the U.S.
  804. Lower T, Henry J, Mandik L, Janosky J, Friday GA Jr. Compliance with allergen immunotherapy. Ann Allergy. 93; 70(6):480–2. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions.
  805. Lowewe G. Specific desensitization in hay fever with commercial allergen extracts. Z Arztl Fortbild (Jena). 66; 60(21):1211–3. It does not meet ALL the inclusion criteria. [PubMed: 5990876]
  806. Lowewe G. Specific desensitization in hay fever with commercial allergen extracts. Z Arztl Fortbild (Jena). 66; 60(21):1211–3. It does not meet ALL the inclusion criteria. [PubMed: 5990876]
  807. Lu FM, Chou CC, Chiang BL, Hsieh KH. Immunologic changes during immunotherapy in asthmatic children: increased IL-13 and allergen-specific IgG4 antibody levels. Ann Allergy Asthma Immunol. 98; 80(5):419–23. It does not meet ALL the inclusion criteria. [PubMed: 9609614]
  808. Lucarelli S, Frediani T, Finocchi M, Marchetti F, Businco E, Businco L. Blocking antibodies after specific hyposensitization therapy in asthmatic children (author’s transl). Ann Sclavo. 76; 18(5):763–6. Does not apply to any of the key questions. [PubMed: 1028390]
  809. Lue KH, Hsieh KH. Changes of allergen-specific antibodies, circulating immune complexes and restoration of polymorphonuclear leukocyte function after hyposensitization. Asian Pac J Allergy Immunol. 89; 7(1):9–14. It does not meet ALL the inclusion criteria. [PubMed: 2751772]
  810. Lue KH, Hsieh KH. Changes of allergen-specific antibodies, circulating immune complexes and restoration of polymorphonuclear leukocyte function after hyposensitization. Asian Pac J Allergy Immunol. 89; 7(1):9–14. It does not meet ALL the inclusion criteria Dose not specified. [PubMed: 2751772]
  811. Luigi A, Senna G, Mezzelani P, Pappalardo G. Safety of specific immunotherapy: a retrospective study. J Investig Allergol Clin Immunol. 94; 4(5):250–4. Not an RCT. [PubMed: 7874322]
  812. Lukan N, Racz O, Mocnejova I, Tkac I. Monitoring antioxidant enzymes in red cells during allergen immunotherapy. J Physiol Biochem. 2008;64(2):143–8. It does not meet ALL the inclusion criteria. [PubMed: 19043984]
  813. Luther B, Oehme J. Results of and experience with immunotherapy in children with asthma or allergic rhinitis (author’s transl). Monatsschr Kinderheilkd. 81; 129(8):456–9. Therapy NOT AVAILABLE in the U.S. [PubMed: 6116184]
  814. Martin-Munoz MF, Pineda F, Muinos T, Fontan M, Nevot S, Bosque M, Jurado Palomo J, Torredemer A, Valdesoiro L, Martinez Canavate AM, Pedemonte C. Marco Changes in IL-10 and specific antibodies associated to successful Dermatophagoides pteronyssinus immunotherapy in children during the first year of treatment. Allergologia et Immunopathologia. 2012. It does not meet ALL the inclusion criteria no clinical outcomes. [PubMed: 22321665]
  815. Vaughn MP. Montelukast might improve compliance with subcutaneous immunotherapy treatments in patients with allergic asthma. Journal of Allergy and Clinical Immunology. 2011;127(1):286. No SIT. [PubMed: 20850867]
  816. Mabry RL, Mabry CS. Immunotherapy for allergic fungal sinusitis: the second year. Otolaryngol Head Neck Surg. 97; 117(4):367–71. It does not meet ALL the inclusion criteriaNot an RCT. [PubMed: 9339798]
  817. Macaulay DB. Hyposensitization with emulsified pollen extracts in Britain. Int Arch Allergy Appl Immunol. 65; 28(1):12–20. Does not apply to any of the key questions. [PubMed: 5324220]
  818. Macchia L, Caiaffa MF, Di Felice G, Pini C, Bariletto G, Strada S, Tursi A. Changes in skin reactivity, specific IgE and IgG levels after one year of immunotherapy in olive pollinosis. Allergy. 91; 46(6):410–8. Does not apply to any of the key questions. [PubMed: 1957991]
  819. Macchia L, Caiaffa MF, Di Felice G, Pini C, Bariletto G, Strada S, Tursi A. Changes in skin reactivity, specific IgE and IgG levels after one year of immunotherapy in olive pollinosis. Allergy. 91; 46(6):410–8. It does not meet ALL the inclusion criteria. [PubMed: 1957991]
  820. Machiels JJ, Buche M, Somville MA, Jacquemin MG, Saint-Remy JM. Complexes of grass pollen allergens and specific antibodies reduce allergic symptoms and inhibit the seasonal increase of IgE antibody. Clin Exp Allergy. 90; 20(6):653–60. Therapy NOT AVAILABLE in the U.S. [PubMed: 2083405]
  821. Machiels JJ, Buche M, Somville MA, Jacquemin MG, Saint-Remy JM. Complexes of grass pollen allergens and specific antibodies reduce allergic symptoms and inhibit the seasonal increase of IgE antibody. Clin Exp Allergy. 90; 20(6):653–60. It does not meet ALL the inclusion criteriaTherapy NOT AVAILABLE in the U.S. [PubMed: 2083405]
  822. Machiels JJ, Lebrun PM, Jacquemin MG, Saint-Remy JM. Significant reduction of nonspecific bronchial reactivity in patients with Dermatophagoides pteronyssinus-sensitive allergic asthma under therapy with allergen-antibody complexes. Am Rev Respir Dis. 93; 147(6 Pt 1):1407–12. Therapy NOT AVAILABLE in the U.S. [PubMed: 8503552]
  823. Machiels JJ, Lebrun PM, Jacquemin MG, Saint-Remy JM. Significant reduction of nonspecific bronchial reactivity in patients with Dermatophagoides pteronyssinus-sensitive allergic asthma under therapy with allergen-antibody complexes. Am Rev Respir Dis. 93; 147(6 Pt 1):1407–12. Therapy NOT AVAILABLE in the U.S. [PubMed: 8503552]
  824. Machiels JJ, Somville MA, Jacquemin MG, Saint-Remy JM. Allergen-antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients. Allergen-antibody complex immunotherapy. Allergy. 91; 46(5):335–48. Does not apply to any of the key questions. [PubMed: 1928657]
  825. Machiels JJ, Somville MA, Lebrun PM, Lebecque SJ, Jacquemin MG, Saint-Remy JM. Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes. J Clin Invest. 90; 85(4):1024–35. Therapy NOT AVAILABLE in the U.S. [PMC free article: PMC296531] [PubMed: 2318962]
  826. Madonini E, Agostinis F, Barra R, Berra A, Donadio D, Pappacoda A, Stefani E, Tierno E. Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study. Int J Immunopathol Pharmacol. 2003;16(1):73–9. It does not meet ALL the inclusion criteriaNot an RCT and doesnt assess severe harms. [PubMed: 12578735]
  827. Madsen F, Frolund L, Christensen M, Frost A, Petersen US. Quality assurance ofallergen-specific immunotherapy during a national outbreak of anaphylaxis: results of a continuous sentinel event surveillance system. J Investig Allergol Clin Immunol. 2009;19(4):253–9. It does not meet ALL the inclusion criteria. [PubMed: 19639720]
  828. Madsen F, Frolund L, Christensen M, Frost A, Petersen US. Quality assurance ofallergen-specific immunotherapy during a national outbreak of anaphylaxis: results of a continuous sentinel event surveillance system. J Investig Allergol Clin Immunol. 2009;19(4):253–9. obs case series. [PubMed: 19639720]
  829. Mahesh PA, Vedanthan PK, Amrutha DH, Giridhar BH, Prabhakar AK. Factors associated with non-adherence to specific allergen immunotherapy in management of respiratory allergy. Indian J Chest Dis Allied Sci. 2010;52(2):91–5. It does not meet ALL the inclusion criteria. [PubMed: 20578401]
  830. Maintenance treatment. Journal of Investigational Allergology and Clinical Immunology. 2010;20(SUPPL 1):19–26. No original data.
  831. Majak P, Rychlik B, Stelmach I. The effect of oral steroids with and without vitamin D3 on early efficacy of immunotherapy in asthmatic children. Clin Exp Allergy. 2009;39(12):1830–41. It does not meet ALL the inclusion criteria. [PubMed: 19817753]
  832. Majak P, Rychlik B, Stelmach I. The effect of oral steroids with and without vitamin D3 on early efficacy of immunotherapy in asthmatic children. Clin Exp Allergy. 2009;39(12):1830–41. Does not apply to any of the key questions. [PubMed: 19817753]
  833. Majak P, Rychlik B, Pulaski L, Blauz A, Agnieszka B, Bobrowska-Korzeniowska M, Kuna P, Stelmach I. Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma. J Allergy Clin Immunol. 2010;125(6):1220–7. Other reason for exclusion (specify):Not a comparison of interest. [PubMed: 20434204]
  834. Majchel AM, Proud D, Freidhoff L, Creticos PS, Norman PS, Naclerio RM. The nasal response to histamine challenge: effect of the pollen season and immunotherapy. J Allergy Clin Immunol. 92; 90(1):85–91. Does not apply to any of the key questions. [PubMed: 1629510]
  835. Majchel AM, Proud D, Freidhoff L, Creticos PS, Norman PS, Naclerio RM. The nasal response to histamine challenge: effect of the pollen season and immunotherapy. J Allergy Clin Immunol. 92; 90(1):85–91. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 1629510]
  836. Majori M, Bertacco S, Piccoli ML, Melej R, Pileggi V, Pesci A. Specific immunotherapy downregulates peripheral blood CD4 and CD8 T-lymphocyte activation in grass pollen-sensitive asthma. Eur Respir J. 98; 11(6):1263–7. It does not meet ALL the inclusion criteria. [PubMed: 9657564]
  837. Majori M, Bertacco S, Piccoli ML, Melej R, Pileggi V, Pesci A. Specific immunotherapy downregulates peripheral blood CD4 and CD8 T-lymphocyte activation in grass pollen-sensitive asthma. Eur Respir J. 98; 11(6):1263–7. It does not meet ALL the inclusion criteria. [PubMed: 9657564]
  838. Majori M, Caminati A, Corradi M, Brianti E, Scarpa S, Pesci A. T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma. Clin Exp Allergy. 2000;30(3):341–7. It does not meet ALL the inclusion criteria. [PubMed: 10691891]
  839. Majori M, Caminati A, Corradi M, Brianti E, Scarpa S, Pesci A. T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma. Clin Exp Allergy. 2000;30(3):341–7. It does not meet ALL the inclusion criteria. [PubMed: 10691891]
  840. MAKINO S. STUDIES ON INHALATION TESTS IN BRONCHIAL ASTHMA. (III). INFLUENCE OF HYPOSENSITIZATION THERAPY ON THE SENSITIVITY OF THE RESPIRATORY TRACT TO ALLERGENS AND ACETYLCHOLINE. Arerugi. 64; 13:83–7. Does not apply to any of the key questions. [PubMed: 14138424]
  841. MAKINO S. STUDIES ON INHALATION TESTS IN BRONCHIAL ASTHMA. (III). INFLUENCE OF HYPOSENSITIZATION THERAPY ON THE SENSITIVITY OF THE RESPIRATORY TRACT TO ALLERGENS AND ACETYLCHOLINE. Arerugi. 64; 13:83–7. Does not apply to any of the key questions. [PubMed: 14138424]
  842. Malling HJ, Bousquet J. Subcutaneous immunotherapy for allergic rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases. Clin Allergy Immunol. 2008;21:343–58. No original data. [PubMed: 18828516]
  843. Malling HJ, Djurup R. Diagnosis and immunotherapy of mould allergy. VII. IgG subclass response and relation to the clinical efficacy of immunotherapy with Cladosporium. Allergy. 88; 43(1):60–70. Does not apply to any of the key questions. [PubMed: 3344936]
  844. Malling HJ, Stahl Skov P. Diagnosis and immunotherapy of mould allergy. VIII. Qualitative and quantitative estimation of IgE in Cladosporium immunotherapy. Allergy. 88; 43(3):228–38. Does not apply to any of the key questions. [PubMed: 2454038]
  845. Malling HJ, Stahl Skov P. Diagnosis and immunotherapy of mould allergy. VIII. Qualitative and quantitative estimation of IgE in Cladosporium immunotherapy. Allergy. 88; 43(3):228–38. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 2454038]
  846. Malling HJ. Diagnosis and immunotherapy of mould allergy. With special reference to Cladosporium herbarum. Dan Med Bull. 90; 37(1):12–22. It does not meet ALL the inclusion criteria. [PubMed: 2178885]
  847. Malling HJ. Immunotherapy as an effective tool in allergy treatment. Allergy. 98; 53(5):461–72. No original data. [PubMed: 9636804]
  848. Malling HJ. Immunotherapy for allergic rhinoconjunctivitis. Clin Allergy Immunol. 2004;18:495–509. No original data. [PubMed: 15042931]
  849. Malling HJ. Immunotherapy for mold allergy. Clin Rev Allergy. 92; 10(3):237–51. No original data. [PubMed: 1477815]
  850. Malling HJ, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. VI. IgE-mediated parameters during a one-year placebo-controlled study of immunotherapy with Cladosporium. Allergy. 87; 42(4):305–14. It does not meet ALL the inclusion criteria. [PubMed: 3303997]
  851. Mancini S, Wietrzykowska R, Viviano G, Pastori A, Giampaolo R. Clinical trial in a child population with bronchial asthma. Minerva Pediatr. 89; 41(7):359–62. italian. Non-English article. [PubMed: 2689855]
  852. Mansoor S. Treatment of bronchial asthma and other allergic diseases with a polyvalent antigen mixture. Landarzt. 68; 44(5):237–40. No original data. [PubMed: 5716606]
  853. Marcoval J, Moreno A, Mana J. Subcutaneous sarcoidosis localised to sites of previous desensitizing injections. Clin Exp Dermatol. 2008;33(2):132–4. It does not meet ALL the inclusion criteria. [PubMed: 18076694]
  854. Marinkovich V. Recent laboratory evidence of benefits from injection therapy for pollinosis. Northwest Med. 70; 69(6):40. No original data. [PubMed: 4193906]
  855. Marogna M, Bruno ME, Massolo A, Falagiani P. Sublingual immunotherapy for allergic respiratory disease in elderly patients: a retrospective study. Eur Ann Allergy Clin Immunol. 2008;40(1):22–9. It does not meet ALL the inclusion criteria. [PubMed: 18700331]
  856. Marogna M, Bruno M, Massolo A, Falagiani P. Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: A long-term (13-year) retrospective study in real life. Int Arch Allergy Immunol. 2007;142(1):70–8. It does not meet ALL the inclusion criteria. [PubMed: 17016060]
  857. Marogna M, Colombo F, Spadolini I, Massolo A, Berra D, Zanon P, Chiodini E, Canonica GW, Passalacqua G. Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen. J Investig Allergol Clin Immunol. 2010;20(2):146–52. Does not apply to any of the key questions Other reason for exclusion (specify):it is about montelukast. [PubMed: 20461969]
  858. Marogna M, Massolo A, Berra D, Zanon P, Chiodini E, Canonica GW, Passalacqua G. The type of sensitizing allergen can affect the evolution of respiratory allergy. Allergy. 2006;61(10):1209–15. It does not meet ALL the inclusion criteria. [PubMed: 16942571]
  859. Marogna M, Spadolini I, Massolo A. Rhinitis and asthma co-morbidity in respiratory allergy due to house dust mite: results of an observational open controlled parallel group study in real-life setting. Eur Ann Allergy Clin Immunol. 2005;37(4):135–42. It does not meet ALL the inclusion criteria. [PubMed: 15916014]
  860. Marogna M, Tiri A, Riva G. Clinical practice improvement program for immunotherapy of respiratory allergic diseases. Int J Immunopathol Pharmacol. 2001;14(2):93–101. It does not meet ALL the inclusion criteria. [PubMed: 12604024]
  861. Marple B, Newcomer M, Schwade N, Mabry R. Natural history of allergic fungal rhinosinusitis: a 4- to 10-year follow-up. Otolaryngol Head Neck Surg. 2002;127(5):361–6. It does not meet ALL the inclusion criteria. [PubMed: 12447228]
  862. Marsh DG, Lichtenstein LM, Norman PS. Induction of IgE-mediated immediate hypersensitivity to group I rye grass pollen allergen and allergoids in non-allergic man. Immunology. 72; 22(6):1013–28. Does not apply to any of the key questions. [PMC free article: PMC1407884] [PubMed: 4113385]
  863. Marsh DG, Lichtenstein LM, Norman PS. Induction of IgE-mediated immediate hypersensitivity to group I rye grass pollen allergen and allergoids in non-allergic man. Immunology. 72; 22(6):1013–28. It does not meet ALL the inclusion criteria. [PMC free article: PMC1407884] [PubMed: 4113385]
  864. Marsh DG, Meyers DA, Freidhoff LR, Ehrlich-Kautzky E, Roebber M, Norman PS, Hsu SH, Bias WB. HLA-Dw2: a genetic marker for human immune response to short ragweed pollen allergen Ra5. II. Response after ragweed immunotherapy. J Exp Med. 82; 155(5):1452–63. Does not apply to any of the key questions. [PMC free article: PMC2186677] [PubMed: 6951004]
  865. Marshalik BE. The clinico-immunological validation of the combined use of specific immunotherapy and radon baths in pollinosis patients. Vopr Kurortol Fizioter Lech Fiz Kult. 90(6):14–7. Other reason for exclusion (specify):Not a language of interest. [PubMed: 2077730]
  866. Marshall GD Jr, Davis F. Dusting off recombinant allergens. Nat Biotechnol. 97; 15(8):718–9. No original data. [PubMed: 9255778]
  867. Martin-DuPan R, Buser F, Neyroud M. Treatment of pollen allergy using the cutaneous checker square method of Blamoutier and Guibert. Schweiz Rundsch Med Prax. 71; 60(44):1469–72. It does not meet ALL the inclusion criteria. [PubMed: 5141542]
  868. Martinez-Canavate Burgos A, Valenzuela-Soria A, Rojo-Hernandez A. Immunotherapy with Alternaria alternata: present and future. Allergol Immunopathol (Madr). 2007;35(6):259–63. It does not meet ALL the inclusion criteria. [PubMed: 18047818]
  869. Martinez-Canavate A, Eseverri JL, Rodenas R, Tabar AI, Gardee J, Torres J, Bone J, Pedemonte C. Evaluation of paediatric tolerance to an extract of Alternaria alternata under two treatment regimes. A multicentre study. Allergol Immunopathol (Madr). 2005;33(3):138–41. It does not meet ALL the inclusion criteria. [PubMed: 15946625]
  870. Martinez-Cocera C, Sastre J, Cimarra M, Quirce S, Fernandez-Rivas M, Enriquez-Matas A, Rodriguez-Alvarez M, Martin S. Immunotherapy with a Phleum pratense allergen extract induces an immune response to a grass-mix allergen extract. J Investig Allergol Clin Immunol. 2010;20(1):13–9. Therapy NOT AVAILABLE in the U.S. [PubMed: 20232769]
  871. Martin-Gil D, Neffen H, Oehling A. Frequency of sensitization to different pollen groups and results of specific immunotherapy. Allergol Immunopathol (Madr). 78; 6(4):325–32. It does not meet ALL the inclusion criteriaNot an RCTand doesnt assess severe harmsDoes not apply to any of the key questions. [PubMed: 735982]
  872. Martorell Aragones A, Vila Martinez R, Colomer Sala J. Bronchial asthma. Clinical evolution with hyposensitization (author’s transl). An Esp Pediatr. 80; 13(2):87–100. It does not meet ALL the inclusion criteria. [PubMed: 7396274]
  873. Maruo H, Hashimoto K, Shimoda K, Shimanuki K, Nakayama T, Yamaguchi H, Shiigai N, Uchimura K, Mitsubayashi T, Akasaka T, et al. Long-term follow up studies of bronchial asthma in children. II. Prognosis and complications, treatment and allergic evaluations. Arerugi. 90; 39(8):662–9. Other reason for exclusion (specify):Not a language of interest. [PubMed: 2241582]
  874. Masamoto T, Ohashi Y, Nakai Y. Specific immunoglobulin E, interleukin-4, and soluble vascular cell adhesion molecule-1 in sera in patients with seasonal allergic rhinitis. Ann Otol Rhinol Laryngol. 99; 108(2):169–76. Does not apply to any of the key questions. [PubMed: 10030236]
  875. Mastrandrea F, Coradduzza G, De Vita L, Minardi A, Scarcia G, Marcucci F, Parmiani S. CD34+ cells in peripheral blood of healthy human beings and allergic subjects: clue to acute and minimal persistent inflammation. Allergol Immunopathol (Madr). 2002;30(4):209–17. Does not apply to any of the key questions Not an RCT. [PubMed: 12199965]
  876. Mastrandrea F, Coradduzza G, Serio G, Scarcia G, Minardi A. T-cell receptor Vbeta repertoire in mite-allergic subjects after sublingual immunotherapy. J Investig Allergol Clin Immunol. 2000;10(3):142–8. Does not apply to any of the key questions. [PubMed: 10923588]
  877. Mastrandrea F, Serio G, Minardi A, Coradduzza G, Rossi N, Scarcia G, Maietta G, Iacobelli A, Lamanna C, Tursi A. IgE responses to Dermatophagoides pteronyssinus native major allergens Der p 1 and Der p 2 during long-term specific immunotherapy. Allergy. 97; 52(11):1115–9. Not an RCT. [PubMed: 9404565]
  878. Mastrandrea F, Serio G, Minardi A, Coradduzza G, Rossi N, Scarcia G, Maietta G, Iacobelli A, Lamanna C, Tursi A. IgE responses to Dermatophagoides pteronyssinus native major allergens Der p 1 and Der p 2 during long-term specific immunotherapy. Allergy. 97; 52(11):1115–9. It does not meet ALL the inclusion criteria. [PubMed: 9404565]
  879. Matkova KP, Silkina AG, Belous VM. Hyposensitizing therapy in an atopic form of bronchial asthma. Vrach Delo. 77(9):60–1. RussianNon-English article. [PubMed: 919485]
  880. Matloff SM, Bailit IW, Parks P, Madden N, Greineder DK. Systemic reactions to immunotherapy. Allergy Proc. 93; 14(5):347–50. It does not meet ALL the inclusion criteria no comparator group. [PubMed: 8288117]
  881. Matoga S, Scislicki A, Haluszka J, Kurzawa R. Results of immunotherapy with HDM (Bencard) in children with bronchial asthma. Pediatr Pol. 89; 64(3):167–72. polishNon-English article. [PubMed: 2602048]
  882. Matsumura T, Tateno K, Nakajima S. A new trial in hyposensitization therapy in bronchial asthma. J Asthma Res. 72; 9(3):113–4. It does not meet ALL the inclusion criteriaNot an RCT and doesnt address any harms of interest.
  883. Maunsell K, Wraith DG, Hughes AM. Hyposensitisation in mite asthma. Lancet. 71; 1(7706):967–8. It does not meet ALL the inclusion criteria. [PubMed: 4102290]
  884. Mavroleon G. Restoration of cytokine imbalance by immunotherapy. Clin Exp Allergy. 98; 28(8):917–20. No original data. [PubMed: 9756193]
  885. Mavroleon G. Restoration of cytokine imbalance by immunotherapy. Clin Exp Allergy. 98; 28(8):917–20. Other reason for exclusion (specify): editorial. [PubMed: 9756193]
  886. May CD, Aduna N. Loss and recovery of leukocyte sensitivity to antigenic histamine release during intensive injection therapy with allergen extract. J Allergy Clin Immunol. 71; 48(5):313–9. It does not meet ALL the inclusion criteria nocx. [PubMed: 4106085]
  887. May CD. Treatment of allergic disorders with injections of allergen extracts. Pediatr Clin North Am. 75; 22(1):221–5. No original data. [PubMed: 1096051]
  888. May CD, Schumacher MJ, Williams CS. Significance of concordant fluctuation and loss of leukocyte sensitivity to two allergens during injection therapy with one nonspecific desensitization. J Allergy Clin Immunol. 72; 50(2):99–108. Does not apply to any of the key questions Not an RCT. [PubMed: 4114296]
  889. McAllen MK, Heaf PJ, McInroy P. Depot grass-pollen injections in asthma: effect of repeated treatment on clinical response and measured bronchial sensitivity. Br Med J. 67; 1(5531):22–5. Therapy NOT AVAILABLE in the U.S. [PMC free article: PMC1840719] [PubMed: 6016569]
  890. McGovern JP, Pierce KE, Lee RE Jr. The allergic child and his challenge to the school. Clin Pediatr (Phila). 71; 10(11):636–44. Other reason for exclusion (specify): review. [PubMed: 5129659]
  891. McHugh SM, Ewan PW. A clinical index: a new method to assess efficacy of allergen immunotherapy. Allergy. 92; 47(2 Pt 1):115–20. It does not meet ALL the inclusion criteria. [PubMed: 1632479]
  892. McHugh SM, Ewan PW. Reduction of increased serum neutrophil chemotactic activity following effective hyposensitization in house dust mite allergy. Clin Exp Allergy. 89; 19(3):327–34. Does not apply to any of the key questions. [PubMed: 2660970]
  893. Mdinaradze MD, Mikheeva GA. State of several indices of nonspecific immunity in children with bronchial asthma under specific hyposensitization therapy. Pediatriia. 71; 50(6):27–31. It does not meet ALL the inclusion criteria Therapy NOT AVAILABLE in the U.S. [PubMed: 5568960]
  894. MEACOCK SC, SHULMAN R, FREEDMAN SO, SEHON AH. IMMUNOLOGIC AND CLINICAL PROPERTIES OF TWO PURIFIED RAGWEED FRACTIONS. J Allergy Clin Immunol. 65; 36:1–11. Does not apply to any of the key questionsTherapy NOT AVAILABLE in the U.S. [PubMed: 14320906]
  895. Measuring quality of life in the treatment of allergic rhinitis with specific immunotherapy - identifying the best suitable instrument. Library unable to locate.
  896. MEDA P, TESEO L. RESULTS OF SPECIFIC DESENSITIZING THERAPY IN ALLERGIC RHINOPATHIES OF YOUNG AGE. Minerva Pediatr. 64; 16:1030–2. It does not meet ALL the inclusion criteria. [PubMed: 14205158]
  897. Meister W. Current problems of long-term therapy and rehabilitation in bronchial asthma and obstructive bronchitis. Z Arztl Fortbild (Jena). 83; 77(11):477–81. No original data. [PubMed: 6136131]
  898. Melam HL, Pruzansky JJ, Patterson R. Correlations between clinical symptoms, leukocyte sensitivity, antigen-binding capacity, and Prausnitz-Kustner activity in a longitudinal study of ragweed pollinosis. J Allergy. 70; 46(5):292–9. Does not apply to any of the key questions- Number of subjects in study is 6 or fewer on active treatment. [PubMed: 4098121]
  899. Melam H, Pruzansky J, Patterson R, Singer S. Clinical and immunologic studies of ragweed immunotherapy. J Allergy. 71; 47(5):262–72. It does not meet ALL the inclusion criteria. [PubMed: 4102486]
  900. Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy. 2000;30(10):1423–9. It does not meet ALL the inclusion criteriaepot txTherapy NOT AVAILABLE in the U.S. [PubMed: 10998019]
  901. Menon P, Menon V, Hilman BC, Wolf R, Bairnsfather L. Antinuclear antibodies and anticytoplasmic antibodies in bronchial asthma. J Allergy Clin Immunol. 89; 84(6 Pt 1):937–43. Does not apply to any of the key questions. [PubMed: 2689497]
  902. Metzger WJ. Indications for allergen immunotherapy during pregnancy. Compr Ther. 90; 16(3):17–26. No original data. [PubMed: 2318030]
  903. Metzger WJ, Richerson HB, Wasserman SI. Generation and partial characterization of eosinophil chemotactic activity and neutrophil chemotactic activity during early and late-phase asthmatic response. J Allergy Clin Immunol. 86; 78(2):282–90. It does not meet ALL the inclusion criteria. [PubMed: 3734281]
  904. Metzger WJ, Turner E, Patterson R. The safety of immunotherapy during pregnancy. J Allergy Clin Immunol. 78; 61(4):268–72. Not an RCT. [PubMed: 632475]
  905. MEULBROEK HJ. ALLERGY TREATMENT PERSONAL OBSERVATIONS WITH REPOSITORY ALLERGY THERAPY. J Kans Med Soc. 64; 65:545–7. It does not meet ALL the inclusion criteriarepository txTherapy NOT AVAILABLE in the U.S. [PubMed: 14216599]
  906. MEULBROEK HJ. THE ASTHMATIC PATIENT ESSENTIALS IN THE MANAGEMENT OF ASTHMA. J Kans Med Soc. 65; 66:76–8. Other reason for exclusion (specify): review. [PubMed: 14270251]
  907. MICHAELIAN G. ALLERGIC ASTHMA AND ITS TREATMENT. J Med Liban. 63; 16:93–101. No original data. [PubMed: 14061393]
  908. Michel FB. Asthmology. Nouv Presse Med. 79; 8(34):2725–7. No original data. [PubMed: 493077]
  909. Miguel Lozano R, Guerra Pasadas F, Arenas Vacas A, Daza Munoz JC, Torres Murillo P, Sanchez Guijo P. Monitoring of various types of immunotherapy with gramineal pollens. II. Variation of humoral immunochemical parameters. Allergol Immunopathol (Madr). 92; 20(6):235–9. It does not meet ALL the inclusion criteria no dose specified. [PubMed: 1296465]
  910. Mikhailov EL. Peroral specific hyposensitization in ambrosia-induced pollinosis. Sov Med. 76(5):110–3. Other reason for exclusion (specify): oral IT. [PubMed: 968591]
  911. Milani M, Pecora S, Burastero S. Observational study of sublingual specific immunotherapy in persistent and intermittent allergic rhinitis: the EFESO trial. Curr Med Res Opin. 2008;24(9):2719–24. It does not meet ALL the inclusion criteria. [PubMed: 18701006]
  912. Milavec-Puretic V, Lipozencic J, Ledic-Drvar D, Smigovec E, Milavec D. Retrospective study of specific immunotherapy - what should be done in the future. Acta Dermatovenerol Croat. 2007;15(4):221–7. Not an RCT. [PubMed: 18093449]
  913. Mileva Zh, Staneva-Stoianova M. Pregnancy and bronchial asthma. Akush Ginekol (Sofiia). 81; 20(2):163–7. No original data. [PubMed: 7013532]
  914. Miller AC. A comparative trial of hyposensitization in 1973 in the treatment of hay fever using Pollinex and Alavac-P. Clin Allergy. 76; 6(6):551–6. Therapy NOT AVAILABLE in the U.S. [PubMed: 827393]
  915. Miller AC. Aqueous extracts in treatment of perennial rhinitis. Practitioner. 68; 201(205):779–81. It does not meet ALL the inclusion criteria Dose not specified. [PubMed: 5726031]
  916. Miller AC. Repository treatment in house dust allergy. Acta Allergol. 71; 26(6):430–7. Therapy NOT AVAILABLE in the U.S. [PubMed: 5172341]
  917. MILLER FF, SMITH RE, LAWSON WJ. REPOSITORY EMULSION THERAPY FOR MOUNTAIN CEDAR POLLINOSIS: A DOUBLE-BLIND STUDY. J Allergy Clin Immunol. 64; 35:7–11. Does not apply to any of the key questions. [PubMed: 14104259]
  918. Mirakian R. Report on ‘Medical and surgical management of rhinitis’ course. Clin Exp Allergy. 95; 25(1):89–92. No original data. [PubMed: 7728628]
  919. Mirakian R, Howarth P, Scadding G. New thinking on the treatment of rhinitis. Practitioner. 97; 241(1574):286–90. No original data. [PubMed: 9218406]
  920. Mirsalim M. Therapeutic results during and after desensitization of allergy patients. Allerg Immunol (Leipz). 72; 18(2):109–16. Other reason for exclusion (specify):obervational, no harms. [PubMed: 4266960]
  921. Misak J, Kimlova I, Paskova Z, Vakocova H, Musil J, Prokopec J. Hay fever from the immunobiochemical aspect. Allerg Immunol (Leipz). 74–75; 20–21(3):297–301. It does not meet ALL the inclusion criteria. [PubMed: 4283452]
  922. Mitchell WF, Davis N, Koenig W, Blank P. Emulsion therapy: a three-year study with ragweed pollinosis. Ann Allergy. 71; 29(11):564–72. It does not meet ALL the inclusion criteria. [PubMed: 4941343]
  923. Mitrokhina NM, Gudkova RG. On the problem of bacterial allergy and specific desentization in rhinosinusopathy and bronchial asthma. Vestn Otorinolaringol. 68; 30(2):62–5. Does not apply to any of the key questions. [PubMed: 4876546]
  924. MITSUI S, OTSUKA M, SHIKAUCHI K, MIBO T, TAKAHASHI M. OBSERVATIONS ON SKIN TESTS AND DESENSITIZATION IN BRONCHIAL ASTHMA. Arerugi. 64; 13:266–7. No original data. [PubMed: 14144792]
  925. MITSUI S, OTSUKA T, SHISHIUCHI K, TOYOSHIMA T, TAKAHASHI M, NEMOTO N, SHIRO T. CONSIDERATIONS ON SPECIFIC AND NON-SPECIFIC DESENSITIZING THERAPY. Sogo Rinsho. 64; 13:233–41. No original. [PubMed: 14136564]
  926. Mobius HJ, Schlote W, Pfeifer H. Polyneuropathy and necrotizing myopathy following desensitization therapy. Nervenarzt. 87; 58(3):190–7. It does not meet ALL the inclusion criteria. [PubMed: 3035390]
  927. Mobs C, Slotosch C, Loffler H, Jakob T, Hertl M, Pfutzner W. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. J Immunol. 2010;184(4):2194–203. It does not meet ALL the inclusion criteriaNot an RCTand doesnt address harms. [PubMed: 20048125]
  928. Modrzynski M, Zawisza E. Possible induction of oral allergy syndrome during specific immunotherapy in patients sensitive to tree pollen. Med Sci Monit. 2005;11(7):CR351–5. It does not meet ALL the inclusion criteria. [PubMed: 15990693]
  929. Modrzynski M, Mazurek H, Zawisza E. The results of extra diagnostic methods in patients allergic to dust mites treated by specific immunotherapy. Przegl Lek. 2005;62(12):1337–42. Not an RCT. [PubMed: 16786743]
  930. Modulation of the level of natural antibodies to endotoxin in bronchial asthma patients receiving mite allergens immunotherapy Abstract. Abstract only.
  931. Mohapatra SS, Lockey RF, Polo F. Weed pollen allergens. Clin Allergy Immunol. 2008;21:127–39. No original data. [PubMed: 18828502]
  932. Moller C. Effect of pollen immunotherapy on food hypersensitivity in children with birch pollinosis. Ann Allergy. 89; 62(4):343–5. It does not meet ALL the inclusion criteria. [PubMed: 2705661]
  933. Moller C, Dreborg S, Einarsson R. Immunotherapy to deciduous tree pollens: specific IgE and IgG antibody patterns. Clin Allergy. 87; 17(6):551–62. Does not apply to any of the key questions Not an RCT. [PubMed: 3436034]
  934. Moller C, Juto P, Dreborg S, Bjorksten B. Blood lymphocyte proliferation response to pollen extract as a monitor of immunotherapy. Allergy. 84; 39(4):291–6. It does not meet ALL the inclusion criteria. [PubMed: 6731754]
  935. Moncayo Coello CV, Rosas Vargas MA, del Rio Navarro BE, Lerma Ortiz L, Velazquez Armenta Y, Sienra Monge JJ. Quality of life in children with allergic rhinitis before and after being treated with specific immunotherapy (cases and controls). Rev Alerg Mex. 2003;50(5):170–5. Not an RCT-spanish-rct Non-English article. [PubMed: 14631587]
  936. Mondragon Pineda ME. Statistical analysis of 100 cases of allergic rhinitis in the "20 de Noviembre" regional hospital. ISSSTE. Rev Alerg Mex. 90; 37(4):129–31. Does not apply to any of the key questions. [PubMed: 2089603]
  937. Moniuszko T, Chyrek-Borowska S, Moniuszko C. Cell-mediated immune response during specific hyposensitization in atopic asthma patients. Arch Immunol Ther Exp (Warsz). 84; 32(4):375–80. It does not meet ALL the inclusion criteria. [PubMed: 6335958]
  938. Monteseirin J, Bonilla I, Chacon P, Vega A, Camacho MJ, Guardia P, Conde J, Sobrino F. Allergen-dependent CD14 modulation and apoptosis in monocytes from allergic patients. Allergy. 2003;58(10):1027–32. It does not meet ALL the inclusion criteria. [PubMed: 14510721]
  939. Monteseirin J, Chacon P, Vega A, Sanchez-Monteseirin H, Asturias JA, Martinez A, Guardia P, Perez-Cano R, Conde J. L-selectin expression on neutrophils from allergic patients. Clin Exp Allergy. 2005;35(9):1204–13. Does not apply to any of the key questions. [PubMed: 16164449]
  940. Monteseirin J, Fernandez-Pineda I, Chacon P, Vega A, Bonilla I, Camacho MJ, Fernandez-Delgado L, Conde J, Sobrino F. Myeloperoxidase release after allergen-specific conjunctival challenge. J Asthma. 2004;41(6):639–43. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions. [PubMed: 15584313]
  941. Monteseirin J, Llamas E, Sanchez-Monteseirin H, Bonilla I, Camacho MJ, Conde J, Sobrino F. IgE-mediated downregulation of L-selectin (CD62L) on lymphocytes from asthmatic patients. Allergy. 2001;56(2):164–8. Does not apply to any of the key questions. [PubMed: 11167378]
  942. Montplaisir S, Pelletier M. Allergic rhinitis. Union Med Can. 85; 114(1):9–10. 12–3. No original data. [PubMed: 3969751]
  943. Monzon S, Venturini M, Colas C, Lezaun A, Casanovas M, Reichelt C, Lara S. Specific immunotherapy with modified Salsola kali extract: Preliminary results. Alergologia e Inmunologia Clinica. It does not meet ALL the inclusion criteria.
  944. Monzon S, Venturini M, Colas C, Lezaun A, Casanovas M, Reichelt C, Lara S. Specific immunotherapy with modified Salsola kali extract: Preliminary results. Alergologia e Inmunologia Clinica. It does not meet ALL the inclusion criteria.
  945. Moreno C, Cuesta-Herranz J, Fernandez-Tavora L, Alvarez-Cuesta E. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy. 2004;34(4):527–31. Not an RCT. [PubMed: 15080803]
  946. Moreno C, Cuesta-Herranz J, Fernandez-Tavora L, Alvarez-Cuesta E. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy. 2004;34(4):527–31. It does not meet ALL the inclusion criteria nocomparrator group. [PubMed: 15080803]
  947. Moreno C, Fernandez-Tavora L, Acero S, Alonso MD, Barahona MJ, Blanco R, Cistero A, Conde J, Fernandez J, Fernandez S, Fernandez-Rivas M, Garcia BE, Garcia-Rodriguez R, Camacho E, Gonzalez-Quevedo T, Gonzalo A, Guardia P, Sanchez-Cano M, Tabar AI, de la Torre F. Tolerance of a cluster schedule on the treatment of seasonal allergic respiratory disease with pollen extracts quantified in mass units. J Investig Allergol Clin Immunol. 2003;13(4):221–7. It does not meet ALL the inclusion criteria no controls. [PubMed: 14989109]
  948. Morfin Maciel BM, Castillo Morfin BM. Scleroderma related to specific immunotherapy. A report of a case. Rev Alerg Mex. 2009;56(4):136–45. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 19768975]
  949. Moriyama K, Nagano S. Intradermal reaction and desensitization in bronchial asthma. Arerugi. 66; 15(9):806–7. Does not apply to any of the key questions. [PubMed: 6005654]
  950. Morris DL, Morris MS, Kroker GF, Sabnis VK. Allergen immunotherapy. Ann Allergy Asthma Immunol. 2003;91(1):96. author reply 97–8. No original data. [PubMed: 12877458]
  951. Morris DL, Morris MS, Kroker GF, Sabnis VK. Allergen immunotherapy. Ann Allergy Asthma Immunol. 2003;91(1):96. author reply 97–8. No original data. [PubMed: 12877458]
  952. Mortemousque B, Bertel F, De Casamayor J, Verin P, Colin J. House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy. 2003;33(4):464–9. It does not meet ALL the inclusion criteria. [PubMed: 12680861]
  953. Mosbech H, Dirkson A, Drebotrg S, Frolund L, Heinig JH, Svenden UG, Soborg M, Taudorf E, Weeke B. Hyposensitization in asthmatics with mPEG-modified and unmodiefied house dust mite extract. IV. Occurrence and prediction of side effects. Allergy: European Journal of Allergy and Clinical Immunology. Therapy NOT AVAILABLE in the U.S Other reason for exclusion (specify): same paper as 3726. [PubMed: 2316824]
  954. Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy. 88; 43(7):523–9. It does not meet ALL the inclusion criteria nocontrols No original data. [PubMed: 3148282]
  955. Mosbech H. House dust mite allergy. Allergy. 85; 40(2):81–91. No original data. [PubMed: 3887973]
  956. Mosbech H, Dirksen A, Dreborg S, Frolund L, Heinig JH, Svendsen UG, Soborg M, Taudorf E, Weeke B. Hyposensitization in asthmatics with mPEG-modified and unmodified house dust mite extract. IV. Occurrence and prediction of side effects. Allergy. 90; 45(2):142–50. Therapy NOT AVAILABLE in the U.S. [PubMed: 2316824]
  957. Mosbech H, Dreborg S, Frolund L, Ljungstedt-Pahlman I, Svendsen UG, Soborg M, Taudorf E, Weeke B. Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract. I. Clinical effect evaluated by diary cards and a retrospective assessment. Allergy. 89; 44(7):487–98. Therapy NOT AVAILABLE in the U.S. [PubMed: 2817305]
  958. Mosbech H, Dreborg S, Frolund L, Ljungstedt-Pahlman I, Svendsen UG, Soborg M, Taudorf E, Weeke B. Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract. II. Effect evaluated by challenges with allergen and histamine. Allergy. 89; 44(7):499–509. Therapy NOT AVAILABLE in the U.S. [PubMed: 2817306]
  959. Mosbech H, Heinig JH, Malling HJ, Weeke B. Hyposensitization in allergic conditions. Evaluation of the clinical effect in allergic bronchial asthma. Ugeskr Laeger. 86; 148(21):1259–62. No original data. [PubMed: 3523912]
  960. Moscato G, Rossi G, Dellabianca A, Pisati A, Vinci G, Biale C. Local immunotherapy by inhalation of a powder extract in asthma due to house dust mite Dermatophagoides pteronyssinus: a double-blind comparison with parenteral immunotherapy. J Investig Allergol Clin Immunol. 91; 1(6):383–94. Therapy NOT AVAILABLE in the U.S. [PubMed: 1669598]
  961. Moss RB. IgG subclass antibody markers in grass pollen immunotherapy. N Engl Reg Allergy Proc. 87; 8(6):409–15. It does not meet ALL the inclusion criteria. [PubMed: 3325818]
  962. Mounier-Kuhn P, Bernard PA. Indications of treatment of rhinopharyngeal allergy with allerglobulin. Apropos of 100 cases. Ann Pediatr (Paris). 72; 19(8):607–11. No SIT. [PubMed: 4118066]
  963. Moverare R, Elfman L, Bjornsson E, Stalenheim G. Changes in cytokine production in vitro during the early phase of birch-pollen immunotherapy. Scand J Immunol. 2000;52(2):200–6. It does not meet ALL the inclusion criteria. [PubMed: 10931388]
  964. Moverare R, Elfman L, Bjornsson E, Stalenheim G. Cytokine production by peripheral blood mononuclear cells following birch-pollen immunotherapy. Immunol Lett. 2000;73(1):51–6. It does not meet ALL the inclusion criteria. [PubMed: 10963811]
  965. Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy. 2002;57(5):423–30. It does not meet ALL the inclusion criteria. [PubMed: 11972482]
  966. Moverare R, Vesterinen E, Metso T, Sorva R, Elfman L, Haahtela T. Pollen-specific rush immunotherapy: clinical efficacy and effects on antibody concentrations. Ann Allergy Asthma Immunol. 2001;86(3):337–42. It does not meet ALL the inclusion criteria. [PubMed: 11289336]
  967. Moverare R, Vesterinen E, Metso T, Sorva R, Elfman L, Haahtela T. Pollen-specific rush immunotherapy: clinical efficacy and effects on antibody concentrations. Ann Allergy Asthma Immunol. 2001;86(3):337–42. It does not meet ALL the inclusion criteria. [PubMed: 11289336]
  968. MUITTARI A. A SPECIFIC HYPOSENSITIZATION IN BRONCHIAL ASTHMA. Duodecim. 64; 80:1141–8. finnish. Non-English article. [PubMed: 14250731]
  969. Munoz D, Sanz ML, Tabar A, Oehling A, Fernandez de Corres L. Circulating immune complexes in pollinosis and chronic bronchopathies. Effect of immunotherapy. Allergol Immunopathol (Madr). 83; 11(5):379–84. Does not apply to any of the key questions Other reason for exclusion (specify):includes arms not allergic diseaseNot an RCT. [PubMed: 6660176]
  970. Munoz-Lopez F. Betting on immunotherapy. Allergol Immunopathol (Madr). 98; 26(1):3–4. No original data. [PubMed: 9585820]
  971. Munoz-Lopez F. Betting on immunotherapy. Allergol Immunopathol (Madr). 98; 26(1):3–4. No original data. [PubMed: 9585820]
  972. Munoz-Lopez F. Immunotherapy--methods of treatment and results in children. Allergol Immunopathol (Madr). 81 Suppl 9:171–3. It does not meet ALL the inclusion criteria. [PubMed: 7349727]
  973. Munoz-Lopez F. Is immunotherapy justified in the treatment of respiratory allergy? Allergol Immunopathol (Madr). 2007;35(3):79–82. It does not meet ALL the inclusion criteria. [PubMed: 17594869]
  974. Munoz-Lopez F. New administration routes in immunotherapy. Allergol Immunopathol (Madr). 2000;28(6):295–300. It does not meet ALL the inclusion criteria no original data. [PubMed: 11269895]
  975. Munro-Ashman D, Frankland AW. Treatment of allergy to house dust with pyridine-extracted alum-precipitated extracts of the house dust mite. Ann Allergy. 76; 36(2):95–8. Therapy NOT AVAILABLE in the U.S. [PubMed: 1252039]
  976. Munro-Ashman D, McEwen H, Feinberg JG. The patient self (P-S) test. Demonstration of a rise in blocking antibodies after treatment with Allpyral. Int Arch Allergy Appl Immunol. 71; 40(3):448–53. Therapy NOT AVAILABLE in the U.S. [PubMed: 5546865]
  977. Murray AB, Ferguson AC, Morrison BJ. Non-allergic bronchial hyperreactivity in asthmatic children decreases with age and increases with mite immunotherapy. Ann Allergy. 85; 54(6):541–4. It does not meet ALL the inclusion criteria. [PubMed: 4014783]
  978. Eriksson NE, Ahlstedt S, Lovhagen O. Immunotherapy in spring-time hay fever. A clinical and immunological study comparing two different treatment extract compositions. ALLERGY. 1979;34(4):233–47. It does not meet ALL the inclusion criteria. [PubMed: 92897]
  979. Nagao M, Hiraguchi Y, Hosoki K, Tokuda R, Usui T, Masuda S, Yamaguchi M, Fujisawa T. Allergen-induced basophil CD203c expression as a biomarker for rush immunotherapy in patients with Japanese cedar pollinosis. Int Arch Allergy Immunol. 2008;146 Suppl 1:47–53. It does not meet ALL the inclusion criteria nocomparator. [PubMed: 18504407]
  980. Nagata M. Allergen-immunotherapy in asthma. Arerugi. 2008;57(1):9–14. No original data - (specify): Non-English article: japanese. [PubMed: 18239440]
  981. Nagata M. Rush immunotherapy in bronchial asthma. Kokyu To Junkan. 92; 40(8):775–81. Non-English article: japanese. [PubMed: 1382305]
  982. Nagata M, Saito K, Kikuchi I, Tabe K, Hagiwara K, Kanazawa M, Sakamoto Y. Immunotherapy attenuates eosinophil transendothelial migration induced by the supernatants of antigen-stimulated mononuclear cells from atopic asthmatics. Int Arch Allergy Immunol. 2004;134 Suppl 1:21–4. It does not meet ALL the inclusion criteria. [PubMed: 15166479]
  983. Nagata M, Shibasaki M, Sakamoto Y, Fukuda T, Makino S, Yamamoto K, Dohi Y. Specific immunotherapy reduces the antigen-dependent production of eosinophil chemotactic activity from mononuclear cells in patients with atopic asthma. J Allergy Clin Immunol. 94; 94(2 Pt 1):160–6. It does not meet ALL the inclusion criteriaiomkrDoes not apply to any of the key questions. [PubMed: 8064068]
  984. Nagata M, Shibasaki M, Sakamoto Y, Yamamoto K, Dohi Y. The influence of rush immunotherapy on the production of interleukin-5 from mononuclear cells. Arerugi. 93; 42(2):158–61. It does not meet ALL the inclusion criteria noc ontrols. [PubMed: 8507157]
  985. Nagata M, Shibasaki M, Sakamoto Y, Yamamoto K, Dohi Y. The influence of rush immunotherapy on the production of interleukin-5 from mononuclear cells. Arerugi. 93; 42(2):158–61. It does not meet ALL the inclusion criteria. [PubMed: 8507157]
  986. Nagata M, Tabe K, Yamamoto H, Maruo H, Kiuch H, Sakamoto Y, Yamamoto K, Dohi Y. The analysis of factors contributing to the safety and efficacy of rush immunotherapy in bronchial asthma. Arerugi. 93; 42(5):628–34. It does not meet ALL the inclusion criteriaOther reason for exclusion (specify): japanese. [PubMed: 8323461]
  987. Nagata M, Tabe K, Yamamoto H, Sakamoto Y, Matsuo H. Clinical significance of allergen specific immunotherapy in adult house-dust-mite-sensitive bronchial asthma: impact on disease severity and medical cost. Arerugi. 99; 48(12):1316–21. It does not meet ALL the inclusion Non-English article: japanese. [PubMed: 10666919]
  988. Nagata M, Yamamoto H, Tabe K, Kimura I, Houya I, Kuramitsu K, Kiuchi H, Yanagihara Y, Sakamoto Y, Yamamoto K, et al. Effect of rush immunotherapy in house-dust-mite (HDM)-sensitive adult bronchial asthma: changes in in vivo and in vitro responses to HDM. Intern Med. 93; 32(9):702–9. It does not meet ALL the inclusion criteria. no controls. [PubMed: 8142674]
  989. Nagata M, Yamamoto H, Tabe K, Tanaka K, Kimura I, Sakamoto K, Sakamoto Y, Yamamoto K, Dohi Y. A clinical evaluation of rush immunotherapy in adult patients with severe bronchial asthma. Arerugi. 89; 38(12):1319–26. It does not meet ALL the inclusion criteria Non-English article: japanese. [PubMed: 2634374]
  990. Nagaya H. Induction of antigen-specific suppressor cells in patients with hay fever receiving immunotherapy. J Allergy Clin Immunol. 85; 75(3):388–94. Does not apply to any of the key questionsStudy evaluates outcomes in animals only or in vitro. [PubMed: 2579117]
  991. Nagaya H. Long-term effects of conventional immunotherapy in southern California. Ann Allergy. 80; 44(4):193–9. It does not meet ALL the inclusion criteria. [PubMed: 6154434]
  992. Nagaya H, Lee SK, Reddy PM, Pascual H, Jerome D, Sadai J, Gupta S, Lauridsen J. Lymphocyte response to grass pollen antigens: a correlation with radioallergosorbent test and effect of immunotherapy. Ann Allergy. 77; 39(4):246–52. It does not meet ALL the inclusion criteria. [PubMed: 911068]
  993. Nagaya H, Maren S, Nagaya N. Allergy immunotherapy as an early intervention in patients with child-onset atopic asthma. Int Arch Allergy Immunol. 2006;139(1):9–15. It does not meet ALL the inclusion criteria. [PubMed: 16272821]
  994. Nagore E, Martinez-Escribano JA, Tato A, Sabater V, Vilata JJ. Subcutaneous nodules following treatment with aluminium-containing allergen extracts. Eur J Dermatol. 2001;11(2):138–40. It does not meet ALL the inclusion criteria. [PubMed: 11275813]
  995. Nakagawa T. IgG subclass changes in response to desensitisation. Monogr Allergy. 86; 19:253–61. Does not apply to any of the key questions. [PubMed: 3762551]
  996. Nakagawa T. The role of IgG subclass antibodies in the clinical response to immunotherapy in allergic disease. Clin Exp Allergy. 91; 21(3):289–96. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 1863891]
  997. Nakagawa T, Kozeki H, Katagiri J, Fujita Y, Yamashita N, Miyamoto T, Skvaril F. Changes of house dust mite-specific IgE, IgG and IgG subclass antibodies during immunotherapy in patients with perennial rhinitis. Int Arch Allergy Appl Immunol. 87; 82(1):95–9. It does not meet ALL the inclusion criteria. [PubMed: 3804457]
  998. Nakagawa T, Takaishi T, Sakamoto Y, Ito K, Miyamoto T, Skvaril F. IgG4 antibodies in patients with house-dust-mite-sensitive bronchial asthma: relationship with antigen-specific immunotherapy. Int Arch Allergy Appl Immunol. 83; 71(2):122–5. It does not meet ALL the inclusion criteriaNot an RCT. [PubMed: 6188704]
  999. Nakagawa T, Yoshinoya S, Sakamoto Y, Ito K, Miyamoto T. Circulating immune complexes in patients with house-dust-mite-sensitive bronchial asthma. Clin Allergy. 84; 14(2):129–38. It does not meet ALL the inclusion criteria. [PubMed: 6705179]
  1000. Nakai Y, Ohashi Y, Tanaka A, Kakinoki Y, Washio Y, Masamoto T, Yamada K, Nakai Y, Ohmoto Y. Cry j 1-induced synthesis of interleukin-5 and interferon-gamma by peripheral blood mononuclear cells of patients with seasonal allergic rhinitis due to Japanese cedar pollens. Acta Otolaryngol Suppl. 98; 538:143–51. It does not meet ALL the inclusion criteria. [PubMed: 9879414]
  1001. Nakajima H, Ohtsuka S, Nishina T, Sugino M, Kimura F, Hanafusa T, Ikemoto T, Shimizu A. Multiple sclerosis after allergen-specific immunotherapy and influenza vaccination. Eur Neurol. 2003;50(4):248–9. Other reason for exclusion (specify):case report. [PubMed: 14634270]
  1002. Nakamura S. Clinical effects of hyposensitization treatment on bronchial asthma. Arerugi. 68; 17(5):348–56. Other reason for exclusion (specify): japanese. [PubMed: 5725555]
  1003. Nakamura S. Results of the skin test and the desensitization therapy for bronchial asthma at the Allergy Center. Iryo. 71; 25(5):351–2. Other reason for exclusion (specify): japanese. [PubMed: 5115162]
  1004. Nakano A, Nakano K, Okawa T, Yamakoshi T, Terada N, Numata T, Konno A. The effect of Japanese cedar-specific immunotherapy on cytokine production in peripheral blood mononuclear cells. Acta Otolaryngol. 2002;122(1):54–60. Therapy NOT AVAILABLE in the U.S. [PubMed: 11876600]
  1005. Nakayama Y, Shimanuki K, Uehara S, Hirakata A. Analysis of 80 cases of childhood asthma provoked by mold allergens. Acta Paediatr Jpn. 71; 13(2):36–43. No SITNot an RCT. [PubMed: 5004839]
  1006. Nalebuff DJ. Modified RAST to determine initial immunotherapy doses. Otolaryngol Head Neck Surg. 85; 93(5):691–2. No original data. [PubMed: 3932944]
  1007. Nalebuff DJ, Fadal RG, Ali M. Determination of initial immunotherapy dose for ragweed hypersensitivity with the modified RAST test. Otolaryngol Head Neck Surg. 81; 89(2):271–4. It does not meet ALL the inclusion criteria. [PubMed: 6787525]
  1008. Nalebuff DJ, Fadal RG, King W. Allergic rhinosinusitis: the total rhinologic disease. Ear Nose Throat J. 93; 72(6):430–1. Other reason for exclusion (specify): letter. [PubMed: 8344184]
  1009. Narasaki N, Suematsu T. Therapy of bronchial asthma. Iryo. 71; 25(5):345–9. Non-English article: Japanese. No original data. [PubMed: 5115161]
  1010. Nash DB, Sullivan SD, Mackowiak J. Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting. Am J Manag Care. 2000;6(1 Suppl):S3–15. quiz S19–20. No original data. [PubMed: 11009751]
  1011. NATERMAN HL. FORMALINIZED POLLEN PROTEIN PRECIPITATES WITH TANNIC ACID OR UREA IN DESENSITIZATION TREATMENT. J Allergy Clin Immunol. 65; 36:226–33. Does not apply to any of the key questions. [PubMed: 14279744]
  1012. Nathan RA, Santilli J, Rockwell W, Glassheim J. Effectiveness of immunotherapy for recurring sinusitis associated with allergic rhinitis as assessed by the Sinusitis Outcomes Questionnaire. Ann Allergy Asthma Immunol. 2004;92(6):668–72. It does not meet ALL the inclusion criteria. [PubMed: 15237770]
  1013. Negrini AC, Troise C, Voltolini S, Siccardi M, Grassia L. Long-term hyposensitization and adverse immunologic responses. A laboratory evaluation. Ann Allergy. 85; 54(6):534–7. It does not meet ALL the inclusion criteria. [PubMed: 3893231]
  1014. Negro Alvarez JM. Costs of specific immunotherapy. J Investig Allergol Clin Immunol. 97; 7(5):362–3. No original data. [PubMed: 9416548]
  1015. Nelson HS, Areson J, Reisman R. A prospective assessment of the remote practice of allergy: comparison of the diagnosis of allergic disease and the recommendations for allergen immunotherapy by board-certified allergists and a laboratory performing in vitro assays. J Allergy Clin Immunol. 93; 92(3):380–6. Other reason for exclusion (specify): reviewof practice methods. [PubMed: 8360388]
  1016. Nelson HS, Brown G, O’Barr TP, Branch LB, Spaulding H, Black JW. Clinical and immunological studies of timothy antigen D immunotherapy. J Allergy Clin Immunol. 76; 57(5):463–72. It does not meet ALL the inclusion criteria. [PubMed: 57131]
  1017. Nenasheva NM, Dotsenko VL, Goriachkina LA, Iarovaia GA. Activity of the prekallikrein-kallikrein system and characteristics of its regulation in various allergies. Vopr Med Khim. 86; 32(5):106–11. No SIT. [PubMed: 3640571]
  1018. Nesterenko VN. Specific hyposensitization in bronchial asthma in children. Med Sestra. 84; 43(2):31–2. RussianNon-English article. [PubMed: 6561376]
  1019. Netterlid E, Hindsen M, Bjork J, Ekqvist S, Guner N, Henricson KA, Bruze M. There is an association between contact allergy to aluminium and persistent subcutaneous nodules in children undergoing hyposensitization therapy. Contact Dermatitis. 2009;60(1):41–9. Does not apply to any of the key questions. [PubMed: 19125720]
  1020. Nettis E, Giordano D, Pannofino A, Ferrannini A, Tursi A. Safety of inhalant allergen immunotherapy with mass units-standardized extracts. Clin Exp Allergy. 2002;32(12):1745–9. It does not meet ALL the inclusion criteria. [PubMed: 12653166]
  1021. Nichani JR, de Carpentier J. Safety of sublingual grass pollen immunotherapy after anaphylaxis. J Laryngol Otol. 2009;123(6):683–4. It does not meet ALL the inclusion criteria. [PubMed: 18501039]
  1022. Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol. 96; 97(6):1207–13. Does not apply to any of the key questions. [PubMed: 8648014]
  1023. Nieminen K, Laaksonen K, Savolainen J. Three-year follow-up study of allergen-induced in vitro cytokine and signalling lymphocytic activation molecule mRNA responses in peripheral blood mononuclear cells of allergic rhinitis patients undergoing specific immunotherapy. Int Arch Allergy Immunol. 2009;150(4):370–6. It does not meet ALL the inclusion criteria. [PubMed: 19571569]
  1024. Nikolaus J, Wettengel R. Immunotherapy of bronchial asthma. Retrospective study on its practicability and results. Prax Klin Pneumol. 82; 36(9):398–403. It does not meet ALL the inclusion criteria. [PubMed: 7145824]
  1025. Nikolaus J, Wettengel R. Immunotherapy of bronchial asthma. Retrospective study on its practicability and results. Prax Klin Pneumol. 82; 36(9):398–403. It does not meet ALL the inclusion criteria. [PubMed: 7145824]
  1026. Nilzen A. Phagocytic activity of leucocytes in rhinitis allergica. Allerg Immunol (Leipz). 74–75; 20–21(1):29–32. It does not meet ALL the inclusion criteria. [PubMed: 4282824]
  1027. Nilzen A. Phagocytic activity of leucocytes in rhinitis allergica. Allerg Immunol (Leipz). 74–75; 20–21(1):29–32. It does not meet ALL the inclusion criteria. [PubMed: 4282824]
  1028. Nish WA, Charlesworth EN, Davis TL, Whisman BA, Valtier S, Charlesworth MG, Leiferman KM. The effect of immunotherapy on the cutaneous late phase response to antigen. J Allergy Clin Immunol. 94; 93(2):484–93. It does not meet ALL the inclusion criteria. [PubMed: 8120276]
  1029. Nishioka GJ, Cook PR, Davis WE, McKinsey JP. Immunotherapy in patients undergoing functional endoscopic sinus surgery. Otolaryngol Head Neck Surg. 94; 110(4):406–12. It does not meet ALL the inclusion criteria nodose. [PubMed: 8170685]
  1030. Nizami RM, Collins-Williams C. Hyposensitization therapy in allergic disease. Ann Allergy. 75; 35(5):296–304. Other reason for exclusion (specify): review. [PubMed: 1103664]
  1031. Noferi A, Volpari AL, Mancuso A. Specific skin reaction of an immediate type in patients with allergic syndromes caused by inhalants after prolonged specific desensitization. Folia Allergol (Roma). 69; 16(5):498–503. It does not meet ALL the inclusion criteria. [PubMed: 5405184]
  1032. Nogami H, Iwanaga T, Kishikawa R, Odajima H, Tsurutani H, Hirose T, Inoue T, Nishima S. Prognosis of intractable asthma. Arerugi. 92; 41(11):1591–6. Does not apply to any of the key questions. [PubMed: 1492793]
  1033. Nolte D. Hyposensitization in asthma--between belief and certainty. Med Klin (Munich). 89; 84(9):459–60. No original data. [PubMed: 2682162]
  1034. Nolte D. Hyposensitization in asthma--between belief and certainty. Med Klin (Munich). 89; 84(9):459–60. No original data. [PubMed: 2682162]
  1035. Nolte H. Optimal maintenance dose immunotherapy based on major allergen content or potency labeling. Allergy. 98; 53(1):99–100. Other reason for exclusion (specify): letter. [PubMed: 9491237]
  1036. Nopp A, Cardell LO, Johansson SG, Oman H. CD-sens: a biological measure of immunological changes stimulated by ASIT. Allergy. 2009;64(5):811–4. It does not meet ALL the inclusion criteria. [PubMed: 19220221]
  1037. Nordvall SL, Berg T, Johansson SG, Lanner A. Clinical studies of a purified timothy pollen extract: desensitization therapy with a purified timothy pollen preparation compared to a crude timothy pollen extract. II. Results of the tests in vitro and their relation to symptoms and tests in vivo. Int Arch Allergy Appl Immunol. 82; 67(2):132–8. It does not meet ALL the inclusion criteria. [PubMed: 6173337]
  1038. Nordvall SL, Renck B, Einarsson R. Specific IgE and IgG antibody responses in children to timothy pollen components during immunotherapy. Allergy. 89; 44(6):380–4. Does not apply to any of the key questions. [PubMed: 2802111]
  1039. Nordvall SL, Renck B, Einarsson R. Specific IgE and IgG antibody responses in children to timothy pollen components during immunotherapy. Allergy. 89; 44(6):380–4. It does not meet ALL the inclusion criteria. [PubMed: 2802111]
  1040. Norman PS. A rational approach to desensitization. J Allergy. 69; 44(3):129–45. Other reason for exclusion (specify):course. [PubMed: 5258820]
  1041. Norman PS. Newer developments in immunotherapy for hay fever. Int Arch Allergy Appl Immunol. 81; 66 Suppl 1:43–7. Other reason for exclusion (specify): review. [PubMed: 7309264]
  1042. Norman PS. Specific therapy in allergy. Pro (with reservations). Med Clin North Am. 74; 58(1):111–25. No original data. [PubMed: 4128901]
  1043. Norman PS. Specific therapy in allergy. Pro (with reservations). Med Clin North Am. 74; 58(1):111–25. Other reason for exclusion (specify): review. [PubMed: 4128901]
  1044. Norman PS. Sublingual swallow immunotherapy in the new world. Ann Allergy Asthma Immunol. 2004;93(5):405–6. Other reason for exclusion (specify): review. [PubMed: 15562876]
  1045. Norman PS. The rationale for immunotherapy in respiratory allergies. Trans Am Clin Climatol Assoc. 78; 89:119–29. No original data. [PMC free article: PMC2279414] [PubMed: 309208]
  1046. Norman PS, Winkenwerder WL, Lichtenstein LM. Maintenance immunotherapy in ragweed hay fever. Booster injections at six week intervals. J Allergy. 71; 47(5):273–82. It does not meet ALL the inclusion criteria. [PubMed: 4102487]
  1047. Norman PS, Winkenwerder WL, Lichtenstein LM. Trials of alum-precipitated pollen extracts in the treatment of hay fever. J Allergy Clin Immunol. 72; 50(1):31–44. It does not meet ALL the inclusion criteria. [PubMed: 4113507]
  1048. Norman PS, Winkenwerder WL, D’Lugoff BC, Tignall J. Controlled evaluations of repository therapy in ragweed hay fever. J Allergy. 67; 39(2):82–92. It does not meet ALL the inclusion criteria. [PubMed: 5340238]
  1049. Norman PS, Winkenwerder WL, D’Lugoff BC, Tignall J. Controlled evaluations of repository therapy in ragweed hay fever. J Allergy. 67; 39(2):82–92. Therapy NOT AVAILABLE in the U.S. [PubMed: 5340238]
  1050. Nouri-Aria KT, Pilette C, Jacobson MR, Watanabe H, Durham SR. IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol. 2005;116(1):73–9. Other reason for exclusion (specify):IL-9 biomarker as 1st endpt; but cx correls. [PubMed: 15990777]
  1051. Nugent JS, Napoli DC. Immunotherapy triggering acute VCD. Allergy. 2002;57(11):1089–90. Other reason for exclusion (specify):case report. [PubMed: 12359021]
  1052. Nuhoglu Y, Ozumut SS, Ozdemir C, Ozdemir M, Nuhoglu C, Erguven M. Sublingual immunotherapy to house dust mite in pediatric patients with allergic rhinitis and asthma: a retrospective analysis of clinical course over a 3-year follow-up period. J Investig Allergol Clin Immunol. 2007;17(6):375–8. It does not meet ALL the inclusion criteria. [PubMed: 18088019]
  1053. Nusslein HG, Kleinlein M, Hemmerlein B, Kalden JR. Different patterns of antigen-induced histamine release during immunotherapy in insect venom and pollen allergy. Agents Actions. 86; 18(1–2):248–50. It does not meet ALL the inclusion criteriatyrosineTherapy NOT AVAILABLE in the U.S. [PubMed: 2425587]
  1054. O’Brien RM, Byron KA, Varigos GA, Thomas WR. House dust mite immunotherapy results in a decrease in Der p 2-specific IFN-gamma and IL-4 expression by circulating T lymphocytes. Clin Exp Allergy. 97; 27(1):46–51. Therapy NOT AVAILABLE in the U.S. [PubMed: 9117880]
  1055. O’Brien RM, Xu H, Rolland JM, Byron KA, Thomas WR. Allergen-specific production of interferon-gamma by peripheral blood mononuclear cells and CD8 T cells in allergic disease and following immunotherapy. Clin Exp Allergy. 2000;30(3):333–40. It does not meet ALL the inclusion criteria. [PubMed: 10691890]
  1056. Obtulowicz K. Pollen-induced allergy. Programming and monitoring of specific immunotherapy. Folia Med Cracov. 88; 29(1–2):21–48. Does not apply to any of the key questions. [PubMed: 3255656]
  1057. Obtulowicz K. Specific immunotherapy in the treatment of hay fever. Pol Tyg Lek. 88; 43(3–4):97–101. polishNon-English article. [PubMed: 3133645]
  1058. Obtulowicz K, Sanokowska E, Radwan J. Specific immunotherapy in hay fever. Allerg Immunol (Paris). 87; 19(3):93–6. It does not meet ALL the inclusion criteria. [PubMed: 3454177]
  1059. Obtulowicz K, Sanokowska E, Radwan J. Specific immunotherapy in hay fever. Allerg Immunol (Paris). 87; 19(3):93–6. It does not meet ALL the inclusion criteria Dose not specified. [PubMed: 3454177]
  1060. Oda N, Yamashita N, Minoguchi K, Takeno M, Kaneko S, Sakane T, Adachi M. Long-term analysis of allergen-specific T cell clones from patients with asthma treated with allergen rush immunotherapy. Cell Immunol. 98; 190(1):43–50. It does not meet ALL the inclusion criteriaiomkrDoes not apply to any of the key questions. [PubMed: 9826445]
  1061. Oehling A. Hyposensitivity treatment of bronchial asthma. Prensa Med Argent. 66; 53(9):776–84. No original data. [PubMed: 6012201]
  1062. Oehling A, Sanz ML, Resano A. The real value of IgG4 determination in immunotherapy follow-up. Int Arch Allergy Immunol. 99; 118(2–4):366–7. Does not apply to any of the key questions. [PubMed: 10224449]
  1063. Oehling A, Sanz ML, Resano A. The real value of IgG4 determination in immunotherapy follow-up. Int Arch Allergy Immunol. 99; 118(2–4):366–7. It does not meet ALL the inclusion criteria Dose not specified. [PubMed: 10224449]
  1064. Ohashi Y. Immunotherapy for allergic rhinitis induced by Japanese cedar pollens. Arerugi. 2008;57(5):519–23. Non-English article: japanese. [PubMed: 18520172]
  1065. Ohashi Y. Immunotherapy for allergic rhinitis induced by Japanese cedar pollens. Arerugi. 2008;57(5):519–23. Non-English article: Japanese. [PubMed: 18520172]
  1066. Ohashi Y, Nakai Y, Kakinoki Y, Ohno Y, Okamoto H, Sakamoto H, Kato A, Tanaka A. The effect of immunotherapy on the serum levels of eosinophil cationic protein in seasonal allergic rhinitis. Clin Otolaryngol Allied Sci. 97; 22(2):100–5. It does not meet ALL the inclusion criteria. [PubMed: 9160918]
  1067. Ohashi Y, Nakai Y, Kakinoki Y, Ohno Y, Tanaka A, Masamoto T, Sakamoto H, Washio Y, Kato A. Immunotherapy affects the seasonal increase in specific IgE and interleukin-4 in serum of patients with seasonal allergic rhinitis. Scand J Immunol. 97; 46(1):67–77. It does not meet ALL the inclusion criteria. [PubMed: 9246210]
  1068. Ohashi Y, Nakai Y, Kihara S, Nakagawa T, Miyamoto T. House dust mite-specific IgE, IgG1, and IgG4 antibodies in patients with perennial rhinitis. Ann Otol Rhinol Laryngol. 87; 96(4):434–7. It does not meet ALL the inclusion criteria. [PubMed: 3619289]
  1069. Ohashi Y, Nakai Y, Okamoto H, Ohno Y, Sakamoto H, Sugiura Y, Kakinoki Y, Tanaka A, Kishimoto K, Washio Y, Hayashi M. Serum level of interleukin-4 in patients with perennial allergic rhinitis during allergen-specific immunotherapy. Scand J Immunol. 96; 43(6):680–6. It does not meet ALL the inclusion criteria. [PubMed: 8658058]
  1070. Ohashi Y, Nakai Y, Okamoto H, Ohno Y, Sakamoto H, Tanaka A, Kakinoki Y. Significant correlation between symptom score and IgG4 antibody titer following long-term immunotherapy for perennial allergic rhinitis. Ann Otol Rhinol Laryngol. 97; 106(6):483–9. Does not apply to any of the key questions. [PubMed: 9199608]
  1071. Ohashi Y, Nakai Y, Sakamoto H, Ohno Y, Sugiura Y, Okamoto H, Tanaka A, Kakinoki Y, Kishimoto K, Hayashi M. Serum levels of soluble interleukin-2 receptor in patients with perennial allergic rhinitis before and after immunotherapy. Ann Allergy Asthma Immunol. 96; 77(3):203–8. It does not meet ALL the inclusion criteria. [PubMed: 8814045]
  1072. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Masamoto T, Kato A, Sakamoto H. The clinical role of specific IgE and IgG4 antibodies in patients having immunotherapy for seasonal allergic rhinitis. Clin Otolaryngol Allied Sci. 98; 23(2):128–35. It does not meet ALL the inclusion criteria. [PubMed: 9597282]
  1073. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Ohno Y, Masamoto T, Sakamoto H, Kato A, Washio Y, Hayashi M. Immunotherapy decreases seasonal rise in serum-soluble CD23 in seasonal allergic rhinitis. Laryngoscope. 98; 108(5):706–11. It does not meet ALL the inclusion criteria. [PubMed: 9591550]
  1074. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Ohno Y, Masamoto T, Sakamoto H, Kato A, Washio Y, Hayashi M. Serum levels of specific IgE, soluble interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 97; 79(3):213–20. It does not meet ALL the inclusion criteria. [PubMed: 9305226]
  1075. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Ohno Y, Masamoto T, Sakamoto H, Kato A, Washio Y, Hayashi M. Soluble intercellular adhesion molecule-1 level in sera is elevated in perennial allergic rhinitis. Laryngoscope. 97; 107(7):932–5. It does not meet ALL the inclusion criteria. [PubMed: 9217134]
  1076. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Washio Y, Kato A, Masamoto T, Sakamoto H, Yamada K. Ten-year follow-up study of allergen-specific immunoglobulin E and immunoglobulin G4, soluble interleukin-2 receptor, interleukin-4, soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in serum of patients on immunotherapy for perennial allergic rhinitis. Scand J Immunol. 98; 47(2):167–78. It does not meet ALL the inclusion criteria. [PubMed: 9496694]
  1077. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Washio Y, Kato A, Masamoto T, Yamada K, Hayashi M. Serologic study of the working mechanisms of immunotherapy for children with perennial allergic rhinitis. Arch Otolaryngol Head Neck Surg. 98; 124(12):1337–46. It does not meet ALL the inclusion criteria. [PubMed: 9865756]
  1078. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Washio Y, Yamada K, Sakamoto H, Nasako Y, Hayashi M, Nakai Y. A comparative study of the clinical efficacy of immunotherapy and conventional pharmacological treatment for patients with perennial allergic rhinitis. Acta Otolaryngol Suppl. 98; 538:102–12. It does not meet ALL the inclusion criteria Not an RCT. [PubMed: 9879409]
  1079. Ohashi Y, Tanaka A, Kakinoki Y, Ohno Y, Sakamoto H, Kato A, Masamoto T, Washio Y, Nakai Y. Effect of immunotherapy on seasonal changes in serum-specific IgE and IgG4 in patients with pollen allergic rhinitis. Laryngoscope. 97; 107(9):1270–5. It does not meet ALL the inclusion criteria Dose not specified. [PubMed: 9292616]
  1080. Ohkubo K. Significance and methods of allergen immunotherapy for pollinosis. Arerugi. 2008;57(2):73–8. No original data. [PubMed: 18349580]
  1081. Ohkubo K, Takizawa R, Gotoh M, Okuda M. Experience of specific immunotherapy with standardized Japanese cedar pollen extract. Arerugi. 2001;50(6):520–7. Non-English article:Japanese Not an RCT. [PubMed: 11517514]
  1082. Ohman JL Jr. Allergen immunotherapy in asthma: evidence for efficacy. J Allergy Clin Immunol. 89; 84(2):133–40. No original data. [PubMed: 2668379]
  1083. Ohman JL Jr. Allergen immunotherapy in asthma: evidence for efficacy. J Allergy Clin Immunol. 89; 84(2):133–40. Other reason for exclusion (specify):CME. [PubMed: 2668379]
  1084. Okano M, Otsuki N, Azuma M, Fujiwara T, Kariya S, Sugata Y, Higaki T, Kino K, Tanimoto Y, Okubo K, Nishizaki K. Allergen-specific immunotherapy alters the expression of B and T lymphocyte attenuator, a co-inhibitory molecule, in allergic rhinitis. Clin Exp Allergy. 2008;38(12):1891–900. It does not meet ALL the inclusion criteria. [PubMed: 19016801]
  1085. Okuda M. A long-term follow-up study after discontinuation of immunotherapy for Japanese cedar pollinosis. Arerugi. 2006;55(6):655–61. Non-English article: Japanese- not and RCT. [PubMed: 16883102]
  1086. Okuda M, Otsuka H. Basophilic cells in allergic nasal secretions. Arch Otorhinolaryngol. 77; 214(4):283–9. It does not meet ALL the inclusion criteriaiomkr, bNot an RCT. [PubMed: 576801]
  1087. Okuda M, Ohkubo K, Gotoh M, Ishida Y. Treatment of Japanese cedar pollinosis and its impact on patient satisfaction. Arerugi. 2004;53(6):596–600. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 15247522]
  1088. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol. 2005;15(1):9–16. No original data. [PubMed: 15864877]
  1089. Olaguibel JM. Long-term benefits of specific immunotherapy (SIT). Drugs Today (Barc). 2008;44 Suppl B:39–41. No original data. [PubMed: 19221617]
  1090. Olaguibel JM, Tabar AI, Garcia Figueroa BE, Cortes C. Immunotherapy with standardized extract of Dermatophagoides pteronyssinus in bronchial asthma: a dose-titration study. Allergy. 97; 52(2):168–78. It does not meet ALL the inclusion criteria. [PubMed: 9105521]
  1091. Olsson N, Rak S, Nilsson G. Demonstration of mast cell chemotactic activity in bronchoalveolar lavage fluid collected from asthmatic patients before and during pollen season. J Allergy Clin Immunol. 2000;105(3):455–61. Does not apply to any of the key questions. [PubMed: 10719293]
  1092. Omnes LF, Bousquet J, Scheinmann P, Neukirch F, Jasso-Mosqueda G, Chicoye A, Champion L, Fadel R. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France. Eur Ann Allergy Clin Immunol. 2007;39(5):148–56. It does not meet ALL the inclusion criteria. [PubMed: 17626329]
  1093. Ornatskaia MM, Mizernitskaia ON. Clinical aspects of specific hyporsensitization in bronchial asthma in children during the 1st year of life. Vopr Okhr Materin Det. 77; 22(7):21–4. Other reason for exclusion (specify): [PubMed: 906373]
  1094. Ortolani C, Pastorello E, Moss RB, Hsu YP, Restuccia M, Joppolo G, Miadonna A, Cornelli U, Halpern G, Zanussi C. Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol. 84; 73(2):283–90. It does not meet ALL the inclusion criteria. [PubMed: 6366027]
  1095. Ortolani C, Pastorello E, Moss RB, Hsu YP, Restuccia M, Joppolo G, Miadonna A, Cornelli U, Halpern G, Zanussi C. Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol. 84; 73(2):283–90. non random trial. [PubMed: 6366027]
  1096. Oryshkevich BA. Allergic rhinitis. N Engl J Med. 92; 326(8):576. No original data. [PubMed: 1580906]
  1097. OSHIMA Y. SPECIFIC HYPOSENSITIZATION TREATMENT OF BRONCHIAL ASTHMA. Arerugi. 65; 14:165–86. Other reason for exclusion (specify): japanese. [PubMed: 14323790]
  1098. Osterballe O. Immunotherapy with grass pollen major allergens. Clinical results from a prospective 3-year double blind study. Allergy: European Journal of Allergy and Clinical Immunology. Does not apply to any of the key questions. [PubMed: 7181048]
  1099. Osterballe O. Nasal and skin sensitivity during immunotherapy with two major allergens 19, 25 and partially purified extract of timothy grass pollen. Allergy. 82; 37(3):169–77. It does not meet ALL the inclusion criteria. [PubMed: 6814282]
  1100. Osterballe O. Specific immunotherapy with purified grass pollen extracts. Dan Med Bull. 84; 31(3):207–26. No original data. [PubMed: 6744952]
  1101. Osterballe O, Egeskjold EM, Johansen AS, Skov P. Anti-IgG antibodies during immunotherapy with purified grass pollen extracts. Allergy. 82; 37(3):209–16. Other reason for exclusion (specify):cx in other paper. [PubMed: 6182816]
  1102. Osterballe O, Ipsen H, Weeke B, Lowenstein H. Specific IgE response toward allergenic molecules during perennial hyposensitization: a three-year prospective double-blind s. J Allergy Clin Immunol. 83; 71(1 Pt 1):40–6. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 6337196]
  1103. Osterballe O, Lowenstein H, Malling HJ, Petersen BN, Weeke B. Is is possible to predict the clinical effect of hyposensitization? Int Arch Allergy Appl Immunol. 82; 68(3):286–8. It does not meet ALL the inclusion criteria. [PubMed: 7085124]
  1104. Osterballe O, Lowenstein H, Prahl P, Skov P, Weeke B. Immunotherapy in hay fever with two major allergens 19, 25 and partially purified extract of timothy grass pollen. A controlled double blind study. In vitro variables, season i. Allergy. 81; 36(3):183–99. It does not meet ALL the inclusion criteria. [PubMed: 7015911]
  1105. Osterballe O, Lowenstein H, Prahl P, Skov P, Weeke B. Immunotherapy in hay fever with two major allergens 19, 25 and partially purified extract of timothy grass pollen. A controlled double blind study. In vitro variables, season i. Allergy. 81; 36(3):183–99. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 7015911]
  1106. Ostergaard MS, Witt K. Clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 2000;342(1) 58; author reply 59. It does not meet ALL the inclusion criteria. [PubMed: 10627213]
  1107. Ostergaard PA, Kaad PH, Kristensen T. A prospective study on the safety of immunotherapy in children with severe asthma. Allergy. 86; 41(8):588–93. It does not meet ALL the inclusion criteriaoseNot an RCT. [PubMed: 3544937]
  1108. Osterhage F, Wippler M, Kalden JR, Deicher H. Determination of specific IgE and IgG serum antibodies during immunotherapy in hay fever patients by RAST. Z Immunitatsforsch Immunobiol. 77; 153(3):189–203. Does not apply to any of the key questions. [PubMed: 930233]
  1109. Osterhage F, Wippler M, Kalden JR, Deicher H. Determination of specific IgE and IgG serum antibodies during immunotherapy in hay fever patients by RAST. Z Immunitatsforsch Immunobiol. 77; 153(3):189–203. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 930233]
  1110. Ostroumov AI, Shliaposhnikov ED. Specific hyposensitization of pollinosis provoked by ambrosia pollen. Sov Med. 68; 31(9):37–41. Other reason for exclusion (specify): [PubMed: 5747030]
  1111. Ostroumov AI, Shliaposhnikov ED. Specific hyposensitization of pollinosis provoked by ambrosia pollen. Sov Med. 68; 31(9):37–41. Non-English article: Russian. [PubMed: 5747030]
  1112. Ostroumov AL, Shliaposhnikov ED, Shliakhova MI, Mnatsakanian RG. Comparative evaluation of 2 methods of treating hay fever. Sov Med. 70; 33(7):44–7. Non allergen- Non-English article: Russian. [PubMed: 5490045]
  1113. Osvath P, Endre L. Comparison of long term treatment of asthmatic children with hyposensitization, ACTH, DSCG and Ketotifen. Allergol Immunopathol (Madr). 84; 12(6):471–7. It does not meet ALL the inclusion criteria. [PubMed: 6099051]
  1114. Osvath P, Endre L. Comparison of long term treatment of asthmatic children with hyposensitization, ACTH, DSCG and Ketotifen. Allergol Immunopathol (Madr). 84; 12(6):471–7. Therapy NOT AVAILABLE in the U.S. [PubMed: 6099051]
  1115. Osvath P, Endre L. Comparison of the results of hyposensitization treatment performed with water extracted allergens and allpyral in asthmatic children. Monatsschr Kinderheilkd. 73; 121(6):211–5. Therapy NOT AVAILABLE in the U.S. [PubMed: 4737375]
  1116. Osvath P, Endre L. Hyposensitization with extracts of house dust and mites adsorbed on aluminium-hydroxyde (allpyral) in children with bronchial asthma (author’s transl). Monatsschr Kinderheilkd. 76; 124(3):110–3. Therapy NOT AVAILABLE in the U.S. [PubMed: 1264078]
  1117. Osvath P, Endre L. Treatment of asthmatic children with a vaccine (Allpyral) containing aluminum hydroxide-absorbed extract. Orv Hetil. 69; 110(27):1549–51. Therapy NOT AVAILABLE in the U.S. [PubMed: 5799552]
  1118. Otsuka H, Mezawa A, Ohnishi M, Okubo K, Seki H, Okuda M. Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy. 91; 21(1):115–9. It does not meet ALL the inclusion criteria. [PubMed: 2021869]
  1119. Ozdemir C, Yazi D, Gocmen I, Yesil O, Aydogan M, Semic-Jusufagic A, Bahceciler NN, Barlan IB. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol. 2007;18(6):508–15. It does not meet ALL the inclusion criteria. [PubMed: 17680909]
  1120. Ozden MG, Kefeli M, Aydin F, Senturk N, Canturk T, Turanli AY. Persistent subcutaneous nodules after immunotherapy injections for allergic asthma. J Cutan Pathol. 2009;36(7):812–4. Other reason for exclusion (specify):case reportNot an RCT. [PubMed: 19519616]
  1121. Ozden MG, Kefeli M, Aydin F, Senturk N, Canturk T, Turanli AY. Persistent subcutaneous nodules after immunotherapy injections for allergic asthma. J Cutan Pathol. 2009;36(7):812–4. Other reason for exclusion (specify):case report. [PubMed: 19519616]
  1122. Kuna P, Samolinski B, Worm M, Pfaar O, Klimek L. Sustained clinical efficacy of sublingual immunotherapy with a high-dose grass pollen extract. European Annals of Allergy and Clinical Immunology. 2011;43(4):117–121. Other reason for exclusion (specify):3rd year of 4440 (Kuna) BUT does not include data for placebo arm Not an RCT. [PubMed: 21980799]
  1123. Majak P, Kaczmarek-Wozniak J, Brzozowska A, Bobrowska-Korzeniowska M, Jerzynska J, Stelmach I. One-year follow-up of clinical and inflammatory parameters in children allergic to grass pollen receiving high-dose ultrarush sublingual immunotherapy. 2010;(7):602–6. Not an RCT. [PubMed: 21314002]
  1124. Pacor ML, Biasi D, Carletto A, Lunardi C. Effectiveness of oral immunotherapy in bronchial asthma caused by Dermatophagoides pternyssinus. Recenti Prog Med. 95; 86(12):489–91. Other reason for exclusion (specify): oral IT. [PubMed: 8588080]
  1125. Pacor ML, Biasi D, Carletto A, Maleknia T, Lunardi C. Oral immunotherapy in oculorhinitis from Gramineae. Recenti Prog Med. 96; 87(1):4–6. Other reason for exclusion (specify): oral IT. [PubMed: 8711254]
  1126. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy. 2001;31(9):1392–7. It does not meet ALL the inclusion criteria. [PubMed: 11591189]
  1127. Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, Canonica GW, Passalacqua G. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120(1):164–70. It does not meet ALL the inclusion criteriatopic dermatatis. [PubMed: 17543376]
  1128. Pajno GB, Peroni DG, Vita D, Pietrobelli A, Parmiani S, Boner AL. Safety of sublingual immunotherapy in children with asthma. Paediatr Drugs. 2003;5(11):777–81. Not an RCT. [PubMed: 14580226]
  1129. Palma-Carlos AG, Palma-Carlos ML. Trichophyton allergy: review of 89 cases. Eur Ann Allergy Clin Immunol. 2006;38(6):177–81. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 16929743]
  1130. Palma-Carlos AG, Palma-Carlos ML, Branco-Ferreira M, Spinola A, Santos MC, Lopes-Pregral A. Nasal allergen challenge and immunotherapy control. Allerg Immunol (Paris). 98; 30(5):153–6. Does not apply to any of the key questions. [PubMed: 9657024]
  1131. Palma-Carlos AG, Spinola-Santos A, Ferreira MB, Santos MC, Palma-Carlos ML. Immunotherapy in allergic rhinitis. Allerg Immunol (Paris). 2001;33(8):323–6. It does not meet ALL the inclusion criteria - No original data. [PubMed: 11763723]
  1132. Paniagua MJ, Bosque M, Asensio O, Larramona H, Marco MT. Immunotherapy with acarus extract in children under the age of 5 years. Allergol Immunopathol (Madr). 2002;30(1):20–4. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 11888488]
  1133. Panzani RC, Ariano R, Augeri G. Monitoring of specific IgG4 antibodies in respiratory allergy due to the pollen of Parietaria judaica. Evidence for a protective role. Allergol Immunopathol (Madr). 96; 24(6):263–8. Not an RCT. [PubMed: 9010562]
  1134. Paranos S, Petrovic S, Vojovic I. Specific skin reactions induced by individual pollen preparations in hypersensitivity persons. Srp Arh Celok Lek. 98; 126(9–10):362–7. yugoslavia. Non-English article. [PubMed: 9863408]
  1135. Park HS, Nahm DH, Kim HY, Suh YJ, Cho JW, Kim SS, Lee SK, Jung KS. Clinical and immunologic changes after allergen immunotherapy with Hop Japanese pollen. Ann Allergy Asthma Immunol. 2001;86(4):444–8. It does not meet ALL the inclusion criteriaNot an RCT and doesnt include any harms. [PubMed: 11345290]
  1136. Parkash D, Garg OP, Shivpuri DN. Hyposensitization in children with bronchial asthma. Indian J Pediatr. 70; 37(271):366–72. It does not meet ALL the inclusion criteria. [PubMed: 5490692]
  1137. Parker WA Jr, Whisman BA, Apaliski SJ, Reid MJ. The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis. J Allergy Clin Immunol. 89; 84(5 Pt 1):667–77. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 2809024]
  1138. Passalacqua G, Canonica GW. Sublingual or injection immunotherapy: the final answer? Allergy. 2004;59(1):37–8. No original data. [PubMed: 14674931]
  1139. Passalacqua G. Preventive effects of sublingual immunotherapy. Drugs Today (Barc). 2008;44 Suppl B:83–6. No original data. [PubMed: 19221627]
  1140. Passalacqua G. Sublingual immunotherapy: accumulated experience. J Investig Allergol Clin Immunol. 97; 7(5):364–6. No original data. [PubMed: 9416549]
  1141. Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS, Canonica GW. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet. 98; 351(9103):629–32. Therapy NOT AVAILABLE in the U.S. [PubMed: 9500318]
  1142. Passalacqua G, Bagnasco M, Mariani G, Falagiani P, Canonica GW. Local immunotherapy: pharmacokinetics and efficacy. Allergy. 98; 53(5):477–84. No original data. [PubMed: 9636806]
  1143. Passalacqua G, Musarra A, Pecora S, Amoroso S, Antonicelli L, Cadario G, Di Gioacchino M, Lombardi C, Ridolo E, Sacerdoti G, Schiavino D, Senna G. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year). Pediatr Allergy Immunol. 2007;18(1):58–62. Does not apply to any of the key questions. [PubMed: 17295800]
  1144. Passalacqua G, Pasquali M, Ariano R, Lombardi C, Giardini A, Baiardini I, Majani G, Falagiani P, Bruno M, Canonica GW. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy. 2006;61(7):849–54. Therapy NOT AVAILABLE in the U.S. [PubMed: 16792583]
  1145. Passali D, De Seta E, Masieri S, Bellussi L. Specific local immunotherapy in young allergic subjects. Acta Otorhinolaryngol Ital. 83; 3(4):403–8. It does not meet ALL the inclusion criteria.
  1146. Passali D, De Seta E, Masieri S, Bellussi L. Specific local immunotherapy in young allergic subjects. Acta Otorhinolaryngol Ital. 83; 3(4):403–8. Does not apply to any of the key questionsOther reason for exclusion (specify):nasal it.
  1147. Pastorello EA, Incorvaia C, Gerosa A, Vassellatti D, Italia M, Pravettoni V. Allergen specific IgG subclass antibody response in hyposensitization with Dermatophagoides pteronyssinus extract. N Engl Reg Allergy Proc. 87; 8(6):417–21. It does not meet ALL the inclusion criteria. [PubMed: 3481429]
  1148. Pastorello EA, Incorvaia C, Gerosa A, Vassellatti D, Italia M, Pravettoni V. Allergen specific IgG subclass antibody response in hyposensitization with Dermatophagoides pteronyssinus extract. N Engl Reg Allergy Proc. 87; 8(6):417–21. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 3481429]
  1149. Patriarca G, Venuti A, Bonini W. Identification of IgG-antibodies in subjects with hay fever before and after specific hyposensitizing treatment. Ann Allergy. 73; 31(5):223–7. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 4697679]
  1150. Patterson R. Clinical efficacy of allergen immunotherapy. J Allergy Clin Immunol. 79; 64(3):155–8. No original data. [PubMed: 469116]
  1151. Paty E, de Blic J, Brunet D, Le Bourgeois M, Garcelon M, Paupe J, Scheinmann P. Accelerated desensitization with Dermatophagoides pteronyssinus in severe asthmatic children. Evaluation after one year of immunotherapy. Arch Fr Pediatr. 90; 47(3):173–9. It does not meet ALL the inclusion criteria. [PubMed: 2111693]
  1152. Paul K, Klettke U, Wahn U. The combined influence of immunotherapy and mite allergen reduction on bronchial hyperresponsiveness in mite-sensitive asthmatic children. Eur J Pediatr. 98; 157(2):109–13. It does not meet ALL the inclusion criteria. [PubMed: 9504783]
  1153. Pauli G, Guisard G, Bessot JC, Oudet P. Development of bronchial tolerance during therapeutic desensitization to dust. Rev Fr Allergol. 72; 12(3):209–17. It does not meet ALL the inclusion criteria. [PubMed: 4652456]
  1154. Pegelow KO, Belin L, Broman P, Heilborn H, Sundin B, Watson K. Immunotherapy with alginate-conjugated and alum-precipitated grass pollen extracts in patients with allergic rhinoconjunctivitis. Allergy. 84; 39(4):275–90. Therapy NOT AVAILABLE in the U.S. [PubMed: 6731753]
  1155. Pence HL, Ward GW. Jr The role of injection therapy in allergic asthma. Postgrad Med. 75; 57(3):137–41. No original data. [PubMed: 47172]
  1156. Peng ZK. Immunologic changes during hyposensitization with the dust mite Dermatophagoides farinae extract in allergic asthma. Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi. 85; 8(4):207–10. 254–5. Non-English article. [PubMed: 4075924]
  1157. Peng ZK. Immunologic changes during hyposensitization with the dust mite Dermatophagoides farinae extract in allergic asthma. Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi. 85; 8(4):207–10. 254–5. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 4075924]
  1158. Peng ZK, Naclerio RM, Norman PS, Adkinson NF Jr. Quantitative IgE- and IgG-subclass responses during and after long-term ragweed immunotherapy. J Allergy Clin Immunol. 92; 89(2):519–29. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 1740582]
  1159. Pereira-Santos MC, Pregal AL, Spinola-Santos A, Alonso E, Palma-Carlos ML, Palma-Carlos AG. Effect of allergen immunotherapy on soluble adhesion molecules. Allerg Immunol (Paris). 2001;33(6):225–8. Does not apply to any of the key questions. [PubMed: 11505805]
  1160. Perennial versus preseasonal immunotherapy in the treatment of rhinoconjunctivitis in subjects allergic to grass pollen. Library unable to locate.
  1161. Perera MG, Bernstein IL, Michael JG, Johansson SG. Predictability of the radioallergosorbent test (RAST) in ragweed pollenosis. Am Rev Respir Dis. 75; 111(5):605–10. Does not apply to any of the key questions. [PubMed: 1130752]
  1162. Perez Martin J, Moreno MA, Valdovinos Aviles H, Madariaga Marquez JB. Inmunoterapia en pediatria con antigenos de allpyral (efectividad clinica). Alergia Mqx. 82; 29(4):111–21. Therapy NOT AVAILABLE in the U.S Other reason for exclusion (specify):allpyral. [PubMed: 7165066]
  1163. Peroni DG, Piacentini GL, Martinati LC, Warner JO, Boner AL. Double-blind trial of house-dust mite immunotherapy in asthmatic children resident at high altitude. Allergy. 95; 50(11):925–30. It does not meet ALL the inclusion criteria. [PubMed: 8748726]
  1164. Perrin LF, Sroussi J, Cea-Gil F, Deviller P, Lasne Y. Serum IgE levels and specific IgE antibodies in house dust mite allergy: predictive value. J Asthma. 83; 20(2):93–6. Does not apply to any of the key questions. [PubMed: 6853433]
  1165. Petersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr). 2005;33(6):296–302. Does not apply to any of the key questions. [PubMed: 16371215]
  1166. Petersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr). 2005;33(6):296–302. It does not meet ALL the inclusion criteria nocontrols. [PubMed: 16371215]
  1167. Petersen KD, Gyrd-Hansen D, Linneberg A, Dahl R, Larsen JN, Lowenstein H, Kronborg C. Willingness to pay for allergy-vaccination among Danish patients with respiratory allergy. Int J Technol Assess Health Care. 2010;26(1):20–9. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 20059777]
  1168. Petersen KD, Kronborg C, Gyrd-Hansen D, Dahl R, Larsen JN, Linneberg A. Characteristics of patients receiving allergy vaccination: to which extent do socio-economic factors play a role? Eur J Public Health. 2010. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PMC free article: PMC3098894] [PubMed: 20484343]
  1169. Petri E, Austgen M, Trendelenburg F. House dust mite allergy and allergic bronchial asthma (II). Clinical aspects of house dust mite allergy and specific therapy in sensitization against house dust mites. ZFA (Stuttgart). 81; 57(13):973–9. No original data. [PubMed: 7018106]
  1170. Petrovskaia IA, Bobkova LP, Evseeva TA, Kostiuk AG, Glinskii VV. A clinical evaluation of different schedules for specific immunotherapy and a comparative analysis of the changes in immunity in pollinosis. Ter Arkh. 89; 61(12):56–60. Not an RCT. [PubMed: 2629148]
  1171. Pfaar O, Klimek L, Fischer I, Sieber J, Amoroso S, Moreno Aguilar C, Shah K, Mosges R. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens. Int Arch Allergy Immunol. 2009;150(1):102–8. It does not meet ALL the inclusion criteria nocontrols. [PubMed: 19339808]
  1172. Pfaar O, Mosges R, Hormann K, Klimek L. Cluster immunotherapy of persistent allergic rhinoconjunctivitis. Safety aspects of induction therapy with mite depot allergen preparations. HNO. 2009;57(11):1099–105. German. Non-English article. [PubMed: 19585090]
  1173. Pfaar O, Mosges R, Hormann K, Klimek L. Safety aspects of Cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis. Eur Arch Otorhinolaryngol. 2010;267(2):245–50. Not an RCT. [PubMed: 19756683]
  1174. Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol. 2007;18(1):47–57. Therapy NOT AVAILABLE in the U.S. [PubMed: 17295799]
  1175. Phelan PD. Dangers of immunotherapy for the treatment of asthma in children. Med J Aust. 90; 153(6):367. Other reason for exclusion (specify): letter. [PubMed: 2233466]
  1176. PHILIPPE J. ON CERTAIN ASPECTS WHICH A SENSITIZATION PROCESS MAY ASSUME. Clinique (Paris). 63; 58:495–7. No original data - Non-English article. [PubMed: 14089604]
  1177. PHILIPPE J. ON CERTAIN ASPECTS WHICH A SENSITIZATION PROCESS MAY ASSUME. Clinique (Paris). 63; 58:495–7. Non-English article. [PubMed: 14089604]
  1178. Piazza I. Comparison between immunotherapy and stemizole in the treatment of seasonal allergic rhinitis. Allergy. No original data.
  1179. Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy. 2001;56(4):301–6. It does not meet ALL the inclusion criteriapre-post data only. [PubMed: 11284796]
  1180. Pilette C, Nouri Aria KT, Jacobson MR, Durham SR. Seasonal increases in interleukin-9 expression and in mast cell infiltration of the nasal mucosa in allergic rhinitis are inhibited by grass pollen immunotherapy; XXII Congress of the European Academy of Allergology and Clinical Immunology (EAACI); 2003; Paris. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions.
  1181. Pilette C, Nouri Aria KT, Jacobson MR, Durham SR. Seasonal increases in interleukin-9 expression and in mast cell infiltration of the nasal mucosa in allergic rhinitis are inhibited by grass pollen immunotherapy; XXII Congress of the European Academy of Allergology and Clinical Immunology (EAACI); 2003; Paris. It does not meet ALL the inclusion criteria.
  1182. Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM, Francis JN, Durham SR. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol. 2007;178(7):4658–66. Does not apply to any of the key questions. [PubMed: 17372025]
  1183. Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM, Francis JN, Durham SR. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol. 2007;178(7):4658–66. It does not meet ALL the. [PubMed: 17372025]
  1184. Pinkawa E. Effect of specific desensitization on serum concentration of protein fractions and immunoglobulins in children with asthma and pollinosis. Pol Tyg Lek. 78; 33(2):61–3. Does not apply to any of the key questions polishNon-English article. [PubMed: 643726]
  1185. Platts-Mills TA. Allergen-specific treatment for asthma: III. Am Rev Respir Dis. 93; 148(3):553–5. No original data (specify):Editorial. [PubMed: 8368622]
  1186. Platts-Mills TA. Ragweed immunotherapy in adult asthma. N Engl J Med. 96; 335(3):204. author reply 205–6. No original data. [PubMed: 8657225]
  1187. Plavsic Z, Petrovic M, Popovac D. Real effect of specific hyposensitisation in therapy of allergic respiratory diseases. Srp Arh Celok Lek. 94; 122(7–8):210–1. Russian Non-English article. [PubMed: 17974388]
  1188. Plewako H, Arvidsson M, Oancea I, Hasseus B, Dahlgren U, Rak S. The effect of specific immunotherapy on the expression of costimulatory molecules in late phase reaction of the skin in allergic patients. Clin Exp Allergy. 2004;34(12):1862–7. It does not meet ALL the inclusion criteria. [PubMed: 15663560]
  1189. Plewako H, Arvidsson M, Oancea I, Hasseus B, Dahlgren U, Rak S. The effect of specific immunotherapy on the expression of costimulatory molecules in late phase reaction of the skin in allergic patients. Clin Exp Allergy. 2004;34(12):1862–7. Other reason for exclusion (specify): mech. [PubMed: 15663560]
  1190. Plewako H, Holmberg K, Oancea I, Gotlib T, Samolinski B, Rak S. A follow-up study of immunotherapy-treated birch-allergic patients: effect on the expression of chemokines in the nasal mucosa. Clin Exp Allergy. 2008;38(7):1124–31. It does not meet ALL the inclusion criteria. [PubMed: 18691293]
  1191. Pokladnikova J, Krcmova I, Vlcek J. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy (Brief record). Annals of Allergy, Asthma and Immunology. It does not meet ALL the inclusion criteria. [PubMed: 18517082]
  1192. Pokladnikova J, Krcmova I, Vlcek J. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy (Brief record). Annals of Allergy, Asthma and Immunology. It does not meet ALL the inclusion criteria asthma not reportedly confirmed with PFTs; dose and units not specified (unsure if there is a parent article)
  1193. Polosa R. Can immunotherapy prevent progression to asthma in allergic individuals? J Allergy Clin Immunol. 2002;110(4):672–3. author reply 273. Other reason for exclusion (specify): Corresp No original data. [PubMed: 12373284]
  1194. Polosa R, Al-Delaimy WK, Russo C, Piccillo G, Sarva M. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective Cohort study. Respir Res. 2005;6:153. Not an RCT. [PMC free article: PMC1351177] [PubMed: 16381607]
  1195. Poncelet-Maton E, Radermecker M, Salmon J. Blood histamine levels in allergology: effect of specific desensitization and of animal immunization. Rev Med Liege. 75; 30(17):563–6. Does not apply to any of the key questions - No SIT. [PubMed: 1166171]
  1196. Portnoy JM, Finegold I. Ragweed immunotherapy in adult asthma. N Engl J Med. 96; 335(3):203–4. author reply 205–6. Other reason for exclusion (specify): letter. [PubMed: 8657223]
  1197. Portnoy J, King K, Kanarek H, Horner S. Incidence of systemic reactions during rush immunotherapy. Ann Allergy. 92; 68(6):493–8. Not an RCT. [PubMed: 1610025]
  1198. Martin Pqrez. Jes s Utilidad de la inmunoterapia en el asma. Alergia Mqx. 98; 45(5):117–8. No original data.
  1199. Pre-seasonal Specific Immunotherapy in rhinoconjunctivitis versus Placebo Abstract. Meeting Abstract.
  1200. Prigal SJ. A ten-year study of repository injections of allergens: local reactions and their management. Ann Allergy. 72; 30(9):529–35. Not an RCT. [PubMed: 5056915]
  1201. Prigal SJ, Stern A, Avedon AB, Franklin HL, Hilton DW, Furman ML. The treatment of pollinosis with small doses of emulsions of ironated ragweed extract. Ann Allergy. 65; 23(9):414–21. It does not meet ALL the inclusion criteria. [PubMed: 5830237]
  1202. Pronk-Admiraal CJ, Schilte PP, Bartels PC. Effect of immunotherapy on eosinophil activation in pollen sensitive children. Clin Lab. 2001;47(5–6):231–8. Does not apply to any of the key questions. [PubMed: 11405601]
  1203. Pumhirun P, Tuchinda S, Nondavanich A, Jarujinda S, Poommark C. Immunological and clinical evaluation during a 12 month period of immunotherapy. Asian Pac J Allergy Immunol. 94; 12(2):111–5. Not an RCT. [PubMed: 7612103]
  1204. Purello-D’Ambrosio F, Gangemi S, Merendino RA, Isola S, Puccinelli P, Parmiani S, Ricciardi L. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy. 2001;31(8):1295–302. Not an RCT. [PubMed: 11529901]
  1205. Purohit A, Niederberger V, Kronqvist M, Horak F, Gronneberg R, Suck R, Weber B, Fiebig H, van Hage M, Pauli G, Valenta R, Cromwell O. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy. 2008;38(9):1514–25. Therapy NOT AVAILABLE in the U.S. [PubMed: 18564326]
  1206. Purser JR. Treatment of hay fever in general practice by hyposensitization, using ‘Pollinex’ Curr Med Res Opin. 76; 4(2):124–7. Therapy NOT AVAILABLE in the U.S. [PubMed: 1277879]
  1207. Quality of Life and Symptoms assessment in sublingual immunotherapy for patients with house-dust mite related perennial rhinitis: definition of a responder profile. Library unable to locate.
  1208. Rahman Mahdy RA, Nada WM, Marei AA. Subcutaneous allergen-specific immunotherapy versus topical treatment in vernal keratoconjunctivitis. Cornea. 2012;31(5):525–528. Does not apply to any of the key questions Other reason for exclusion (specify):vernal keratoconjunctivitis, which is not a condition that we have included in our study. The only types of conjunctivitis included in our study are seasonal and perennial allergic conjunctivitis. [PubMed: 22314814]
  1209. Mösges R, Graute V, Christ H, Sieber HJ, Wahn U, Niggemann B. Safety of ultra-rush titration of sublingual immunotherapy in asthmatic children with tree-pollen allergy. 2010;(8):1135–8. It does not meet ALL the inclusion criteria no interval and no cumulative dose. [PubMed: 21121080]
  1210. RACKEMANN FM, LAMSA T. THE NATURAL HISTORY OF RAGWEED HAY FEVER; A TWENTY-YEAR STUDY OF 120 PATIENTS. J Allergy Clin Immunol. 65; 36:258–64. Not an RCT. [PubMed: 14279748]
  1211. RACKEMANN FM. PRINCIPLES OF SPECIFIC DESENSITIZATION TO POLLEN. Acta Allergol. 64; 19:197–206. Therapy NOT AVAILABLE in the U.S. [PubMed: 14185472]
  1212. Radcliffe MJ, Lewith GT, Turner RG, Prescott P, Church MK, Holgate ST. Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study. BMJ. 2003;327(7409):251–4. Therapy NOT AVAILABLE in the U.S. [PMC free article: PMC167158] [PubMed: 12896934]
  1213. Radermecker M, Maldague MP, Gustin M. Increased complement-mediated leukocytic histamine release in atopics. Int Arch Allergy Appl Immunol. 82; 68(4):365–70. Other reason for exclusion (specify): mechs. [PubMed: 6178702]
  1214. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol. 2008;121(6):1467–72. 1472.e1. It does not meet ALL the inclusion criteria- Other reason for exclusion (specify): mechs. [PubMed: 18423565]
  1215. Ragusa FV, Passalacqua G, Gambardella R, Campanari S, Barbieri MM, Scordamaglia A, Canonica GW. Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience. J Investig Allergol Clin Immunol. 97; 7(3):151–4. Other reason for exclusion (specify):retrospectiveNot an RCT. [PubMed: 9252872]
  1216. Ragusa VF, Massolo A. Non-fatal systemic reactions to subcutaneous immunotherapy: a 20-year experience comparison of two 10-year periods. Eur Ann Allergy Clin Immunol. 2004;36(2):52–5. It does not meet ALL the inclusion criteria. [PubMed: 15061395]
  1217. Railey MD, Adair MA, Burks AW. Allergen immunotherapy for allergic rhinitis. Curr Allergy Asthma Rep. 2008;8(1):1–3. No original data. [PubMed: 18377767]
  1218. Rak S. Effects of immunotherapy on the inflammation in pollen asthma. Allergy. 93; 48(17 Suppl):125–8. discussion 143–4. It does not meet ALL the inclusion criteria. [PubMed: 8109703]
  1219. Rak S. Quality of life (QoL): impact of specific immunotherapy (SIT) on social and physical ability. Drugs Today (Barc). 2008;44 Suppl B:35–8. No original data. [PubMed: 19221616]
  1220. Rak S, Bjornson A, Hakanson L, Sorenson S, Venge P. The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure. J Allergy Clin Immunol. 91; 88(6):878–88. It does not meet ALL the inclusion criteria. [PubMed: 1744358]
  1221. Rak S, Hakanson L, Venge P. Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season. J Allergy Clin Immunol. 90; 86(5):706–13. It does not meet ALL the inclusion criteria. [PubMed: 2229837]
  1222. Rak S, Hakansson L, Venge P. Eosinophil chemotactic activity in allergic patients during the birch pollen season: the effect of immunotherapy. Int Arch Allergy Appl Immunol. 87; 82(3–4):349–50. Does not apply to any of the key questions. [PubMed: 3570501]
  1223. Rak S, Hallden G, Sorenson S, Margari V, Scheynius A. The effect of immunotherapy on T-cell subsets in peripheral blood and bronchoalveolar lavage fluid in pollen-allergic patients. Allergy. 93; 48(6):460–5. Other reason for exclusion (specify): mech. [PubMed: 8238803]
  1224. Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol. 88; 82(3 Pt 1):470–80. It does not meet ALL the inclusion criteria. [PubMed: 3170995]
  1225. Ramaiah RS, Gallagher MA, Biagi RW. House dust mite allergy and hyposensitisation. A retrospective study. Br J Clin Pract. 80; 34(10):282–3. Therapy NOT AVAILABLE in the U.S Other reason for exclusion (specify):allpyral. [PubMed: 7459193]
  1226. Randhawa IS, Junaid I, Klaustermeyer WB. Allergen immunotherapy in a patient with human immunodeficiency virus: effect on T-cell activation and viral replication. Ann Allergy Asthma Immunol. 2007;98(5):495–7. It does not meet ALL the inclusion criteria. [PubMed: 17521037]
  1227. Randomized double-blind trial of a combination of cromoglycate disodium administration and specific desensitization treatment in adults with perennial extrinsic asthma and nonspecific bronchial hyperreactivity. Library unable to locate.
  1228. Rank MA, Oslie CL, Krogman JL, Park MA, Li JT. Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors. Allergy Asthma Proc. 2008;29(4):400–5. It does not meet ALL the inclusion criteria. [PubMed: 18702889]
  1229. Ransom JH. Clinical and laboratory evaluation of alum-precipitated ragweed extract. Ann Allergy. 70; 28(5):221–6. Does not apply to any of the key questions. It does not meet ALL the inclusion criteria.
  1230. RAPAPORT HG. THE VALUE OF HYPOSENSITIZATION IN THE TREATMENT OF POLLEN ALLERGY IN CHILDREN. J Asthma Res. 64; 15:257–60. No original data. [PubMed: 14135444]
  1231. RAPAPORT HG. THE VALUE OF HYPOSENSITIZATION IN THE TREATMENT OF POLLEN ALLERGY IN CHILDREN. J Asthma Res. 64; 15:257–60. Other reason for exclusion (specify): review. [PubMed: 14135444]
  1232. Razzouk H, Fay A. A case of generalized accident caused by pollen sensitization. Mars Med. 72; 109(6):445–8. Not an RCT. [PubMed: 5084473]
  1233. Rebien W, Puttonen E, Maasch HJ, Stix E, Wahn U. Clinical and immunological response to oral and subcutaneous immunotherapy with grass pollen extracts. A prospective study. Eur J Pediatr. 82; 138(4):341–4. It does not meet ALL the inclusion criteria. [PubMed: 7128644]
  1234. Reha CM, Ebru A. Specific immunotherapy is effective in the prevention of new sensitivities. Allergol Immunopathol (Madr). 2007;35(2):44–51. Not an RCT. [PubMed: 17428399]
  1235. Reich M, Zwacka G, Markert UR. Nonspecific plasma proteins during sublingual immunotherapy. Chem Immunol Allergy. 2003;82:99–108. Does not apply to any of the key questions. [PubMed: 12947996]
  1236. Reid MJ, Schwietz LA, Whisman BA, Moss RB. Mountain cedar pollinosis: can it occur in non-atopics? N Engl Reg Allergy Proc. 88; 9(3):225–32. Does not apply to any of the key questions. [PubMed: 3412291]
  1237. Reisman RE, Arbesman CE. Clinical and immunological studies following immunotherapy with aqueous and alum precipitated reagweed fraction A. Int Arch Allergy Appl Immunol. 73; 44(2):161–70. Therapy NOT AVAILABLE in the U.S. [PubMed: 4196142]
  1238. Reisman RE, Wypych JI, Arbesman CE. Relationship of immunotherapy, seasonal pollen exposure and clinical response to serum concentrations of total IgE and ragweed-specific IgE. Int Arch Allergy Appl Immunol. 75; 48(6):721–30. It does not meet ALL the inclusion criteria. [PubMed: 1170137]
  1239. Relyveld EH, Henocq E, Philippe J, Meaume JE, Cousin J, Fanet G, Raynaud M. Purified and on aluminum hydroxide adsorbed dust in specific desensitization treatments. Rev Fr Allergol. 68; 8(2):81–90. Therapy NOT AVAILABLE in the U.S. [PubMed: 5717858]
  1240. Rennie AG, Cant JS, Foulds WS, Pennington TH, Timbury MC. Ocular vaccinia. Lancet. 74; 2(7875):273–5. No SIT. [PubMed: 4135695]
  1241. Rennie AG, Cant JS, Foulds WS, Pennington TH, Timbury MC. Ocular vaccinia. Lancet. 74; 2(7875):273–5. Does not apply to any of the key questions No SIT. [PubMed: 4135695]
  1242. Renovanz BH. Allergic bronchopneumopathies and immunotherapy. Med Monatsschr. 76; 30(3):121–2. Other reason for exclusion (specify): review. [PubMed: 958137]
  1243. Renz H. Immunotherapy in broad allergy spectrum. Dtsch Med Wochenschr. 2002;127(23):1274–5. No original data. [PubMed: 12053290]
  1244. Report by the Federal Society of Pneumologists. Allergic bronchial asthma: chances for hyposensitization. MMW Fortschr Med. 99; 141(27):43–4. No original data. [PubMed: 10904585]
  1245. Reyes Moreno A, Castrejon Vazquez MI, Miranda Feria AJ. Failure of allergen-based immunotherapy in adults with allergic asthma. Rev Alerg Mex. 2003;50(1):8–12. Not an RCT. [PubMed: 12822542]
  1246. Rhinitis allergica due to house dust mite in children: long lasting effect of sublingual immunotherapy. Library unable to locate.
  1247. Rhinitis. Journal of Investigational Allergology and Clinical Immunology. 2010;20(SUPPL 1):37–42. No original data.
  1248. Ricca V, Ciprandi G, Pesce G, Riccio A, Varese P, Pecora S, Canonica GW. Preseasonal specific immunotherapy with modified Phleum pratense allergenic extracts: tolerability and effects. Allergol Immunopathol (Madr). 97; 25(4):167–75. Therapy NOT AVAILABLE in the U.S. [PubMed: 9269506]
  1249. Richter I, Kriebel I. Allergic reactions to the house-dust mite in children with obstructive disease of the respiratory tract (author’s transl). Med Klin. 75; 70(37):1484–7. It does not meet ALL the inclusion criteria. [PubMed: 1186568]
  1250. Richter I, Oehme J. Experiences with cutaneous allergy testing and specific hyposensitization in routine pediatric hospital practice. Monatsschr Kinderheilkd. 72; 120(10):410–2. It does not meet ALL the inclusion criteria. [PubMed: 4635017]
  1251. Rieckenberg MR, Khan RH, Day JH. Physician reported patient response to immunotherapy: a retrospective study of factors affecting the response. Ann Allergy. 90; 64(4):364–7. It does not meet ALL the inclusion criteria. [PubMed: 2321812]
  1252. Rienzo VD, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica WG, Passalacqua G. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy. 2005;35(5):560–4. Other reason for exclusion (specify):Survey. [PubMed: 15898975]
  1253. Rikardsson SG, Love YB, Jorgensen GH, Gislason D, Ludviksson BR. Allergen immunotherapy in Iceland 1977–2006. Laeknabladid. 2010;96(7–8):463–8. Not an RCT. [PubMed: 20601746]
  1254. Rivlin J, Kuperman O, Freier S, Godfrey S. Suppressor T-lymphocyte activity in wheezy children with and without treatment by hyposensitization. Clin Allergy. 81; 11(4):353–6. It does not meet ALL the inclusion criteria. [PubMed: 6457703]
  1255. Robinson J, Brigden W. Recurrent pericarditis. Br Med J. 68; 2(5600):272–5. No SIT. [PMC free article: PMC1985865] [PubMed: 5646538]
  1256. Rocha EM. Effect of 2 therapeutic protocols in minor forms of respiratory allergy. Allerg Immunol (Paris). 86; 18(2):29–41. It does not meet ALL the inclusion criteria. [PubMed: 3453709]
  1257. Rocklin RE. Clinical and immunologic aspects of allergen-specific immunotherapy in patients with seasonal allergic rhinitis and/or allergic asthma. J Allergy Clin Immunol. 83; 72(4):323–38. No original data. [PubMed: 6194195]
  1258. Rocklin RE, Sheffer AL, Greineder DK, Melmon KL. Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med. 80; 302(22):1213–9. Other reason for exclusion (specify): mech. [PubMed: 6154241]
  1259. Roder A, Darrelmann N, Klingenberg W, Krull M, Suttorp N, Noga O. Simultaneous SCIT with 2 separate allergen extracts demonstrates comparable safety compared to SCIT with a single allergen extract. J Investig Allergol Clin Immunol. 2009;19(6):512–3. It does not meet ALL the inclusion criteria. [PubMed: 20128433]
  1260. Roder E, Berger MY, de Groot H, Gerth van Wijk R. Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial. Clin Exp Allergy. 2008;38(10):1659–67. Does not apply to any of the key questions. [PubMed: 18631346]
  1261. Rodriguez Medina R, Lopez Duran JL, Gasca Bauza MR, Cortez Gonzalez E, Zamora Limon E. Effect of immunotherapy with allergens in asthmatic children with integral treatment. Rev Alerg Mex. 2000;47(5):162–5. Not an RCT. [PubMed: 11729390]
  1262. Rodriguez Perez N, Ambriz Moreno Mde J. Safety of immunotherapy and skin tests with allergens in children younger than five years. Rev Alerg Mex. 2006;53(2):47–51. It does not meet ALL the inclusion criteriaNot an RCT. [PubMed: 16884027]
  1263. Rodriguez Santos O. Sublingual immunotherapy with allergenic extract of Dermatophagoides pteronyssinus in asthmatic children. Rev Alerg Mex. 2004;51(5):177–80. Other reason for exclusion (specify):Spanish-rct Non-English article. [PubMed: 15794407]
  1264. Rodriguez-Perez N, Ambriz-Moreno Mde J, Canonica GW, Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol. 2008;101(3):304–10. Not an RCT. [PubMed: 18814454]
  1265. Rogala B, Gluck J. Allergen-specific IgE in circulating immune complexes in patients with inhalant allergy undergoing specific immunotherapy. J Investig Allergol Clin Immunol. 99; 9(3):183–9. Does not apply to any of the key questions. [PubMed: 10412681]
  1266. Rogala B, Gumprecht J, Gawlik R, Strojek K. Platelet aggregation in IgE-mediated allergy with elevated soluble Fc epsilon RII/CD23 level. J Investig Allergol Clin Immunol. 95; 5(3):161–5. Does not apply to any of the key questions- Therapy NOT AVAILABLE in the U.S. [PubMed: 7582163]
  1267. Rogala B, Jarzab J, Karawajczyk M, Jawor B, Rogala E. Effect of specific immunotherapy on IgE immune complexes in seasonal allergic rhinitis. Pneumonol Alergol Pol. 92; 60 Suppl 1:57–62. Therapy NOT AVAILABLE in the U.S Other reason for exclusion (specify):tyrosine-absorbed. [PubMed: 1292849]
  1268. Rogala B, Markiewicz-Bendkowska IB, Brzoza Z, Gluck J, Oles E. Side-effects of injective allergen immunotherapy administered to intermittent or persistent allergic rhinitis patients. Rhinology. 2007;45(2):134–9. Not an RCT. [PubMed: 17708460]
  1269. Roger A, Justicia JL, Navarro LA, Eseverri JL, Ferres J, Malet A, Alva V. Observational Study of the Safety of an Ultra-Rush Sublingual Immunotherapy Regimen to Treat Rhinitis due to House Dust Mites. Int Arch Allergy Immunol. 2010;154(1):69–75. It does not meet ALL the inclusion criteria. [PubMed: 20664280]
  1270. Rohatgi N, Dunn K, Chai H. Cat- or dog-induced immediate and late asthmatic responses before and after immunotherapy. J Allergy Clin Immunol. 88; 82(3 Pt 1):389–97. It does not meet ALL the inclusion criteria. [PubMed: 3049744]
  1271. Rolinck-Werninghaus C, Hamelmann E, Keil T, Kulig M, Koetz K, Gerstner B, Kuehr J, Zielen S, Schauer U, Kamin W, Von Berg A, Hammermann J, Weinkauf B, Weidinger G, Stenglein S, Wahn U. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy. 2004;59(9):973–9. Does not apply to any of the key questions. [PubMed: 15291906]
  1272. Rolinck-Werninghaus C, Kopp M, Liebke C, Lange J, Wahn U, Niggemann B. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol. 2005;136(2):134–41. It does not meet ALL the inclusion criteria. Does not apply to any of the key questions. [PubMed: 15650310]
  1273. Romanski B, Pawlik K, Wilawska-Klubo T. The advances of hyposensibilisation therapy in bronchial asthma patients allergic to house dust antigen. Allerg Immunol (Leipz). 77; 23(3):211–3. Does not apply to any of the key questions. [PubMed: 147019]
  1274. Romo A, Lorente F, Romo MT, Garcia MJ, Lorenzo C. Oral immunotherapy versus parenteral immunotherapy. Allergol Immunopathol (Madr). 96; 24 Suppl 1:92–103. Other reason for exclusion (specify): oral IT. [PubMed: 8815728]
  1275. Rose G, Arlian L, Bernstein D, Grant A, Lopez M, Metzger J, Wasserman S, Platts-Mills TA. Evaluation of household dust mite exposure and levels of specific IgE and IgG antibodies in asthmatic patients enrolled in a trial of immunotherapy. J Allergy Clin Immunol. 96; 97(5):1071–8. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions Not an RCT. [PubMed: 8626984]
  1276. Rose G, Arlian L, Bernstein D, Grant A, Lopez M, Metzger J, Wasserman S, Platts-Mills TA. Evaluation of household dust mite exposure and levels of specific IgE and IgG antibodies in asthmatic patients enrolled in a trial of immunotherapy. J Allergy Clin Immunol. 96; 97(5):1071–8. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions Not an RCT. [PubMed: 8626984]
  1277. Rossi RE, Monasterolo G. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients. Int Arch Allergy Immunol. 2004;135(1):44–53. Does not apply to any of the key questions. [PubMed: 15286445]
  1278. Rossi RE, Monasterolo G, Coco G, Operti D. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis. Int Arch Allergy Immunol. 2005;138(2):105–10. It does not meet ALL the inclusion criteria. [PubMed: 16174987]
  1279. Rotne H. Very late reactions to allergen-specific immunotherapy caused by physical exercise. Allergy. 2000;55(2):194. It does not meet ALL the inclusion criteriaNot an RCT. [PubMed: 10726737]
  1280. Ruiz de Leon Loriga J, Lluch Perez M, Valero Santiago A, Zamorano Calderon M, Huguet Casals J, Malet Casajuana A, Garcia Calderon PA. Evaluation of immune parameters (including specific IgG4) during immunotherapy. Allergol Immunopathol (Madr). 89; 17(3):119–27. Does not apply to any of the key questions. [PubMed: 2479244]
  1281. Rumpold H, Jarolim E, Bonitz W, Tejkl M, Breitenbach M, Scheiner O, Kraft D. IgE and IgG antibody response in patients with type I allergy to birch pollen. Wien Klin Wochenschr. 89; 101(3):107–10. Does not apply to any of the key questions Other reason for exclusion (specify):healthy controls. [PubMed: 2922932]
  1282. Rush allergen subcutaneous immunotherapy administered with infusion pump. Meeting abstract. [PubMed: 22018619]
  1283. Rush sublingual immunotherapy in Parietaria allergic patients. Duplicate of 1333. [PubMed: 8939269]
  1284. Barberi S, Villa MP, Pajno GB, La Penna F, Barreto M, Cardelli P, Amodeo R, Tabacco F, Caminiti L, Ciprandi G. Immune response to sublingual immunotherapy in children allergic to mites. J Biol Regul Homeost Agents. 2011;25(4):627–34. Not an RCT. [PubMed: 22217994]
  1285. Hendrix SG, Patterson R, Zeiss CR, Pruzansky JJ, Suszko IM, McQueen RC, Slavin RG, Miller MP, Lieberman PL, Sheffer AL. A multi-institutional trial of polymerized whole ragweed for immunotherapy of ragweed allergy. J Allergy Clin Immunol. 1980;66(6):486–94. Not an RCT. [PubMed: 7000872]
  1286. Shulman ST. Allergies, allergies. Pediatric Annals. 2011;40(4):177–178. It does not meet ALL the inclusion criteria. [PubMed: 21485990]
  1287. Sabbah A, Bonnaud F, Sonneville A, Bonneau JC, Pinon H. Specific immunotherapy using Alpha-Fraction-Retard-D. pteronyssinus. Double-blind study in asthma. Allerg Immunol (Paris). 91; 23(2):58–60. french. Non-English article. [PubMed: 1854430]
  1288. Sadan N, Rhyne MB, Mellits ED, Goldstein EO, Levy DA, Lichtenstein LM. Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement. N Engl J Med. 69; 280(12):623–7. It does not meet ALL the inclusion criteria. [PubMed: 4180015]
  1289. Sade K, Berkun Y, Dolev Z, Shalit M, Kivity S. Knowledge and expectations of patients receiving aeroallergen immunotherapy. Ann Allergy Asthma Immunol. 2003;91(5):444–8. It does not meet ALL the inclusion criteria. [PubMed: 14692426]
  1290. Sade K, Kivity S, Levy A, Fireman E. The effect of specific immunotherapy on T-cell receptor repertoire in patients with allergy to house-dust mite. Allergy. 2003;58(5):430–4. Does not apply to any of the key questions. [PubMed: 12752331]
  1291. Safefy of cluster schedule for immunotherapy in allergic rinithis or asthma in children sensitised to grass pollen. Meeting abstract.
  1292. Safety and compliance of cluster-immunotherapy achieving the maintenance dose on the first treatment day with highly polymerised allergen extracts. Meeting abstract.
  1293. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study. Duplicate of 5825. [PubMed: 17114889]
  1294. Safety and efficacy of perennial immunotherapy with a depot vaccine in patients suffering from asthma and/or allergic rhinitis hypersensitive to alternaria tenius. Library unable to locate.
  1295. Salvaggio JE. Allergenic extract immunotherapy. Chest. 86; 90(5 Suppl):53S–57S. No original data. [PubMed: 3769599]
  1296. SALVAGGIO JE, LESKOWITZ S. A COMPARISON OF THE IMMUNOLOGIC RESPONSES OF NORMAL AND ATOPIC INDIVIDUALS TO PARENTERALLY INJECTED. ALUM PRECIPITATED PROTEIN ANTIGEN. Int Arch Allergy Appl Immunol. 65; 26:264–79. Therapy NOT AVAILABLE in the U.S. [PubMed: 14291543]
  1297. Salzano FA. Specific nasal provocation test with powder allergen. Allergy. 97; 52(33 Suppl):32–5. It does not meet ALL the inclusion criteria. [PubMed: 9188946]
  1298. Salzano FA. Specific nasal provocation test with powder allergen. Allergy. 97; 52(33 Suppl):32–5. Therapy NOT AVAILABLE in the U.S. [PubMed: 9188946]
  1299. Sanchez Palacios A, Schamann Medina F, Lamas Ru-Figueroa A, Bosch Millares C, Ramos Santos S, Garcia Marrero JA. Comparative clinical-immunological study of oral and subcutaneous immunotherapy in children with extrinsic bronchial asthma. Allergol Immunopathol (Madr). 89; 17(6):323–9. It does not meet ALL the inclusion criteria. [PubMed: 2635834]
  1300. Sanchez Palacios A, Schamann F, Garcia JA. Sublingual immunotherapy with cat epithelial extract. Personal experience. Allergol Immunopathol (Madr). 2001;29(2):60–5. Not an RCT. [PubMed: 11450599]
  1301. Sanchez-Morillas L, Reano Martos M, Iglesias Cadarso A, Perez Pimiento A, Rodriguez Mosquera M, Dominguez Lazaro AR. Vasculitis during immunotherapy treatment in a patient with allergy to Cupressus arizonica. Allergol Immunopathol (Madr). 2005;33(6):333–4. It does not meet ALL the inclusion criteria. [PubMed: 16371222]
  1302. Sandberg ET. Immunotherapy for dust mite sensitivity. Hosp Pract (Minneap). 2000;35(3):45. No original data. [PubMed: 10737239]
  1303. Sanders S. The treatment of seasonal hay fever and asthma in children. A controlled trial of pre-seasonal depot pollen therapy. Practitioner. 66; 196(176):811–5. Therapy NOT AVAILABLE in the U.S. [PubMed: 5936067]
  1304. Santilli E. Specific hyposensitizing therapy in bronchial asthma and allergic bronchopathies. Folia Allergol (Roma). 69; 16(4):430–1. No original data. [PubMed: 5400586]
  1305. Santilli J, Nathan R, Glassheim J, Rockwell W. Patients receiving immunotherapy report it is effective as assessed by the rhinitis outcomes questionnaire (ROQ) in a private practice setting. Ann Allergy Asthma Immunol. 2001;86(2):219–21. It does not meet ALL the inclusion criteria. [PubMed: 11258693]
  1306. Santos OR. Sublingual immunotherapy in allergic rhinitis and asthma in 2–5 year-old children sensitized to acarus. Revista Alergia Mexico Spanish. Non-English article. [PubMed: 19058484]
  1307. Saraclar Y, Sekerel BE, Kalayci O, Adalioglu G, Tuncer A. The effect of house dust mite specific immunotherapy on cysteinyl leukotriene production by blood leukocytes in subjects with perennial allergic rhinitis and asthma. J Investig Allergol Clin Immunol. 98; 8(2):98–104. Not an RCT. [PubMed: 9615303]
  1308. Satoh Y, Sugimoto K, Kuroki H, Fuzimoto N, Suzuki H. Evaluation of rapid injection immunotherapy by antigen specific IgE and IgG4 antibodies. Arerugi. 89; 38(3):246–53. Does not apply to any of the key questions. [PubMed: 2751431]
  1309. Savolainen J, Nieminen K, Laaksonen K, Laiho T, Jacobsen L, Lahesmaa R, Terho EO, Valovirta E. Allergen-induced in vitro expression of IL-18, SLAM and GATA-3 mRNA in PBMC during sublingual immunotherapy. Allergy. 2007;62(8):949–53. It does not meet ALL the inclusion criteria no clinical outcomes. [PubMed: 17620074]
  1310. Scadding GW, Shamji MH, Jacobson MR, Lee DI, Wilson D, Lima MT, Pitkin L, Pilette C, Nouri-Aria K, Durham SR. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy. 2010;40(4):598–606. It does not meet ALL the inclusion criteria- Other reason for exclusion (specify): mech. [PubMed: 20184605]
  1311. Scheinmann P, Ponvert C, Rufin P, De Blic J. Immunotherapy in young children. Clin Allergy Immunol. 2004;18:567–83. No original data. [PubMed: 15042936]
  1312. Schiappoli M, Ridolo E, Senna G, Alesina R, Antonicelli L, Asero R, Costantino MT, Longo R, Musarra A, Nettis E, Crivellaro M, Savi E, Massolo A, Passalacqua G. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. Clin Exp Allergy. 2009;39(10):1569–74. Not and RCT. [PubMed: 19486027]
  1313. Schuchardt P, Huhnerfuss S. Specific desensitization of pollinosis by various allergen extracts (author’s transl). Z Erkr Atmungsorgane. 76; 146(2):115–9. Other reason for exclusion (specify):weird extract. [PubMed: 828359]
  1314. Schultze-Werninghaus G. Treatment of bronchial asthma with consideration also of the upper airway. MMW Fortschr Med. 2006;148(5):32–6. No original data. Non-English article. [PubMed: 16518936]
  1315. Scranton SE, Gonzalez EG, Waibel KH. Incidence and characteristics of biphasic reactions after allergen immunotherapy. J Allergy Clin Immunol. 2009;123(2):493–8. [PubMed: 19064282]
  1316. Seasonal variability in BHR and sputum cells count in subjects with rhinitis and effect of 3 yrs specific immunotherapy. Excluded at data abstraction.
  1317. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med. 93; 178(6):2123–30. Does not apply to any of the key questions - Other reason for exclusion (specify): mechs. [PMC free article: PMC2191292] [PubMed: 7902409]
  1318. Seidenberg J, Pajno GB, Bauer CP, La Grutta S, Sieber J. Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents. J Investig Allergol Clin Immunol. 2009;19(2):125–31. It does not meet ALL the inclusion criteria. [PubMed: 19476016]
  1319. Selivanova KF, Alekseichuk AM, Ponomarenko LP, Baranovskaia TK, Baklazhova NK. Characteristics of pollinoses in the Crimea and the effectiveness of specific hyposensitization. Vrach Delo. 83(5):82–5. Other reason for exclusion (specify): [PubMed: 6224349]
  1320. Selivanova KF, Alekseichuk AM, Ponomarenko LP, Baranovskaia TK, Baklazhova NK. Characteristics of pollinoses in the Crimea and the effectiveness of specific hyposensitization. Vrach Delo. 83(5):82–5. Non-English article: Russian. [PubMed: 6224349]
  1321. Serafini U, Ricci M, Bonini S. Immunotherapy of bronchial asthma. Panminerva Med. 82; 24(4):289. No original data. [PubMed: 7170117]
  1322. Serna-Candel C, Moreno-Perez O, Soriano V, Martinez A. Churg-Strauss syndrome triggered by hyposensitization to Alternaria fungus. Clin Rheumatol. 2007;26(12):2195–6. It does not meet ALL the inclusion criteria. [PubMed: 17674119]
  1323. Serrano P, Algorta J, Martinez A, Gonzalez-Quevedo T, Velazquez E, Diaz M. Prospective safety study of immunotherapy administered in a cluster schedule. J Investig Allergol Clin Immunol. 2004;14(4):312–9. It does not meet ALL the inclusion criteria. [PubMed: 15736717]
  1324. Serrano P, Justicia JL, Sanchez C, Cimarra M, Fernandez-Tavora L, Orovitg A, Moreno C, Guerra F, Alva V. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study. Ann Allergy Asthma Immunol. 2009;102(3):247–52. It does not meet ALL the inclusion criteria. [PubMed: 19354072]
  1325. Settipane RA, Chafee FH, Settipane GA. Pollen immunotherapy during pregnancy: long-term follow-up of offsprings. Allergy Proc. 88; 9(5):555–61. It does not meet ALL the inclusion criteria. [PubMed: 3234759]
  1326. Seymour M, Chowdhury BA. Immunotherapy with a ragweed vaccine. N Engl J Med. 2007;356(1):86. author reply 87. No original data- Other reason for exclusion (specify): letter. [PubMed: 17202461]
  1327. Shaikh WA, Shaikh SW. Allergies in India: a study on medication compliance. J Indian Med Assoc. 2009;107(7):462–3. Does not apply to any of the key questions. [PubMed: 20112853]
  1328. Sharkey P, Portnoy J. Rush immunotherapy: experience with a one-day schedule. Ann Allergy Asthma Immunol. 96; 76(2):175–80. It does not meet ALL the inclusion criteria. [PubMed: 8595538]
  1329. Shearer GM, Chougnet C, Shearer MS. Atopic disease and immunologic response. Science. 97; 276(5309):17–8. author reply 18–9. No original data. [PubMed: 9122696]
  1330. Shim JY, Kim BS, Cho SH, Min KU, Hong SJ. Allergen-specific conventional immunotherapy decreases immunoglobulin E-mediated basophil histamine releasability. Clin Exp Allergy. 2003;33(1):52–7. It does not meet ALL the inclusion criteria Dose not specified; yet good cx outcomes data. [PubMed: 12534549]
  1331. Shimada T. Specific desensitization of nasal allergy using house dust. Nippon Jibiinkoka Gakkai Kaiho. 71; 74(5):833–47. Other reason for exclusion (specify):house dust. [PubMed: 5165278]
  1332. Shimada T, Ishikawa T, Fujita Y, Miyashita H. Recent studies on nasal allergy (VII). The changes of the serum IgE level and specific IgE antibodies in patients with nasal allergy by hyposensitization therapy using mite (Dermatophagoides farinae) antigen (author’s transl). Nippon Jibiinkoka Gakkai Kaiho. 75; 78(6):519–27. No original data. [PubMed: 1172529]
  1333. Shimada T, Ishikawa T, Miyashita H, Fujita Y. Current studies on nasal allergy (4)--the effect of desensitization therapy with mite (Dermatophagoides farinae) extract in patients with nasal allergy. Nippon Jibiinkoka Gakkai Kaiho. 73; 76(12):1405–13. No original data. [PubMed: 4799613]
  1334. Shioda H, Mishima K, Tomita A, Inaba Y, Iikura T. Pollen allergy--hyposensitization treatment in asthmatic children sensitive to ragweed. Arerugi. 70; 19(10):731–8. Other reason for exclusion (specify): japanese. [PubMed: 5477364]
  1335. SHIVPURI DN, DUA KL. HYPOSENSITIZATION TREATMENT OF 250 PATIENTS WITH BRONCHIAL ASTHMA IN INDIA AGAINST LOCAL ALLERGENS. A SEVEN-YEAR FOLLOW-UP. Ann Allergy. 64; 22:632–7. It does not meet ALL the inclusion criteria. [PubMed: 14227997]
  1336. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. Duplicate of 6222. [PubMed: 9257783]
  1337. Side effects during immunotherapy with purified grass pollen extracts. Part of 4181.
  1338. Sieber J, Merk H, Ott H. Seasonal sublingual immunotherapy is efficacious in allergic rhinitis from the first treatment season on also under high grass pollen exposure: the ECRIT study; XXVII EAACI Congress of the European Academy of Allergology and Clinical Immunology; 2008; Barcelona. Other reason for exclusion (specify): mtg abst only.
  1339. Sieber J, Koberlein J, Mosges R. Sublingual immunotherapy in daily medical practice: effectiveness of different treatment schedules - IPD meta-analysis. Curr Med Res Opin. 2010;26(4):925–32. Does not apply to any of the key questions. [PubMed: 20163297]
  1340. Siergiejko Z, Rogalewska AM. The effect of specific immunotherapy on bronchial hyperreactivity in patients with bronchial asthma. Pol Merkur Lekarski. 2000;9(52):641–4. Other reason for exclusion (specify): [PubMed: 11144047]
  1341. SILBERT NE. COMPREHENSIVE THERAPY IN CHRONIC OBSTRUCTIVE LUNG DISEASE GP. 64; 30:115–9. No SIT. [PubMed: 14225116]
  1342. Silvestri M, Spallarossa D, Battistini E, Sabatini F, Pecora S, Parmiani S, Rossi GA. Changes in inflammatory and clinical parameters and in bronchial hyperreactivity asthmatic children sensitized to house dust mites following sublingual immunotherapy. J Investig Allergol Clin Immunol. 2002;12(1):52–9. It does not meet ALL the inclusion criteria. [PubMed: 12109533]
  1343. Simberg S, Sala E, Tuomainen J, Ronnemaa AM. Vocal symptoms and allergy--a pilot study. J Voice. 2009;23(1):136–9. It does not meet ALL the inclusion criteria. [PubMed: 17624725]
  1344. Simons FE, HayGlass KT. Immunotherapy with a ragweed vaccine. N Engl J Med. 2007;356(1):86–7. author reply 87. No original data. [PubMed: 17205611]
  1345. Skov-Stahl P, Norh S, Weeke B. Basophil histamine release in patients with hay fever. Results compared with specific IgE and total IgE during immunotherapy. Clin Exp Immunol. 77; 27(3):432–9. Does not apply to any of the key questions- Other reason for exclusion (specify): mechs. [PMC free article: PMC1540951] [PubMed: 67913]
  1346. Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol. 2004;114(4):831–7. Therapy NOT AVAILABLE in the U.S. [PubMed: 15480323]
  1347. Smith TR, Alexander C, Kay AB, Larche M, Robinson DS. Cat allergen peptide immunotherapy reduces CD4(+) T cell responses to cat allergen but does not alter suppression by CD4(+) CD25(+) T cells: a double-blind placebo-controlled study. Allergy. 2004;59(10):1097–101. Does not apply to any of the key questions. [PubMed: 15355469]
  1348. Smits WL, Giese JK, Letz KL, Inglefield JT, Schlie AR. Safety of rush immunotherapy using a modified schedule: a cumulative experience of 893 patients receiving multiple aeroallergens. Allergy Asthma Proc. 2007;28(3):305–12. It does not meet ALL the inclusion criteria. [PubMed: 17619559]
  1349. Sobel G. Ragweed pollenosis, eleven-year study: comparison of various preparations. Ann Allergy. 66; 24(12):677–89. It does not meet ALL the inclusion criteria. [PubMed: 5926863]
  1350. Sobel G. Treatment of grass pollenosis with various preparations: a thirteen year study. Ann Allergy. 68; 26(9):483–92. It does not meet ALL the inclusion criteria. [PubMed: 5682239]
  1351. Soda R, Okada C, Takahashi K, Katagi S, Kanehiro A, Kimura G, Okamoto S, Tada S, Kimura I. Predicting the clinical efficacy of house dust mite immunotherapy in bronchial asthmatics by multiple quantification analysis type II. Arerugi. 93; 42(12):1771–5. Does not apply to any of the key questions. [PubMed: 8110037]
  1352. Soda R, Takahashi K, Miyashita K, Katagi S, Yamagata K, Gotou M, Kimura G, Okamoto S, Okano T, Kawada N, et al. A study to predict the clinical efficacy of house dust mite immunotherapy in bronchial asthmatics. Arerugi. 93; 42(4):522–8. Other reason for exclusion (specify): japanese. [PubMed: 8323449]
  1353. Soda R, Takahashi K, Miyashita K, Katagi S, Yamagata K, Gotou M, Kimura G, Okamoto S, Okano T, Kawada N, et al. A study to predict the clinical efficacy of house dust mite immunotherapy in bronchial asthmatics. Arerugi. 93; 42(4):522–8. Other reason for exclusion (specify): japanese. [PubMed: 8323449]
  1354. Sokol W. Effectiveness of allergy immunotherapy for asthma. West J Med. 95; 163(4):368. No original data. [PMC free article: PMC1303134] [PubMed: 7483595]
  1355. Sokolova TS, Botvin’eva VV, Zhukovskii AM, Zakhidov IuV, Reviakina VA. Immunologic indices in evaluation of the effectiveness of treatment of atopic bronchial asthma in children. Pediatriia. 83(12):21–3. Other reason for exclusion (specify): Non-English article: Russian- Not an RCT. [PubMed: 6672722]
  1356. Sokolova TS, Vaniukov NV, Mdinaradze MD, Titova SM. Experience with specific hyposensitization of children with the atopic form of bronchial asthma during the 1st years of life. Vopr Okhr Materin Det. 72; 17(1):74–9. Other reason for exclusion (specify): [PubMed: 4642502]
  1357. Solari JE, Loo J, Felices A, Casas J. Immunotherapy for patients with persistent allergic rhinitis unsatisfied with free chronic pharmacotherapy. Allergol Immunopathol (Madr). 2006;34(3):102–6. It does not meet ALL the inclusion criteria. [PubMed: 16750119]
  1358. Song CH, Heiner DC. Successful replacement of allergen-specific immunotherapy by allergen-mixture therapy. Ann Allergy Asthma Immunol. 95; 75(5):402–8. It does not meet ALL the inclusion criteria. [PubMed: 7583861]
  1359. Sosa Jimenez G, Lopez Garcia A, Galindo Garcia JA, Paz Martinez D, Carrillo Tamez R, Papaqui Tapia S. Incidence of adverse reactions to immunotherapy in allergic patients at Puebla University Hospital. Rev Alerg Mex. 98; 45(6):147–9. Not an RCT. [PubMed: 9951326]
  1360. Soyogul Gurer U, Buyukozturk S, Palanduz S, Rayaman E, Colakoglu B, Cevikbas A. The effects of allergen-specific immunotherapy on polymorphonuclear leukocyte functions in patients with seasonal allergic rhinitis. Int Immunopharmacol. 2005;5(4):661–6. Does not apply to any of the key questions. [PubMed: 15710335]
  1361. Specific immunotherapy for rhinoconjunctivitis to grass pollens by the sub-lingual route: A double-blind study against placebo. Library unable to locate.
  1362. Specific immunotherapy improves the clinical response in patients with allergic rhinoconjunctivitis. Meeting abstract.
  1363. Specific immunotherapy in grass-pollen allergic asthma combination with inhaled steroid therapy vs specific immunotherapy alone. Library unable to locate.
  1364. Specific immunotherapy with delayed release D. Pteronyssinus alpha fraction. A double blind study in asthma. Duplicate of 4919.
  1365. Specific immunotherapy with tablets. Krankenpfl J. 2005;43(7–10):260. No original data. [PubMed: 16515331]
  1366. Speer F. Adverse reactions to minute doses of antigen used in hyposensitization. J Asthma Res. 73; 10(4):219–22. It does not meet ALL the inclusion criteria. [PubMed: 4744916]
  1367. Speer F, Carrasco LC. Hyposensitization in ragweed pollinosis. Ann Allergy. 76; 37(6):391–7. It does not meet ALL the inclusion criteria. [PubMed: 999058]
  1368. SPEER F, BOYDEN MS, CROZIER W. DELAYED REACTIONS TO HYPOSENSITIZATION. Ann Allergy. 64; 22:434–7. It does not meet ALL the inclusion criteria. [PubMed: 14215929]
  1369. Spiegelman J, Friedman H, Tuft L. Immunologic responses of pollinosis patients treated with alum-precipitated pyridine ragweed extract. Ann Allergy. 67; 25(5):262–74. It does not meet ALL the inclusion criteria. [PubMed: 6024247]
  1370. Spiegelman J, Tuft L, Friedman H. Hemagglutination titer changes of pollinosis patients treated with alum-precipitated pyridine ragweed extract. Int Arch Allergy Appl Immunol. 67; 32(1):27–30. Does not apply to any of the key questions. [PubMed: 6075540]
  1371. Spinozzi F, Cimignoli E, Broccucci L, Gerli R, Cernetti C, Rambotti P. Immunotherapy in allergic diseases. Evaluation of short-term efficacy of aluminum hydroxide-absorbed slow-release preparations. Clin Ter. 91; 136(4):245–51. Not an RCT. [PubMed: 1827386]
  1372. Squillace SP. Immunotherapy in adult asthma. J Fam Pract. 96; 42(5):455. No original dataOther reason for exclusion (specify):journal club review of Peter’s NEJM 1996 article.
  1373. Stammberger H. The treatment of housedustmite-allergy-three years’ experience with hyposensitization with D.pteronyssinus-Preparations (D.P.) (author’s transl). Laryngol Rhinol Otol (Stuttg). 80; 59(12):820–8. Therapy NOT AVAILABLE in the U.S. [PubMed: 7278471]
  1374. Starr MS, Weinstock M. Studies in pollen allergy. 3. The relationship between blocking antibody levels and symptomatic relief following hyposensitisation with allpyral in hay fever subjects. Int Arch Allergy Appl Immunol. 70; 38(5):514–21. Therapy NOT AVAILABLE in the U.S. [PubMed: 4191851]
  1375. Stasiak-Barmuta A, Dabrowska I, Piotrowska T, Hofman J. Study on specific immunotherapy with the aid of 3M Diagnostic Systems’ tests. Pneumonol Alergol Pol. 92; 60 Suppl 1:53–6. Does not apply to any of the key questions- Other reason for exclusion (specify): mechs. [PubMed: 1292848]
  1376. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Excluded at data abstraction. [PubMed: 16792582]
  1377. STEVENET M. ASTHMA AND ASTHMA-LIKE CHRONIC BRONCHITIS IN THE ELDERLY SUBJECT. COMPARATIVE VALUE OF SPECIFIC DESENSITIZATION. Toulouse Med. 63; 64:773–80. It does not meet ALL the inclusion criteria. [PubMed: 14083627]
  1378. Stevens WJ, Bridts CH. IgG-containing and IgE-containing circulating immune complexes in patients with asthma and rhinitis. J Allergy Clin Immunol. 84; 73(2):276–82. Does not apply to any of the key questions. [PubMed: 6699311]
  1379. Stevens WJ, Verhelst JA, van den Bogaert W, Bridts CH. Clinical and biological evaluation of semi-rush and ordinary immunotherapy schemes in type I allergic respiratory diseases. Allergy. 85; 40(6):447–52. It does not meet ALL the inclusion criteria. [PubMed: 4051145]
  1380. Stewart GE 2nd, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol. 92; 90(4 Pt 1):567–78. No original data. [PubMed: 1401640]
  1381. Stosovic R, Bogic M, Tomic Spiric V. Long-term efficacy and safety of sublingual immunotherapy in seasonal allergic rhinitis; XXVII EAACI Congress of the European Academy of Allergology and Clinical Immunology; 2008; Barcelona. Other reason for exclusion (specify): mtg abst only.
  1382. Strimas J. Asthma in children. N Engl J Med. 92; 327(16):1174–5. No original data. [PubMed: 1528220]
  1383. Strimas J. Asthma in children. N Engl J Med. 92; 327(16):1174–5. No original data. [PubMed: 1528220]
  1384. Study of Desensitization Treatment on Bronchial Asthma. Library unable to locate.
  1385. Study of prolonged hyposensitization with D. pteronyssinus extract in allergic rhinitis. Excluded at data abstraction. [PubMed: 589769]
  1386. Sublingual allergoid immunotherapy with a 4-day updosing phase versus traditional initial scheme, or drugs alone. A controlled, randomised study in rhinitic patients with or without mild allergic asthma. Library unable to locate.
  1387. Sublingual immunotherapy (SLIT) with grass pollen allergen for grasspollen induced rhinoconjunctivitis in children. Meeting abstract.
  1388. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. Part of 4243. [PubMed: 15230823]
  1389. Sublingual immunotherapy in allergic rhinitis and asthma in 2–5 year-old children sensitized to mites. Duplicate of 4990. [PubMed: 19058484]
  1390. Sublingual immunotherapy in alternaria-induced rhinitis. Meeting abstract.
  1391. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. Excluded at data abstraction. [PubMed: 7551201]
  1392. Sublingual immunotherapy in the treatment of allergic asthma in children: a controlled study. Library unable to locate.
  1393. Sublingual Immunotherapy with House Dust Extract for House Dust-Mite Allergic Rhinitis in Children. Excluded at data abstraction. [PubMed: 20864799]
  1394. Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. Duplicate of 4573. [PubMed: 10505460]
  1395. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Excluded at data abstraction. [PubMed: 8955574]
  1396. Sullivan CJ. Simultaneous aqueous ragweed extract and alum-precipitated pyridine ragweed extract used prophylactically. Ann Allergy. 71; 29(2):71–5. It does not meet ALL the inclusion criteria. [PubMed: 5559428]
  1397. Sullivan CJ, Phipatanakul CS, Slavin RG. Combined use of aqueous and alum-precipitated pyridine ragweed extracts. Ann Allergy. 72; 30(4):195–202. It does not meet ALL the inclusion criteria. [PubMed: 5017673]
  1398. Suppression of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus). Excluded at data abstraction. [PubMed: 2758353]
  1399. Svanborg N. Desensitization during Lomudal treatment. Acta Allergol. 75; 30 suppl 12:106–12. No SIT. [PubMed: 811064]
  1400. Symington IS, O’Neill D, Kerr JW. Comparision of a glutaraldehyde-modified pollen--tyrosine adsorbate with an alum-precipitated pollen vaccine in the treatment of hay fever. Clin Allergy. 77; 7(2):189–94. Therapy NOT AVAILABLE in the U.S. [PubMed: 872364]
  1401. Symposium B. II. Basic and clinical studies on the desensitization therapy. Meeting abstract. [PubMed: 5808114]
  1402. Sykora T, Tamele L, Zemanova M, Petras M. Efficacy and safety of specific allergen immunotherapy with standardized depod allergen H-AI depot. (pollens). Alergie. 2004;6(3):170–178. Therapy NOT AVAILABLE in the U.S.
  1403. Tabar AI, Fernandez-Tavora L, Alonso R, Castillo R, Cistero-Bahima A, de la Torre-Morin F, Fernandez J, Garcia-Figueroa BE, Fernandez S, Garcia-Gonzalez JJ, Garcia-Robaina JC, Moreno F, Lobaton P, Sanchez-Machin I, de la Torre-Martinez F. Olerance of a cluster schedule with a house dust mite extract quantified in mass units: multicentre study. J Investig Allergol Clin Immunol. 2004;14(3):193–7. It does not meet ALL the inclusion criteria. [PubMed: 15552712]
  1404. Tabar AI, Garcia BE, Rodriguez A, Olaguibel JM, Muro MD, Quirce S. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy. 93; 48(6):450–3. It does not meet ALL the inclusion criteria. [PubMed: 8238801]
  1405. Tabar AI, Lizaso MT, Garcia BE, Echechipia S, Olaguibel JM, Rodriguez A. Tolerance of immunotherapy with a standardized extract of Alternaria tenuis in patients with rhinitis and bronchial asthma. J Investig Allergol Clin Immunol. 2000;10(6):327–33. It does not meet ALL the inclusion criteria. [PubMed: 11206932]
  1406. Tabe K, Mizukoshi T, Nishi Y, Noguchi T, Shuh S, Kobayashi Y, Shibasaki M, Yamamoto H, Nagata M, Sakamoto Y, Matsuo H. A trial of new protocol of rush immunotherapy with standardized mite antigen. Arerugi. 99; 48(5):526–32. Not an RCT. [PubMed: 10390900]
  1407. Tahamiler R, Canakcioglu S, Yilmaz S, Isildak H. Long-term immunotherapy for perennial allergic rhinitis: relationship of specific IgG levels to skin-prick test results and clinical symptoms and signs. Ear Nose Throat J. 2008;87(12):E29. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 19105132]
  1408. Tahamiler R, Yener M, Canakcioglu S. The use of serum and nasal eosinophilic cationic protein in the evaluation of the effectiveness of immunotherapy in patients with allergic rhinitis. Kulak Burun Bogaz Ihtis Derg. 2006;16(4):155–9. Does not apply to any of the key questions. [PubMed: 16905905]
  1409. Takeuchi H, Yamamoto Y, Kitano H, Enomoto T. Changes in thymus- and activation-regulated chemokine (TARC) associated with allergen immunotherapy in patients with perennial allergic rhinitis. J Investig Allergol Clin Immunol. 2005;15(3):172–6. Does not apply to any of the key questions. [PubMed: 16261952]
  1410. Takeuchi K, Kishioka C, Yuta A, Sakakura Y, Masuda S, Ukai K, Majima Y. Clinical efficacy of immunotherapy with house dust in the patients with perennial nasal allergy. Arerugi. 2000;49(8):627–33. Not an RCT. [PubMed: 11021014]
  1411. Taki K. Relation between desensitization and skin reaction in allergic diseases. Kumamoto Med J. 68; 21(3):95–107. It does not meet ALL the inclusion criteriaDoes not apply to any of the key questions- Other reason for exclusion (specify):strange extracts.
  1412. Tamir R, Castracane JM, Rocklin RE. Generation of suppressor cells in atopic patients during immunotherapy that modulate IgE synthesis. J Allergy Clin Immunol. 87; 79(4):591–8. Does not apply to any of the key questions. [PubMed: 2951427]
  1413. Tamir R, Katz Y, Pick AI. Specific immunotherapy in allergic bronchial asthma. Harefuah. 92; 123(12):536–40. Hebrew. Non-English article. [PubMed: 1289204]
  1414. Tamir R, Levy I, Duer S, Pick AI. Immediate adverse reactions to immunotherapy in allergy. Allergy. 92; 47(3):260–3. It does not meet ALL the inclusion criteria.
  1415. Tanac R, Demir E, Aksu G, Sari G, Kutukculer N. Effect of immunotherapy on autoimmune parameters in children with atopic asthma. Turk J Pediatr. 2002;44(4):294–7. Does not apply to any of the key questions. [PubMed: 12458803]
  1416. Tanaka A, Ohashi Y, Nakai Y. Decrease of serum levels of soluble CD23 during immunotherapy in patients with perennial allergic rhinitis. Ann Otol Rhinol Laryngol. 99; 108(2):193–200. Does not apply to any of the key questions. [PubMed: 10030240]
  1417. Tanaka A, Ohashi Y, Kakinoki Y, Nakai Y. Immunotherapy suppresses both Th1 and Th2 responses by allergen stimulation, but suppression of the Th2 response is a more important mechanism related to the clinical efficacy of immunotherapy for perennial allergic rhinitis. Scand J Immunol. 98; 48(2):201–11. Does not apply to any of the key questions. [PubMed: 9716113]
  1418. Tari MG, Mancino M, Madonna F, Buzzoni L, Parmiani S. Immunologic evaluation of 24 month course of sublingual immunotherapy. Allergol Immunopathol (Madr). 94; 22(5):209–16. It does not meet ALL the inclusion criterialinical outcomes reported elsewhereDoes not apply to any of the key questions. [PubMed: 7840022]
  1419. Tari MG, Mancino M, Pozzuoli G, Mauro B, Verga A, Monti G. Immunotherapy with alginate-conjugated two grass pollen extract in patients with allergic rhinoconjunctivitis. Allergol Immunopathol (Madr). 90; 18(1):35–40. Therapy NOT AVAILABLE in the U.S. [PubMed: 2382596]
  1420. Taudorf E. Oral immunotherapy of adults with allergic rhinoconjunctivitis. Clinical effects in birch and grass pollinosis. Dan Med Bull. 92; 39(6):542–60. No original data. [PubMed: 1468264]
  1421. Taudorf E, Laursen L, Lanner A, Bjorksten B, Dreborg S, Weeke B. Specific IgE, IgG, and IgA antibody response to oral immunotherapy in birch pollinosis. J Allergy Clin Immunol. 89; 83(3):589–94. Does not apply to any of the key questions. [PubMed: 2647818]
  1422. Taylor G. DSCG and hyposensitization. Acta Tuberc Pneumol Belg. 74; 65(3–4):345–52. No original data. [PubMed: 4219100]
  1423. Taylor G. DSCG and hyposensitization. Acta Tuberc Pneumol Belg. 74; 65(3–4):345–52. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 4219100]
  1424. Tebyrica JN. Tebyrica C. N Imunoterapia com extrato de Dermatophagoides pteronyssinus em criancas asmaticas. Arq. bras med. 83; 57(5):223–8. portuguese Non-English article.
  1425. Tekul N. Results obtained in Istanbul in respiratory allergy ailments by desensitizing therapy. Rev Fr Allergol. 67; 7(1):40–2. It does not meet ALL the inclusion criteria. [PubMed: 5597283]
  1426. Telang JV, Mahashur AA, Shah SP, Kamat SR. Experience with intradermal antigenic tests and immunotherapy in bronchial asthma. J Assoc Physicians India. 86; 34(3):189–90. It does not meet ALL the inclusion criteria. [PubMed: 3733646]
  1427. Tella R, Bartra J, San Miguel M, Olona M, Bosque M, Gaig P, Garcia-Ortega P. Effects of specific immunotherapy on the development of new sensitisations in monosensitised patients. Allergol Immunopathol (Madr). 2003;31(4):221–5. It does not meet ALL the inclusion criteria. [PubMed: 12890414]
  1428. The cities study: Conventional immunotherapy-investigating existing schedules. Meeting abstract. [PubMed: 22018620]
  1429. The clinical and immunological efficacy of house dust mite specific sublingual and subcutaneous immunotherapy in children; randomised, 3 years follow-up. Meeting abstract.
  1430. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005;115(3 Suppl 2):S483–523. No original data. [PubMed: 15753926]
  1431. The influence of medical economy from the aspect of medical direct costs by a difference of the number of the pollen scattering on an allergen-specific immunotherapy for Japanese cedar pollinosis (Brief record). Abstract only.
  1432. The results of specific immunotherapy for house dust mites in patients with allergic rhinitis. Library unable to locate. [PubMed: 18628641]
  1433. The role of allergen specific immunotherapy (SIT) in the treatment of mild persistent allergic rhinitis (MPAR) without concomitanat asthma. Library unable to locate.
  1434. The role of ragweed pollen in autumnal asthma. Excluded at data abstraction. [PubMed: 68044]
  1435. Thechangesofspecifictcellsimmuno-responseto housedustmite(HDM)inasthmaticchildrentreated with subcutaneous HDM specific immunotherapy. Meeting abstract.
  1436. Thomson JG, Karsh J. Polyarteritis nodosa presenting as serous otitis media in a patient receiving hyposensitization therapy. J Rheumatol. 86; 13(5):958–60. Other reason for exclusion (specify):case report. [PubMed: 2880996]
  1437. Till S, Walker S, Dickason R, Huston D, O’Brien F, Lamb J, Kay AB, Corrigan C, Durham S. IL-5 production by allergen-stimulated T cells following grass pollen immunotherapy for seasonal allergic rhinitis. Clin Exp Immunol. 97; 110(1):114–21. Does not apply to any of the key questions. [PMC free article: PMC1904804] [PubMed: 9353157]
  1438. Tipton WR, Nelson HS. Experience with daily immunotherapy in 59 adult allergic patients. J Allergy Clin Immunol. 82; 69(2):194–9. It does not meet ALL the inclusion criteria. [PubMed: 7056950]
  1439. Toader V, Cosgarea M. Effectiveness and potentials of specific hyposensitizing treatment for allergic rhinitis in children. Rev Chir Oncol Radiol O R L Oftalmol Stomatol Otorinolaringol. 85; 30(2):81–8. Romanian Non-English article. [PubMed: 3161145]
  1440. Tolerability and efficacy of sublingual immunotherapy in cat allergic subjects studied inan environmental exposure chamber. Meeting abstract.
  1441. Tomioka H. Bronchial asthma and anti-allergic agents. Nippon Naika Gakkai Zasshi. 92; 81(9):1448–54. Other reason for exclusion (specify): japanese. [PubMed: 1280670]
  1442. Tonnel AB, Scherpereel A, Douay B, Mellin B, Leprince D, Goldstein N, Delecluse P, Andre C. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy. 2004;59(5):491–7. It does not meet ALL the inclusion criteriaOther reason for exclusion (specify):units not measurable. [PubMed: 15080829]
  1443. Torres Costa JC, Moreira Silva JP, Delgado L, Vaz M. Effects of immunotherapy on symptoms, PEFR, spirometry, and airway responsiveness in patients with allergic asthma to house-dust mites (D. pteronyssinus) on inhaled steroid therapy. Allergy. Therapy NOT AVAILABLE in the U.S Other reason for exclusion (specify):depot IT. [PubMed: 8792920]
  1444. Tournier G, Baculard A, Salmon E. Treatment of asthma in infants and children. Rev Prat. 88; 38(2):86–93. No original data. [PubMed: 3279508]
  1445. Treatment of grass pollen allergy with a patch: A randomised double-blind placebo controlled clinical trial. Meeting abstract.
  1446. Trede NS, Urbanek R. Combination of parenteral and oral immunotherapy in grass pollen-allergic children. A double-blind controlled study of clinical and immunological efficacy. Allergy. 89; 44(4):272–80. Therapy NOT AVAILABLE in the U.S It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 2735516]
  1447. Trento H, Oehling A, Ona J. Effects of immunotherapy on histamine release: a study in allergy to dermatophagoides and house dust. Allergol Immunopathol (Madr). 82; 10(4):295–300. It does not meet ALL the inclusion criteria. [PubMed: 6184978]
  1448. Trevino RJ. Comparison of results of immunotherapy based on skin end-point titration, prick testing, and scratch testing. Otolaryngol Head Neck Surg. 94; 111(5):550–2. Does not apply to any of the key questions No SIT. [PubMed: 7970790]
  1449. Trindade JC. Depot extracts in desensitization treatment of bronchial asthma in children. Rev Port Pediatr. 73; 4(1):46–61. Portuguese. Non-English article. [PubMed: 4769471]
  1450. Tripodi S, Di Rienzo Businco A, Benincori N, Scala G, Pingitore G. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol. 2006;139(2):149–52. Therapy NOT AVAILABLE in the U.S. [PubMed: 16374025]
  1451. Troise C, Bignardi D, Modena P, Pissacroia C, Di Berardino F. Preventive symptomatic immunotherapy versus placebo in seasonal rhinitis due to grasses in children and to Parietaria in adult patients. Allerg Immunol (Paris). 2000;32(6):246–9. Therapy NOT AVAILABLE in the U.S. [PubMed: 10971859]
  1452. Tsai LC, Hung MW, Tang RB. Changes of serum-specific IgE antibody titer during hyposensitization in mite-sensitive asthmatic children. J Asthma. 90; 27(2):95–100. It does not meet ALL the inclusion criteria. [PubMed: 2347816]
  1453. Tsai LC, Tang RB, Hung MW, Chen HM, Tsai SJ. Expression of serum IL-2, IL-2R, and CD8 levels during hyposensitization in house-dust-sensitive asthmatics. J Asthma. 90; 27(5):307–13. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 2122966]
  1454. Tsai YG, Chien JW, Chen WL, Shieh JJ, Lin CY. Induced apoptosis of TH2 lymphocytes in asthmatic children treated with Dermatophagoides pteronyssinus immunotherapy. Pediatr Allergy Immunol. 2005;16(7):602–8. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 16238586]
  1455. Tsai YG, Chien JW, Chen WL, Shieh JJ, Lin CY. Induced apoptosis of TH2 lymphocytes in asthmatic children treated with Dermatophagoides pteronyssinus immunotherapy. Pediatr Allergy Immunol. 2005;16(7):602–8. It does not meet ALL the inclusion criteria norelvant comparison. [PubMed: 16238586]
  1456. Tuchinda M, Chai H. Effect of immunotherapy in chronic asthmatic children. J Allergy Clin Immunol. 73; 51(3):131–8. [PubMed: 4734568]
  1457. Tuft L. Immunotherapy, hay fever, and asthma. JAMA. 80; 244(15):1672–3. It does not meet ALL the inclusion criteria no SIT- No original data- letterto editor. [PubMed: 7411819]
  1458. Tuft L, Spiegelman J, Stupniker S, Brown E, Torsney PJ, Gilday F. The use of alum precipitated pyridine pollen extract in the treatment of ragweed pollinosis. Am J Med Sci. 65; 250(6):668–74. Therapy NOT AVAILABLE in the U.S. [PubMed: 5846512]
  1459. Turkcapar N, Kinikli G, Sak SD, Duman M. Specific immunotherapy-induced Sjogren’s syndrome. Rheumatol Int. 2005;26(2):182–4. Not an RCT. [PubMed: 15965636]
  1460. Turska W, Guga-Pelikan A. Oral immunotherapy in patients with hypersensitivity to plant pollen. Pneumonol Alergol Pol. 95; 63(3–4):176–80. Other reason for exclusion (specify): [PubMed: 7647730]
  1461. Wahn U, Malling HJ, Kleine-Tebbe J. Sublingual immunotherapy in children - Ready for prime time? Pediatric Allergy and Immunology. 2010;21(4 PART 1):559–563. No original dataOther reason for exclusion (specify): review. [PubMed: 20636895]
  1462. Uekawa M, Ohashi Y, Esaki Y, Tamura T, Takeda M, Sakamoto H, Nakai Y. Whole blood histamine release rate during immunotherapy for nasal allergy. Acta Otolaryngol Suppl. 91; 486:202–8. It does not meet ALL the inclusion criteria. [PubMed: 1726850]
  1463. Ukai K, Amesara R, Masuda S, Nakamato S, Ohkawa C, Okamoto K, Sakakura Y. The evaluation of hyposensitization with sugi pollen extracts in patients with nasal allergy to Japanese sugi pollen. Arerugi. 94; 43(2 Pt 1):101–5. Other reason for exclusion (specify): japanese. [PubMed: 8147711]
  1464. Ukai K, Amesara R, Masuda S, Nakamoto S, Ohkawa C, Okamoto K, Sakakura Y. The evaluation of hyposensitization with house dust in patients with nasal allergy to house dust-mite. Arerugi. 94; 43(1):16–21. Other reason for exclusion (specify): japanese. [PubMed: 8147704]
  1465. Ukai K, Sakakura Y, Yoshii S, Taniguchi C, Mitsui H, Itoh Y, Miyoshi Y. Quantitative study of serum blocking antibody during the course of immunotherapy in nasal allergy (author’s transl). Nippon Jibiinkoka Gakkai Kaiho. 79; 82(5):463–9. Does not apply to any of the key questions. [PubMed: 479978]
  1466. Umetsu DT, Hahn JS, Perez-Atayde AR, Geha RS. Serum sickness triggered by anaphylaxis: a complication of immunotherapy. J Allergy Clin Immunol. 85; 76(5):713–8. It does not meet ALL the inclusion criteria- Does not apply to any of the key questions. [PubMed: 4056255]
  1467. Urbanek R, Behrle M, Kuhn W. House dust mite allergy. Padiatr Padol. 91; 26(1):25–30. It does not meet ALL the inclusion criteria. [PubMed: 2057207]
  1468. Ushakova TA, Titova SM. Diagnosis and specific hyposensitization of pollen rhinopathy (hay fever). Vestn Otorinolaringol. 73; 35(1):25–8. Non-English article: Russian. [PubMed: 4781543]
  1469. Vaccine therapy in asthma. Br Med J. 66; 1(5481):186–7. No original data. [PMC free article: PMC1843378] [PubMed: 5901723]
  1470. Vackova L, Spicak V, Milotova J, Mosnova H. Study of the effect of pollen desensitization in children. Cesk Pediatr. 69; 24(1):29–32. Other reason for exclusion (specify): [PubMed: 5772987]
  1471. Vala IJ, Dahle R. Hyposensitization in bronchial asthma. A follow-up study of patients. Tidsskr Nor Laegeforen. 73; 93(21):1513–5. Non-English article: norwegian. [PubMed: 4766368]
  1472. Valovirta E. Can the natural course of allergy and asthma be changed by allergen vaccinations? Allergy. 99; 54 Suppl 50:27–9. No original data. [PubMed: 10466033]
  1473. Valovirta E. Capacity of specific immunotherapy in prevention of allergic asthma in children: the Preventive Allergy Treatment Study (PAT). J Investig Allergol Clin Immunol. 97; 7(5):369–70. No original data. [PubMed: 9416551]
  1474. Valovirta E. PAT--the Preventive Allergy Treatment Study design and preliminary results. Wien Med Wochenschr. 99; 149(14–15):442–3. Other reason for exclusion (specify):preliminary data.Not abstractable. [PubMed: 10584290]
  1475. Valovirta E, Viander M, Koivikko A, Vanto T, Lindstrom P, Wager O, Pekkola-Heino K, Ingeman L, Kekomaki R. Circulating immune complexes during immunotherapy in allergy to dog. Allergy. 89; 44(2):123–31. It does not meet ALL the inclusion criteria. [PubMed: 2785775]
  1476. Van Bever HP, Bosmans J, De Clerck LS, Stevens WJ. Modification of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus) or grass pollen. Allergy. 88; 43(5):378–85. It does not meet ALL the inclusion criteria. [PubMed: 3414914]
  1477. Van Bever HP, Bridts CH, Moens MM, De Rijck TE, Mertens AV, De Clerck LS, Stevens WJ. Lymphocyte transformation test with house dust mite (Dermatophagoides pteronyssinus) in normal children, asthmatic children and asthmatic children receiving hyposensitization. Clin Exp Allergy. 93; 23(8):661–8. It does not meet ALL the inclusion criteria. [PubMed: 8221269]
  1478. Van Metre TE Jr. Design of protocols to evaluate the safety and efficacy of allergenic extracts. Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M. 87(80):229–37. No original data. [PubMed: 3688865]
  1479. Van Metre TE Jr, Marsh DG, Adkinson NF Jr, Kagey-Sobotka A, Khattignavong A, Norman PS Jr, Rosenberg GL. Immunotherapy decreases skin sensitivity to cat extract. J Allergy Clin Immunol. 89; 83(5):888–99. Does not apply to any of the key questions. [PubMed: 2654256]
  1480. van Neerven RJ, Arvidsson M, Ipsen H, Sparholt SH, Rak S, Wurtzen PA. A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy. 2004;34(3):420–8. Does not apply to any of the key questions- It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 15005736]
  1481. Van Ree R, Van Leeuwen WA, Dieges PH, Van Wijk RG, De Jong N, Brewczyski PZ, Kroon AM, Schilte PP, Tan KY, Simon-Licht IF, Roberts AM, Stapel SO, Aalberse RC. Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy. Clin Exp Allergy. 97; 27(1):68–74. It does not meet ALL the inclusion criteria. [PubMed: 9117883]
  1482. van Straaten L, Rischmann O, Terrasson de Fougeres G. Value of extemporaneous combination of standard allergens with alumina hydroxide in the desensitization of respiratory pollinosis. J Med Lyon. 71; 52(203):229–41. It does not meet ALL the inclusion criteria. [PubMed: 5136563]
  1483. van Straaten L, Rischmann O, Terrasson de Fougeres G. Value of extemporaneous combination of standard allergens with alumina hydroxide in the desensitization of respiratory pollinosis. J Med Lyon. 71; 52(203):229–41. It does not meet ALL the inclusion criteria. [PubMed: 5136563]
  1484. van Voorst Vader PJ. Voorhorst’s desensitization with purified house dust extract. Ned Tijdschr Geneeskd. 69; 113(47):2128–30. Does not apply to any of the key questions –dutch Non-English article. [PubMed: 5361671]
  1485. van Wijk RG, Dieges PH, van Toorenenbergen AW. Seasonal variability in nasal sensitivity to house dust mite extract. Rhinology. 87; 25(1):41–8. It does not meet ALL the inclusion criteria. [PubMed: 3576060]
  1486. Vaniukov NV, Murav’ev AA. Sensitivity of the broncho-pulmonary tissue to acetylcholine and the effect of specific desensitization in children with asthma. Pediatriia. 72; 51(7):17–21. Other reason for exclusion (specify): Russian. [PubMed: 5046998]
  1487. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, Kay AB, Durham SR. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest. 93; 92(2):644–51. Does not apply to any of the key questions. [PMC free article: PMC294897] [PubMed: 8349803]
  1488. Vaughn MP. Montelukast might improve compliance with subcutaneous immunotherapy treatments in patients with allergic asthma. J Allergy Clin Immunol. 2010. No original data. [PubMed: 20850867]
  1489. Velazquez BL, Segura DL, Barbosa DE, Vazquez MI, Tapia JG, Altamirano SC, Feria AJ. Determination of interleukins and IgG4 in patients with allergic rhinitis with and without immunotherapy. Rev Alerg Mex. 2004;51(4):139–44. Does not apply to any of the key questions. [PubMed: 15491078]
  1490. Veling MC, Trevino RJ. The treatment of allergic rhinitis with immunotherapy: a review of 1,000 cases. Ear Nose Throat J. 2001;80(8):542–3. It does not meet ALL the inclusion criteria. [PubMed: 11523472]
  1491. Ventura MT, D’Erasmo M, di Gioia R, Tummolo RA, Buquicchio R. Adverse reaction to specific immunotherapy for house-dust mite in a patient with Anisakis allergy. J Eur Acad Dermatol Venereol. 2008;22(2):259–60. It does not meet ALL the inclusion criteria. [PubMed: 18211437]
  1492. Ventura MT, Giuliano G, Buquicchio R, Accettura F, Carbonara M. Local and systemic reactions occurring during immunotherapy: an epidemiological evaluation and a prospective safety-monitoring study. Immunopharmacol Immunotoxicol. 2008;30(1):153–61. It does not meet ALL the inclusion criteriaNot an RCT. [PubMed: 18306111]
  1493. VERAN P, COTTIN S. ASTHMA IN THE ADULT, CORTICOTHERAPY AND SPECIFIC DESENSITIZATION. Clinique (Paris). 63; 58:457–61. No original data. [PubMed: 14089598]
  1494. Verbov JL. Nodules following hay fever desensitizing injections. Clin Exp Dermatol. 89; 14(4):332. It does not meet ALL the inclusion criteria. [PubMed: 2591104]
  1495. Vergara S, Nelson Tratamiento de la rinitis alqrgica en la embarazada. Rev. otorrinolaringol. cir. cabeza cuello. 2007;67(2):157–161. No original dataOther reason for exclusion (specify):4 page review.
  1496. Verstraeten JM, Verstraeten AF. Clinical evaluation of hyposensitization in allergic rhinitis: comparison of the results obtained with three different extracts. Material from a 3-year study. Ann Allergy. 87; 58(6):416–20. Does not apply to any of the key questions. [PubMed: 3592311]
  1497. Verstraeten JM. Asthma and hyposensitization. Experience gained in 3,065 cases. Acta Tuberc Pneumol Belg. 70; 61(3):303–15. Not an RCT. [PubMed: 5511533]
  1498. Vervloet D, Khairallah E, Arnaud A, Charpin J. A prospective national study of the safety of immunotherapy. Clin Allergy. 80; 10(1):59–64. It does not meet ALL the inclusion criteria. [PubMed: 7363446]
  1499. Viander M, Koivikko A. The seasonal symptoms of hyposensitized and untreated hay fever patients in relation to birch pollen counts: correlations with nasal sensitivity, prick tests and RAST. Clin Allergy. 78; 8(4):387–96. [PubMed: 709787]
  1500. Viander M. Humoral and cell-mediated immune responses to fractions of birch pollen extract. Allergy. 80; 35(1):57–64. Does not apply to any of the key questions. [PubMed: 7369496]
  1501. Viander M, Nieminen E, Valovirta E, Vanto T, Ingeman L, Koivikko A. A sandwich enzyme immunoassay for the detection of human IgG antibodies to dog allergens. Int Arch Allergy Appl Immunol. 87; 83(1):64–71. Does not apply to any of the key questions. [PubMed: 2437057]
  1502. Vinuya RZ. Specific allergen immunotherapy for allergic rhinitis and asthma. Pediatr Ann. 2000;29(7):425–32. No original data. [PubMed: 10911632]
  1503. von Hertzen LC, Laatikainen T, Pennanen S, Makela MJ, Haahtela T. Is house dust mite monosensitization associated with clinical disease? Allergy. 2008;63(3):379–81. No SIT. [PubMed: 18269683]
  1504. Vooren PH. Double blind desensitization in asthma. Ned Tijdschr Geneeskd. 69; 113(47):2127–8. Other reason for exclusion (specify):dutch. [PubMed: 4902929]
  1505. Voorhorst R. Clinical significance of house-dust mite hypersensitivity for the pathogenesis of bronchial asthma. Med Klin. 72; 67(18):646–51. It does not meet ALL the inclusion criteria. [PubMed: 4402270]
  1506. Shaikh WA, Shaikh SW. A prospective study on the safety of sublingual immunotherapy in pregnancy. Allergy: European Journal of Allergy and Clinical Immunology. 2012. Not an RCT. [PubMed: 22486626]
  1507. Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. 2010;(1 Pt 2):e160–5. It does not meet ALL the inclusion criteria. [PubMed: 19732370]
  1508. Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. 2010;(1 Pt 2):e160–5. Other reason for exclusion (specify):no clinical outcomes, study of harms only. [PubMed: 19732370]
  1509. Wagner CJ, Taylor RJ, Nelson HS. Lability of blocking antibody during ragweed immunotherapy. Ann Allergy. 83; 50(1):19–22. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 6600384]
  1510. Wahn U, Siraganian RP. Efficacy and specificity of immunotherapy with laboratory animal allergen extracts. J Allergy Clin Immunol. 80; 65(6):413–21. It does not meet ALL the inclusion criteria. [PubMed: 7372963]
  1511. Wahn U. Do asthmatic children benefit from specific immunotherapy? Clin Exp Allergy. 99; 29(2):143. No original data. [PubMed: 10051713]
  1512. Wahn U. Hyposensitization in allergic diseases of the respiratory tract: indications, effectiveness, management. Dtsch Med Wochenschr. 91; 116(18):701–4. No original data. [PubMed: 2026100]
  1513. Wahn U, Maasch HJ, Geissler W. Leukocyte histamine release and humoral changes during oral and subcutaneous hyposensitization of grass pollen allergic children. Helv Paediatr Acta. 84; 39(2):137–44. Does not apply to any of the key questions. [PubMed: 6085730]
  1514. Waldman RH, Bergmann KC. Stimulation of secretory antibody following oral antigen administration. Adv Exp Med Biol. 87:216B, 1677–84. Does not apply to any of the key questions. [PubMed: 3425454]
  1515. Wang CR, Chuang CY, Lin KT, Chen MY, Lee GL, Chen CY. Immunochemical characterization and therapeutic effect of house dust extract in bronchial asthma. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 92; 25(2):69–77. Does not apply to any of the key questions. [PubMed: 1473374]
  1516. Wang CR, Liu ST, Liu MF, Lee GL, Wang GR, Chuang CY. The effect of allergen immunotherapy on in vitro IL-4 and IFN-gamma production by peripheral mononuclear cells in house dust-sensitive Chinese patients with bronchial asthma. Asian Pac J Allergy Immunol. 99; 17(4):249–54. Does not apply to any of the key questions. [PubMed: 10698463]
  1517. Wang HY, Lin XP, Hao CL, Zhang CQ, Sun BQ, Zheng JP, Chen P, Sheng JY, Wu A, Zhong NS. Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients. Zhonghua Jie He He Hu Xi Za Zhi. 2006;29(10):679–87. Non-English article:chinese. [PubMed: 17129496]
  1518. Wang JY, Hsieh KH. The effect of immunotherapy on the in vitro productions of histamine, prostaglandin E2 and leukotriene C4 in asthmatic children. Asian Pac J Allergy Immunol. 89; 7(2):119–24. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 2624666]
  1519. Wang JY, Lei HY, Hsieh KH. The effect of immunotherapy on interleukin-1 and tumor necrosis factor production of monocytes in asthmatic children. J Asthma. 92; 29(3):193–201. It does not meet ALL the inclusion criteria. [PubMed: 1601837]
  1520. Wang Q, Liu Z, Zhang Z, Liu S. Perennial allergic rhinitis: stepwise regression analysis on the correlation with the efficacy of allergen-specific immunotherapy. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006;20(11):481–3. Non-English article Chinese – Not and RCT. [PubMed: 16929823]
  1521. Wang YF. Quick immunotherapy for pollinosis. Zhonghua Er Bi Yan Hou Ke Za Zhi. 93; 28(2):69–71. 123. Not an RCT. [PubMed: 8217283]
  1522. Wang Y, Wang X, Zheng S. Changes in the levels of artemisia pollen specific antibodies during rush immunotherapy for pollinosis. Zhonghua Er Bi Yan Hou Ke Za Zhi. 97; 32(4):216–7. Does not apply to any of the key questions Non-English article chinese. [PubMed: 10743168]
  1523. Wantke F, Gotz M, Jarisch R. Spontaneous histamine release in whole blood in patients before and after 4 months of specific immunotherapy. Clin Exp Allergy. 93; 23(12):992–5. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 10779291]
  1524. Warner JO, Price JF. Hyposensitisation with house dust mite vaccine in bronchial asthma. Br Med J. 76; 2(6041):945. No original data. [PMC free article: PMC1688488] [PubMed: 974689]
  1525. Warner JO. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy. 86; 16(5):387–8. No original data. [PubMed: 3779937]
  1526. Warren WP. Mold hyposensitization in rhinitis: a two-year study. Ann Allergy. 72; 30(3):122–5. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 4400966]
  1527. Washio Y, Ohashi Y, Tanaka A, Kakinoki Y, Sugiura Y, Sakamoto H, Yamada K, Matsuda M, Uekawa M, Okamoto H, Nakai Y. Suplatast tosilate affects the initial increase in specific IgE and interleukin-4 during immunotherapy for perennial allergic rhinitis. Acta Otolaryngol Suppl. 98; 538:126–32. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 9879412]
  1528. Weber RW. Prairie sage, Artemisia ludoviciana. Ann Allergy Asthma Immunol. 2005;95(6):A6. Does not apply to any of the key questions No original data. [PubMed: 16400884]
  1529. Wedler E, Schneeweiss B, Tacke A. Clinical experimental studies on the desensitization of allergic children. Allerg Asthma (Leipz). 67; 13(6):290–3. It does not meet ALL the inclusion criteriaNot an RCT. [PubMed: 5601337]
  1530. Wedler E, Schneeweiss B, Tacke A. On the behavior of humoral serum factors in children with bronchial asthma under specific desensitization. Padiatr Grenzgeb. 68; 7(5):355–61. It does not meet ALL the inclusion criteriaTherapy NOT AVAILABLE in the U.S. [PubMed: 5734428]
  1531. Weiner JM. Allergen injection immunotherapy. Med J Aust. 2006;185(4):234. No original data. [PubMed: 16922673]
  1532. Weiner J, Abramson M, Pury R, Wilson J. Ragweed immunotherapy in adult asthma. N Engl J Med. 96; 335(3):203. author reply 205. No original data. [PubMed: 8657222]
  1533. Welsh PW, Butterfield JH, Yunginger JW, Agarwal MK, Gleich GJ. Allergen-controlled study of intranasal immunotherapy for ragweed hay fever. J Allergy Clin Immunol. 83; 71(5):454–60. Other reason for exclusion (specify):intranasal it. [PubMed: 6601670]
  1534. Wen T, Cai Y, Chen X, Xiang L, Wang B, Zhuang Y. Safety analysis of dust mite allergen for diagnosis and immunotherapy of asthma and rhinitis. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 99; 17(5):274–6. Other reason for exclusion (specify):questionnaireNot an RCT. [PubMed: 12563856]
  1535. Werner M, Gronemeyer W, Fuchs E. Results of specific desensitization with aqueous allergen extracts. Dtsch Med Wochenschr. 70; 95(16):877–82. It does not meet ALL the inclusion criteria. [PubMed: 5439541]
  1536. Weyer A, Doinel C, Debbia M, L’Heritier C, Rivat L, Le Mao J, Hirth C, David B. Grass pollen hyposensitization versus placebo therapy. II. Immunotherapy-induced changes in serum IgE and IgG levels. Allergy. 81; 36(5):319–28. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 7032342]
  1537. Weyer A, Heritier CL, David B. Grass pollen hyposensitization versus placebo therapy. Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M. 83(78):101–7. It does not meet ALL the inclusion criteria. [PubMed: 6354089]
  1538. White KM, Nugent JS, Rathkopf MM. Dust-mite avoidance measures in patients on immunotherapy. Allergy Asthma Proc. 2008;29(1):40–4. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 18302837]
  1539. Wihl JA, Ipsen H, Petersen BN, Munch EP, Janniche H, Lowenstein H. Immunotherapy with partially purified and standardized tree pollen extracts. II. Results of skin prick tests and nasal provocation tests from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy. 88; 43(5):363–9. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 3046406]
  1540. Wilcock LK, Francis JN, Durham SR. Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin Exp Allergy. 2004;34(9):1373–8. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 15347369]
  1541. Wilson CW, Black JH, McEwen LM, Ganderton MA. The treatment of allergic rhinitis and asthma by percutaneous desensitisation. J Ir Med Assoc. 67; 60(360):205–6. Therapy NOT AVAILABLE in the U.S Other reason for exclusion (specify):used enzymes. [PubMed: 6046162]
  1542. Wilson DR, Irani AM, Walker SM, Jacobson MR, Mackay IS, Schwartz LB, Durham SR. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy. 2001;31(11):1705–13. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 11696046]
  1543. Winther L, Malling HJ, Mosbech H. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects. Allergy. 2000;55(9):827–35. It does not meet ALL the inclusion criteria Not an RCT. [PubMed: 11003446]
  1544. Wise SK, Woody J, Koepp S, Schlosser RJ. Quality of life outcomes with sublingual immunotherapy. Am J Otolaryngol. 2009;30(5):305–11. It does not meet ALL the inclusion criteria. [PubMed: 19720247]
  1545. Wolf SI. Allergen immunotherapy in young children. J Allergy Clin Immunol. 95; 96(4):568–70. No original data. [PubMed: 7560676]
  1546. Wolfromm R, Vallery-Radot C, Guibert L, Zalman Z. Desensitization by the extemporaneous combination of aluminum hydroxide with allergens (delayed-action allergens). Acta Allergol. 69; 24(3):202–15. It does not meet ALL the inclusion criteria. [PubMed: 5395957]
  1547. Wortmann F. Oral desensitization in children. Allerg Asthma (Leipz). 65; 11(3):118–23. It does not meet ALL the inclusion criteria.
  1548. Wozniak KD, Gutschmidt E, Stadie W. Specific desensitization of pollinosis using aqueous antigen extracts. Z Gesamte Inn Med. 73; 28(12):375–8. No original data. [PubMed: 4729268]
  1549. Wrzyszcz M. Effect of specific desensitization on acid phosphatase release from peripheral blood leukocytes in allergic (atopic) bronchial asthma. Pol Tyg Lek. 80; 35(38):1445–7. Does not apply to any of the key questions. [PubMed: 7465439]
  1550. Wurcel Victoria. Eficacia y seguridad de la inmunoterapia en el tratamiento del asma y alergia. Evid. actual. prbct. ambul. 2004;7(6):186–187. No original data.
  1551. Wurtzen PA, Lund G, Lund K, Arvidsson M, Rak S, Ipsen H. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy. 2008;38(8):1290–301. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 18510696]
  1552. Wuthrich B, Hafner G. Pollinosis. II. Specific hyposensitization: indications and results of treatment. A study with the allergen preparation Stallergenes-Depot in the pollen season of 1976, 1977 and 1978. Schweiz Med Wochenschr. 80; 110(8):281–90. It does not meet ALL the inclusion criteria. [PubMed: 7367848]
  1553. Wuthrich B, Storck H. Therapy of pollinosis. With special reference to specific hyposensitization with semi-delayed preparations. Clin Ter. 70; 55(1):3–10. No original data. [PubMed: 5499231]
  1554. Wuthrich B. Causal treatment of allergic bronchial asthma. Allergen elimination and hyposensitization. Schweiz Rundsch Med Prax. 86; 75(5):83–8. It does not meet ALL the inclusion criteria. [PubMed: 3952411]
  1555. Wuthrich B, Bucher Ch, Jorg W, Bircher A, Eng P, Schneider Y, Schnyder F, Eigenmann P, Senti G. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. J Investig Allergol Clin Immunol. 2003;13(3):145–8. It does not meet ALL the inclusion criteria. [PubMed: 14635462]
  1556. Xiao SF, Okuda M, Ohnishi M, Okubo K. Specific IgA and IgG antibodies to house dust mite Dermatophagoides farinae in nasal secretions. Arerugi. 94; 43(5):634–44. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 8031257]
  1557. Yamanaka K, Yuta A, Kakeda M, Sasaki R, Kitagawa H, Gabazza EC, Okubo K, Kurokawa I, Mizutani H. Induction of IL-10-producing regulatory T cells with TCR diversity by epitope-specific immunotherapy in pollinosis. J Allergy Clin Immunol. 2009;124(4):842–5. e7. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PubMed: 19703707]
  1558. Yang WH, Dorval G, Osterland CK, Gilmore NJ. Circulating immune complexes during immunotherapy. J Allergy Clin Immunol. 79; 63(5):300–7. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions.
  1559. Ye YM, Lee SK, Kim SH, Nahm DH, Suh CH, Park HS. Changes of serum cytokines after the long term immunotherapy with Japanese hop pollen extracts. J Korean Med Sci. 2006;21(5):805–10. It does not meet ALL the inclusion criteriaoes not apply to any of the key questions. [PMC free article: PMC2721987] [PubMed: 17043410]
  1560. Yilmaz M, Bingol G, Altintas D, Kendirli SG. Effect of SIT on quality of life. Allergy. 2000;55(3):302. It does not meet ALL the inclusion criteria. [PubMed: 10753028]
  1561. Yin KS. Changes in the rate of histamine release from basophils and plasma levels cyclic nucleotides in allergic asthmatics after hyposensitization. Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi. 84; 7(4):231–3. 255. Does not apply to any of the key questions. [PubMed: 6085727]
  1562. Yuksel H, Tanac R, Gousseinov A, Demir E. Sublingual immunotherapy and influence on urinary leukotrienes in seasonal pediatric allergy. J Investig Allergol Clin Immunol. 99; 9(5):305–13. It does not meet ALL the inclusion criteria. [PubMed: 10582199]
  1563. Yunginger JW, Gleich GJ. Seasonal changes in IgE antibodies and their relationship to IgG antibodies during immunotherapy for ragweed hay fever. J Clin Invest. 73; 52(5):1268–75. It does not meet ALL the inclusion criteria measurements; no cx endpt. [PMC free article: PMC302383] [PubMed: 4735589]
Copyright Notice
Bookshelf ID: NBK133229
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (4.7M)

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...